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ABSTRACT 
 
Leptin is an adipocyte-derived hormone/cytokine that 
links nutritional status with neuroendocrine and immune 
functions. As a hormone, leptin regulates food intake and 
basal metabolism, and is sexually dimorphic — that is, its 
serum concentration is higher in females than in males with a 
similar body fat mass. As a cytokine, leptin can affect thymic 
homeostasis and the secretion of acute-phase reactants such 
as interleukin-1 (IL-1) and tumour-necrosis factor-α (TNF-α). 
Similar to other pro-inflammatory cytokines, leptin promotes T 
helper 1 (Th1)-cell differentiation and can modulate the onset 
and progression of autoimmune responses in several animal 
models of disease.  
We report here that leptin can act as a negative signal 
for the proliferation of human naturally occurring 
Foxp3+CD4+CD25+ regulatory T (Treg) cells. Indeed, freshly 
isolated Treg cells produced leptin and expressed high 
amounts of leptin receptor (ObR). In vitro neutralization with 
leptin monoclonal antibody (mAb), during anti-CD3 and anti-
CD28 stimulation, resulted in Treg cell proliferation, which 
was interleukin-2 (IL-2) dependent. Treg cells that proliferated 
in the presence of leptin mAb had increased expression of 
Foxp3 and remained suppressive. The phenomena appeared 
secondary to leptin signalling via ObR and, importantly, leptin 
neutralization reversed the anergic state of the Treg cells, as 
indicated by downmodulation of the cyclindependent kinase 
inhibitor p27 (p27kip1) and the phosphorylation of the 
extracellular-related kinases 1 (ERK1) and ERK2. Together 
with the finding of enhanced proliferation of Treg cells 
observed in leptin- and ObR-deficient mice, these results 
suggest a potential for therapeutic interventions in immune 
and autoimmune diseases. 
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1. Background 
 
1.1 Leptin  
Living organisms require a relatively steady energy 
supply to sustain biological functions. Moreover, energy 
reserves must not only be sufficient to serve all physiological 
needs, but must also be wisely allocated to a wide variety of 
often competing physiological functions. Energy intake and 
energy expenditure undergo substantial daily and seasonal 
fluctuations, however.  
Immunity requires adequate and balanced energy supply for 
optimal function. Although the risk of infection and death is 
highest when energy reserves are not sufficient, obesity, a 
state of energy excess, has also been associated with 
increased susceptibility to infection, bacteremia, and poor 
wound healing (Samartin and Chandra 2001).  
The discovery of the adipocyte-derived hormone leptin, the 
levels of which reflect the amount of energy stored in the 
adipose tissue and are altered by conditions such as fasting 
and overfeeding, has proved to be fundamental to our 
understanding of the concept of energy availability influencing 
several physiological systems. More specifically, the past few 
years of research on leptin — the product of the obese (ob) 
gene — have provided important insights into the intricate 
network that links nutrition, metabolism and immune 
homeostasis (Friedman and Halaas 1998). Leptin is mainly 
produced by the adipose tissue in proportion to the body fat 
mass and, at lower levels, by tissues such as the stomach, 
skeletal muscle and placenta. Although an important role of 
leptin is to regulate body weight through the inhibition of food 
intake and stimulation of energy expenditure by increased 
thermogenesis, recent evidence has indicated that leptin is 
much more than a 'fat-o-stat' sensor (Matarese et al. 2002). 
Indeed, leptin-deficient (ob/ob) mice and leptin-receptor-
deficient (db/db) mice are not only severely obese, but also 
have a series of marked abnormalities that are secondary to 
the effects of leptin on reproduction (Chehab et al. 1996), 
haematopoiesis (Bennet et al. 1996), angiogenesis (Sierra-
Honigmann et al. 1998), insulin secretion (Friedman and 
Halaas 1998), metabolism of bone (Ducy et al. 2000), lipids 
and glucose and, last but not least, innate and adaptive 
immunity.  
 
 
 
1.2 Leptin as a neuroendocrine and immune mediator 
Leptin is a 16-kDa nonglycosylated protein encoded by 
the obese (ob) gene, which is located on human chromosome 
7 and on mouse chromosome 6. In both humans and mice, 
mutations of the ob gene are associated with hyperphagia 
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and obesity, reduced energy expenditure, and other 
reproductive, neuroendocrine, and metabolic dysfunction. 
Serum leptin is usually higher in obese individuals and has a 
strong sexual dimorphism, being higher in females than 
males matched by age and body weight (Friedman and 
Halaas 1998). 
Leptin is classically considered a hormone because it 
regulates the balance between food intake and energy 
expenditure, signaling to the brain the changes in stored 
energy. Serum leptin is directly correlated with the body fat 
stores, increasing with fat accumulation, and decreasing 
during fasting. Leptin gene expression is regulated by several 
factors, including other hormones. Insulin stimulates leptin 
secretion during feeding, while a decrease in insulin levels 
anticipates a fall in leptin during starvation. Glucocorticoids 
also operate synergistically with insulin in the secretion of 
leptin from cultured adipocytes, although an inverse 
relationship between leptin and glucocorticoids is generally 
observed (Friedman and Halaas 1998). Finally, leptin 
expression is inhibited by testosterone, increased by ovarian 
sex steroids, and directly influences the hypothalamic-
pituitary-adrenal axis, the reproductive system, 
hematopoiesis, and angiogenesis. 
Many studies have linked the immune and 
neuroendocrine systems. Physiological responses to stress 
usually involve finely integrated interactions between the 
autonomic nervous system and the hypothalamo-pituitary-
adrenal (HPA) axis and the immune system and metabolism 
(Turnbull and Rivier 1999, Addad et al. 2002). For example, 
peripheral inflammation stimulates the central release of 
corticotrophin-releasing hormone (CRH), which in turn 
regulates the stress response through the production of 
adrenocorticotrophic hormone (ACTH) — a hormone that 
promotes the synthesis and release of glucocorticoids from 
the adrenal glands. The glucocorticoids — hormones that get 
their name from their ability to raise levels of blood glucose — 
have potent anti-inflammatory effects and dampen humoral 
and cell-mediated immune responses. Interestingly, 
mediators that are common to the neuroendocrine and 
immune systems, such as the cytokines interleukin-1 (IL-1), 
IL-6 and tumour-necrosis factor (TNF), can all modulate 
inflammation through the HPA axis (Turnbull and Rivier 1999, 
Addad et al. 2002). Indeed, these peripherally derived 
cytokines can cross the blood–brain barrier and act on the 
hypothalamus and pituitary gland to regulate the secretion of 
ACTH in response to inflammation. These cytokines also 
mediate a negative feedback on their own peripheral pro-
inflammatory activity and are counter-regulated by 
endogenous glucocorticoids produced by the HPA axis. 
Leptin is one of the mediators that are common to the 
neuroendocrine and immune systems (Zhang et al. 1994). In 
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immune system, leptin, together with c-reactive protein 
(CRP), IL-1 and IL-6, can act as an early acute-phase 
reactant, produced at high levels during inflammation, sepsis 
and fever, and it can be induced by other inflammatory 
mediators such as TNF and IL-1 (Friedman and Halaas 1998, 
Landman et al. 2003, Orbak et al. 2003). However, although 
these findings have been demonstrated in several systems, 
other studies have not found increased leptin in inflammatory 
conditions in humans, including acute experimental 
endotoxaemia, newborn sepsis, HIV infection and during anti-
inflammatory therapy (Bornstein et al. 1998, Koc et al. 2003, 
Yarasheski et al. 1997).  
The neuroendocrine role of leptin is most evident in 
conditions such as fasting — during which the production of 
leptin by adipose tissue is markedly reduced — or in relation 
to the effects of sex hormones on its production (testosterone 
reduces the secretion of leptin, whereas oestrogens increase 
its production). The link between leptin and sex hormones is 
also indicated by the marked gender dimorphism, manifested 
by a higher serum concentration in females than in males 
with similar body fat mass (Friedman and Halaas 1998). 
The fact that leptin has effects on both neuroendocrine and 
immune systems should not come as a surprise, given the 
functional connection and anatomical contiguity between 
adipocytes and lymphoid cells (Matarese et al. 2002). 
Morphologically, aggregations of lymphoid tissue, including 
the lymph nodes, omentum, thymus and bone marrow, are 
associated with adipose tissue (Matarese et al. 2002). Fat 
deposits do not simply have a structural, metabolic and heat-
insulating function, but provide a microenvironment that helps 
the immune system to sustain immune responses. In 
particular, lymphoid and adipose tissue interact locally 
through common mediators known as adipokines — 
adipocyte-derived molecules that bridge metabolism and 
immune homeostasis (these molecules include leptin, 
adiponectin, chemokines and other pro-inflammatory 
cytokines).  
 
 
 
1.3 Leptin signaling in immune cells  
Leptin, as previously mentioned, is mainly secreted by 
the adipose tissue, which is also present within both primary 
and secondary lymphoid organs and has a significant 
metabolic and immunomodulatory role (Laharrague et al. 
1998). Leptin’s three-dimensional structure is similar to that of 
a cytokine consisting of a four α helix bundle motif which is 
common to the IL-6, IL-12, IL-15 family of cytokines (Zhang et 
al. 1997) (indeed leptin belongs to the family of long-chain 
helical cytokines). Leptin receptor (ObR), is also a member of 
the class I cytokine receptor superfamily and has at least six 
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isoforms as a result of alternative splicing with cytoplasmatic 
domains of different length, known as OBRa, OBRb, OBRc, 
OBRd, OBRe and OBRf (Tartaglia et al. 1995, Tartaglia et al. 
1997). These receptors are membrane-spanning 
glycoproteins with fibronectin type III domains in the 
extracellular region and with a shared 200-amino-acid module 
containing four conserved cysteine residues and two 
membrane proximal cytokine-like binding motifs, Trp-Ser-
Xaa-Trp-Ser. The short forms of the leptin receptor are 
expressed by several non-immune tissues and seem to 
mediate the transport and degradation of leptin. The long 
form of OBR, known as OBRb, is expressed by the 
hypothalamus in areas that are responsible for the secretion 
of neuropeptides and neurotransmitters that regulate 
appetite, body weight (Friedman and Halaas 1998, Tartaglia 
et al. 1995, Tartaglia et al. 1997) and bone mass. 
Interestingly, OBRb is also expressed by endothelial cells, 
pancreatic β cells, the ovary, CD34+ haematopoietic bone-
marrow precursors, monocytes/macrophages, T and B cells 
(Friedman and Halaas 1998, Park et al. 2001, Sierra-
Honigmann et al. 1998, Ducy et al. 2000, Lord et al. 1998, 
Sancez-Margalet et al. 2003, Tartaglia et al. 1995, Tartaglia 
et al. 1997).  
After binding leptin, OBRb-associated Janus-family tyrosine 
kinase 2 (JAK2) becomes activated by auto- or cross-
phosphorylation and tyrosine phosphorylates the cytoplasmic 
domain of the receptor. Four of the phosphorylated tyrosine 
residues function as docking sites for cytoplasmic adaptors 
such as signal transducer and activator of transcription 
(STAT) factors, particularly STAT3 (in some cases, also 
STAT1 and STAT5) (Banks et al. 2000, Bjorbaek et al. 2001, 
Sweeney et al. 2002). The membrane distal tyrosine (position 
1138) functions as a docking site for STAT3, which is a 
substrate of JAK2. After subsequent dimerization, STAT3 
translocates to the nucleus and induces the expression of 
suppressor of cytokine signalling 3 (SOCS3) and other 
genes. SOCS3 takes part in a feedback loop that inhibits 
leptin signalling by binding to phosphorylated tyrosines. SRC 
homology 2 (SH2) domain-containing phosphatase 2 (SHP2) 
is recruited to Tyr985 and Tyr974, and activates extracellular 
signal-regulated kinase 1/2 (ERK1/2) and p38 mitogen-
activated protein kinase (MAPK) pathways through the 
adaptor protein growth factor receptor-bound protein 2 
(GRB2), ultimately inducing the expression of FOS and JUN. 
After leptin binding, JAK2 can induce phosphorylation of the 
insulin receptor substrate 1/2 (IRS1/2) proteins that are 
responsible for the activation of phosphatidylinositol 3-kinase 
(PI3K) (Tartaglia et al. 1995, Tartaglia et al. 1997, Banks et 
al. 2000, Bjorbaek et al. 2001, Sweeney et al. 2002, Martin-
Romero and Sanchez-Margalet 2001, Van den Brink et al. 
2000). Moreover, Src associated in mitosis protein (Sam68), 
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an RNA-binding protein, regulator of RNA metabolism and 
effector of the PI3K is currently thought to function as an 
adaptor protein by binding to activated STAT-3 and to the p85 
subunit of PI3K. Phosphotyrosine phosphatase 1B (PTP1B), 
which is localized on the surface of the endoplasmic 
reticulum, is involved in negative regulation of OBRb 
signalling through the dephosphorylation of JAK2 after 
internalization of the OBRb complex. 
 
 
 
1.4 Leptin in innate and adaptive immunity 
Mice lacking leptin or its functional receptor have a 
number of defects in both cell-mediated and humoral 
immunity (Chandra et al. 1980, Mandel et al. 1978). Similarly, 
humans with congenital leptin deficiency have a much higher 
incidence of infection-related death during childhood (Ozata 
et al. 1999), whereas recombinant human leptin 
(rmetHuLeptin) administration in two children with congenital 
leptin deficiency normalized absolute numbers of naive 
CD4CD45RA T cells and nearly restored the proliferation 
response and the cytokine release profile from their 
lymphocytes (Farooqui et al. 2002). A number of studies in 
mice have shown that the effect of leptin on the immune 
system is both direct and indirect, i.e., via modulation of 
central or peripheral pathways. Leptin has a well-established 
role in all cells involved in innate immunity, which “inflexibly” 
senses either specific pathogen-associated molecular 
patterns, formally not expressed by host tissues, or 
endogenous molecules released from “stressed” cells. In 
particular, leptin seems to promote activation of and 
phagocytosis by monocytes/macrophages and their secretion 
of leukotriene B4 (LTB4), cyclooxygenase 2 (COX2), nitric 
oxide and pro-inflammatory cytokines (Zarkesh-Esfahani et 
al. 2001, Dixit et al. 2003). The products of the inducible form 
of COX2 — prostaglandins and leukotrienes (also known as 
eicosanoids) — as well as nitric oxide, are all involved in the 
regulation of inflammation, chemotaxis and cytokine 
production, and therefore markedly impact the immune 
response. Moreover, leptin can induce chemotaxis of 
neutrophils and the release of oxygen radicals (such as 
superoxide anion and hydrogen peroxide) (Caldefie-Chezet et 
al. 2003, Zarkesh-Esfahani et al. 2004).These mediators can 
be particularly harmful to cells, as they can denature proteins 
and damage membrane lipids (by peroxidation of unsaturated 
fatty acids), carbohydrates and nucleic acids. At least in 
human neutrophils, leptin seems to mediate its effects 
through an indirect mechanism, probably involving the 
release of TNF from monocytes (Zarkesh-Esfahani et al. 
2004). Leptin also affects natural killer (NK)-cell development 
and activation both in vitro and in vivo (Siegmund et al. 2002). 
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As NK cells express OBRb and db/db mice have a deficit of 
NK cells resulting from abnormal NK-cell development, it is 
possible that leptin might influence the 
development/maintenance of a normal peripheral NK-cell 
pool. Indeed, an important role of OBRb in NK-cell physiology 
is indicated by the ability of OBRb to influence NK-cell 
cytotoxicity through direct activation of signal transducer and 
activator of transcription 3 (STAT3) and the transcription of 
genes encoding IL-2 and perforin (Siegmund et al. 2002, 
Zhao et al. 2003, Tian et al. 2002). Last but not least, it has 
recently been shown that leptin can stimulate the production 
of growth hormone by peripheral-blood mononuclear cells 
(PBMCs) through protein kinase C (PKC)- and nitric oxide-
dependent pathways (Dixit et al. 2003). This effect of leptin 
on the production of growth hormone might be important in 
immune homeostasis, given the fact that this cytokine-like 
hormone has marked influences on immune responses by 
controlling the survival and proliferation of immune cells. The 
effects of leptin on adaptive immune responses have been 
extensively investigated on human CD4+ T cells. Addition of 
physiological concentrations of leptin to a Mixed Lymphocytes 
Reaction (MLR) induces a dose-dependent increase in CD4+ 
T-cell proliferation (Lord et al. 1998). However, leptin has 
different effects on proliferation and cytokine production by 
human naive (CD45RA+) and memory (CD45RO+) CD4+ T 
cells (both of which express OBRb). Leptin promotes 
proliferation and IL-2 secretion by naive T cells, whereas it 
minimally affects the proliferation of memory cells (on which it 
promotes a bias towards Th1-cell responses).  Furthermore, 
leptin increases the expression of adhesion molecules, such 
as intercellular adhesion molecule 1 (ICAM1, CD54) and very 
late antigen 2 (VLA2, CD49B), by CD4+ T cells, possibly 
through the induction of pro-inflammatory cytokines such as 
interferon-α (IFN-α). Increased expression of adhesion 
molecules could then be responsible for the induction of 
clustering, activation and migration of immune cells to sites of 
inflammation (Lord et al. 1998). Another important role of 
leptin in adaptive immunity is highlighted by the observation 
that leptin deficiency in ob/ob mice is associated with 
immunosuppression and thymic atrophy — a finding similar to 
that observed in acute starvation (Lord et al. 1998). Acute 
caloric deprivation causes a rapid decrease of serum leptin 
concentration accompanied by reduced Delayed-Type-
Hypersensitivity (DTH) responses and thymic atrophy, which 
are reversible with administration of leptin (Lord et al. 1998, 
Howard et al. 1999, Lord et al. 2001). The thymic atrophy in 
ob/ob mice (or wild-type starved animals) affects the cortex of 
the thymus, in which most CD4+CD8+ T cells are found, and 
leptin replacement reduces the rate of apoptosis of such cells 
(Howard et al. 1999). Despite the evidence of direct effects of 
leptin on immune responses in vitro, a major problem remains 
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whether leptin can influence immune responses in vivo. This 
task is particularly difficult because of the complexity of the 
network of interactions that link leptin to several endocrine 
pathways. For example, the immune abnormalities 
associated with high cortisol levels and hyperglycaemia in 
obese ob/ob or db/db mice could simply be a consequence of 
obesity rather than direct effects of leptin (Lord et al. 1998, 
Howard et al. 1999). To help clarify this issue, studies of food 
restriction, which can reduce cortisol and glucose levels in 
ob/ob mice, have shown that only leptin replacement can fully 
restore normal immune responses in ob/ob mice, whereas 
experimentally induced reduction of serum levels of cortisol 
and glucose cannot reverse immune deficiency abnormalities. 
Although still controversial, these observations seem to 
indicate that the immune abnormalities in ob/ob mice cannot 
be simply ascribed to high circulating levels of cortisol and 
glucose, and that leptin might instead have direct effects on 
the immune system that are independent of the metabolic 
abnormalities associated with leptin (Lord et al. 1998, Howard 
et al. 1999). Another important issue is whether the effects of 
leptin during acute starvation can be ascribed to its central or 
peripheral actions. Recent experiments have shown that 
peripheral leptin has a dominant role in maintaining T-cell-
mediated immune responses in rodents. Direct injection of 
leptin into the central nervous system (CNS) cannot 
compensate for the immunosuppression that is associated 
with starvation-induced hypoleptinaemia (Zhang et al. 2002). 
These findings might have therapeutic implications, as they 
indicate a lack of direct action of leptin on the CNS for 
reversal of starvation-induced immunosuppression, despite 
the beneficial effects of leptin on hormonal stress associated 
with starvation (reduced secretion of ACTH and 
glucocorticoids). In this regard, it is notable that T cells are 
sensitive to the supply of cellular nutrients, such as glucose 
(Frauwirth et al. 2002), because they do not have glycogen 
stores and, therefore, depend on the import of extracellular 
glucose to meet their metabolic needs (Khaled et al. 2002). 
By stimulating glucose uptake through extracellular signal-
regulated kinase 1 (ERK1)/ERK2- and phosphatidylinositol 3-
kinase (PI3K)-dependent pathways, leptin might help to 
restore the impaired T-cell function caused by starvation 
(Lord et al. 1998). In this context, it is worth mentioning that 
other long-chain helical cytokines similar to leptin (such as IL-
3, IL-7 and IL-15) are important in promoting the uptake and 
metabolism of glucose (Khaled et al. 2002). In the case of IL-
3, withdrawal of this cytokine from the culture medium leads 
to decreased lymphocyte uptake of glucose through reduced 
cell-surface expression of glucose transporter proteins. It can 
be hypothesized that similar effects might occur in the case of 
leptin, given the fact that leptin can also regulate cellular 
expression of the same transporters (Berti and Gammeltoft 
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1999). The effects on lymphocyte metabolism are also 
important because they are linked in part to pro-survival 
effects in both physiological and pathological conditions (such 
as in autoreactivity). For example, leptin might help to 
promote lymphocyte survival by upregulating lymphocyte 
surface expression of glucose transporters, such as GLUT1 
and GLUT4. Other pro-survival effects of leptin could result 
from the ability of leptin to upregulate expression of the anti-
apoptotic proteins BCL-2 and BCL-XL (which protect T cells 
from apoptosis and thymocytes from glucocorticoid-induced 
apoptosis) (Fujita et al. 2002, Shimabukuro et al. 1998, Najib 
and Sanchez-Margalet 2002). 
 
 
 
1.5 Leptin in organ-specific autoimmunity: multiple 
sclerosis and type 1 diabetes 
Considering that congenital deficiency of leptin can 
associate with increased frequency of infection and related 
mortality (Ozata et al. 1999), it was hypothesized that a low 
concentration of serum leptin might contribute to increased 
susceptibility to infection by reducing T helper cell priming 
and by affecting thymic function (Lord et al. 1998, Howard et 
al. 1999). On the contrary, the Th1-promoting effects of leptin 
have been linked with clarity to an enhanced susceptibility to 
develop experimentally induced autoimmune disease 
including experimental autoimmune encephalomyelitis (EAE), 
type 1 diabetes (T1D), and antigen-induced arthritis (AIA) 
(Ozata et al. 1999). This aspect is also of interest in relation 
to the well-known gender bias in susceptibility to 
autoimmunity. Autoimmune diseases are frequently more 
prevalent in females, and females are relatively 
hyperleptinemic, whereas males are relatively hypoleptinemic 
(Friedman an Halaas 1998,Ozata et al. 1999). It has been 
speculated that leptin could in part contribute to the gender-
biased susceptibility to autoimmunity, and some work in mice 
seems to support this possibility. While more experimental 
evidence is needed to unequivocally define the role of leptin 
in several autoimmune conditions, it is nonetheless exciting 
that new developments in the field are leading to several new 
lines of inquiry. In this context, it is worth mentioning that 
leptin may only represent one of the many factors derived 
from the adipose tissue and neuroendocrine system that – in 
addition to playing an important function in the regulation of 
food intake and metabolism – also affect significantly the 
immune response. These mediators include adiponectin, 
visfatin, neuropeptide Y (NPY), and ghrelin (Tilg and 
Moschen 2006). 
Multiple sclerosis (MS) is a chronic, immune-mediated, 
human chronic inflammatory disorder of the central nervous 
system (CNS) (Williams et al. 1994). The most studied model 
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of MS in animals is EAE, in which autoimmunity to CNS 
components is induced in susceptible strains of mice through 
immunization with self-antigens derived from basic myelin 
protein. The disease is characterized by autoreactive T cells 
that traffic to the brain and to the spinal cord and injure the 
myelin sheaths of CNS, with the result of chronic or relapsing-
remitting paralysis (depending on the antigen and the strain 
of mice used). It has long been known that myelin-reactive 
Th1 CD4+ cells can induce and/or transfer disease, and Th1 
cytokines are elevated in the CNS inflammatory lesions of 
EAE. In contrast, Th2 cytokines typically associate with 
recovery from EAE and/or protection from the disease 
(Williams et al. 1994). It has been shown that leptin is 
involved in both the induction and in the progression of EAE 
(Matarese et al. 2001, Sanna et al. 2003). Genetically, leptin-
deficient mice are resistant to induction of both active and 
adoptively transferred EAE. This protection is reversed by 
leptin administration and associates with a switch from Th2- 
to Th1-type responses and IgG1 to IgG2a isotype switch. 
Similarly, in susceptible wild-type C57BL/6J mice, leptin 
worsens disease by increasing IFN-γ release and IgG2a 
production (Matarese et al. 2001). Importantly, a surge of 
serum leptin anticipates the onset of clinical manifestations of 
EAE. The peak of serum leptin correlates with inflammatory 
anorexia, weight loss, and the development of pathogenic T 
cell responses against myelin. Lymphomononuclear infiltrates 
in the CNS of EAE mice indicate in situ production of leptin in 
active inflammatory lesions, thus representing a significant 
local source of leptin (Sanna et al. 2003). Systemic and/or in 
situ leptin secretion was instead lacking in EAE-resistant 
mice. Taken together, these data suggest an involvement of 
leptin in CNS inflammation in the EAE model of MS.  
In the human disease, it has been reported that the 
secretion of leptin is increased in both serum and 
cerebrospinal fluid (CSF) of naive-to-treatment patients with 
MS, an aspect that positively correlates with the secretion of 
IFN-γ in the CSF and inversely correlates with the percentage 
of circulating Treg cells, a subset of lymphocytes that is 
reduced in patients with MS as compared with healthy 
matched controls. Of note, the number of peripheral Treg 
cells in patients with MS inversely correlates with the serum 
levels of leptin, suggesting a link between the number of Treg 
cells and leptin secretion (Matarese et al. 2005). Considering 
that Treg cells are generated in the thymus, it is not known 
whether peripheral leptin or that produced in the perithymic 
adipose tissue could affect Treg cells generation/function in 
autoimmunity prone subjects. This aspect is not defined yet 
and is object of current extensive investigation. In any case, 
the fact that increased leptin secretion occurs in acute phases 
of MS and correlates with CSF production of IFN-γ is of 
possible interest for the pathogenesis and clinical follow-up of 
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patients with MS. As mentioned before, increased leptin 
secretion is present both in the serum and in the CSF of 
patients with MS and does not correlate with body mass 
index (BMI) (Matarese et al. 2005). The increase of leptin in 
the CSF is higher than in the serum, suggesting possible 
secondary in situ synthesis of leptin in the CNS and/or an 
increased transport across the blood-brain-barrier following 
enhanced systemic production. A recent gene microarray 
analysis of Th1 lymphocytes from active MS lesions has 
shown elevated transcripts of many genes of the 
neuroimmunoendocrine axis, including leptin (Lock et al. 
2002). Leptin transcripts were also abundant in gene 
expression profiles of human Th1 clones, confirming that 
leptin gene transcription is induced concomitantly with the 
polarization toward Th1 responses – which are often involved 
in T-cell-mediated autoimmune diseases including MS. 
Moreover, in situ secretion of leptin near inflammatory T cells 
and macrophages was observed in active EAE lesions 
(Sanna et al. 2003). A possible explanation for the in situ 
elevated levels of leptin in the CSF of patients with MS could 
be the inflammatory cell itself, as suggested by studies with 
autoreactive human myelin basic protein (hMBP)-specific T 
cells from patients with MS that produced leptin and 
upregulated the expression of leptin receptor after activation 
Sanna et al. 2003, Matarese et al. 2005). Both anti-leptin and 
anti-leptin receptor blocking antibodies reduced the 
proliferative responses of the hMBP-specific T cell lines to 
antigen stimulation, underlying a possibility of leptin-based 
intervention on this autocrine loop to block autoreactivity. 
Finally, recent reports have shown increased secretion of 
serum leptin before relapses in patients with MS during 
treatment with IFN-β, and a capacity of leptin to enhance in 
vitro secretion of TNF-α, IL-6, and IL-10 from peripheral 
blood mononuclear cells of patients with MS in acute phase 
of the disease but not in patients with stable disease 
(Batocchi et al. 2003). In view of all these considerations, we 
suggest that leptin could be one of the many proinflammatory 
factors that act in concert to promote the pathogenic 
(autoreactive) Th1 responses targeting neuroantigens in MS.  
Moreover, leptin is also important in spontaneous 
autoimmune diabetes in non-obese diabetic (NOD) mice 
(Atkinson and Leiter 1999). Leptin accelerates autoimmune 
diabetes in females NOD/LtJ mice (Matarese et al. 2002). 
Fluctuations in serum leptin levels have been also observed 
in a study performed by our group in an animal model of 
CD4+ T cell-mediated autoimmune disease, such as type 1 
diabetes (T1D). Non-obese diabetic (NOD/LtJ) female mice, 
spontaneously prone to the development of beta-cell 
autoimmunity, have higher serum leptin levels, as compared 
to NOD/LtJ males and non-susceptible strains of mice, and 
show a serum leptin surge preceding the appearance of 
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hyperglycaemia (Matarese et al. 2002). Furthermore, early in 
life leptin administration significantly anticipated the onset of 
diabetes and increased mortality and inflammatory infiltrates 
in beta-islets; this phenomenon correlated with increased 
secretion of IFN-γ in leptin-treated NOD mice (Matarese et al. 
2002). More recently, it has been found that a natural leptin 
receptor mutants of the NOD/LtJ strain of mice (named 
NOD/LtJ-db5J) display reduced susceptibility to T1D (Lee et 
al. 2005). These data further support the role of leptin in the 
pathogenesis of T1D. These NOD-db5J mice are obese, 
hyperphagic and show hyperglycaemia associated with 
hyperinsulinaemia. The leptin receptor mutation affects the 
extracellular domain of the leptin receptor probably impairing 
the leptin-binding and/or receptor dimerization. This effect is 
likely able to alter the intracellular signalling machinery, thus 
impairing the pathogenicity of anti-islets autoreactive T cells. 
Indeed, these mice show mild-low grade infiltration of the 
islets. Further studies are needed to address the molecular 
machinery determining the phenotype of resistance observed 
in these mice as well as the possibility to interfere with T1D 
pathogenesis by blocking the leptin axis.  
 
 
 
1.6 T regulatory cells 
          The adaptive immune system of higher vertebrates 
provides a more efficient and specific immune defense 
against infectious microorganisms than that afforded by the 
innate immune system. The hallmark of the adaptive immune 
system is the random generation of antigen receptors in 
developing lymphocyte clones through a process of somatic 
cell gene rearrangement mediated by the recombination-
activating gene recombinase. The essentially unlimited 
specificities of this anticipatory recognition system provides 
an efficient counterbalance to the short reproduction cycles 
and high mutation rates of infectious microorganisms. 
However, the diversity of antigen recognition afforded by the 
system also poses the threat of autoimmunity because of the 
generation of self-reactive receptors. Expanded and 
developed in the framework of the clonal selection 
hypothesis, the idea of immunological ‘tolerance’ proposed a 
requirement for the elimination of autoreactive lymphocyte 
clones during development (Burnet 1957, Talmage 1957). A 
vast body of experimentation over the past half century has 
elucidated both cellular and molecular mechanisms leading to 
deletion or functional inactivation of autoreactive T and B 
cells in the primary lymphoid organs, thymus and bone 
marrow, respectively, or in the periphery. Collectively, these 
mechanisms act in a cell-intrinsic way and are therefore 
dubbed ‘recessive tolerance’, as elimination of an individual 
autoreactive lymphocyte clone does not affect other self-
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reactive clones. Over the past decade a population of so-
called ‘regulatory T cells’ (Treg cells) has been linked to the 
prevention of autoimmunity. Treg cells act in a dominant, 
trans-acting way to actively suppress immune activation, 
thereby functioning as critical mediators of self-tolerance and 
immune homeostasis. 
The idea of a dominant form of immunological 
tolerance involving a specialized population of ‘suppressor’ T 
cells acting both to terminate conventional immune responses 
and to prevent autoimmune pathology was proposed over 30 
years ago (Gershon and Kondo 1971). Early studies 
envisaged suppressor cell cascades involving multiple 
suppressor factors, anti-idiotypic T cell networks, ‘suppressor-
inducer’ and ‘contra-suppressor’ cells (Dorf and Benacerraf 
1984). However, the mechanisms responsible for these 
suppressive phenomena were never fully characterized at the 
molecular or biochemical level. Moreover, key findings of 
those studies were found to be demonstrably inaccurate and 
the field of suppressor T cell biology was largely discredited 
(Moller 1988). The present renaissance of the study of 
dominant tolerance can be ascribed mainly to the observation 
that mice thymectomized early in life develop organ-specific 
autoimmunity and that cells derived from adult spleen can 
prevent this disease (Nishizuka and Sakakura 1969). Using 
this model or models of lymphopenia-induced autoimmunity, 
several groups made critical observations demonstrating that 
specific CD4+ T cell subsets, fractionated based on 
expression of various cell surface markers, including CD5 
and CD45RB, are capable of preventing autoimmune disease 
(Sakaguchi 2004, Shevach 2000). Efforts to better define the 
subset of cells mediating suppression of autoimmunity 
culminated in the identification of CD4+ T cells constitutively 
expressing the interleukin 2 receptor-α (IL-2Rα) chain (CD25) 
as being highly ‘enriched’ in suppressor activity (Sakaguchi et 
al. 1995). These ‘naturally arising’ CD4+CD25+ Treg cells 
became the best candidates for the T cell population 
mediating dominant tolerance to self. To emphasize their 
origin and importance, Treg cell production has been called 
the ‘third function’ of the thymus (Seddon and Mason 2000). 
The identification of a cell surface marker (CD25) allowing the 
enrichment of Treg cells has greatly facilitated the more 
rigorous study of T cell–mediated dominant tolerance. 
Another important milestone in the field was the development 
of an in vitro T cell suppression assay (Thornton and 
Shevach 1998, Takahashi et al. 1998, Read et al. 1998). 
After T cell receptor (TCR) crosslinking in vitro, Treg cells are 
unable to proliferate or produce IL-2 but are able to inhibit 
proliferative responses and cytokine production by effector T 
cells. However, this in vitro anergy belies a more complex 
activity in vivo. Adoptive transfer experiments suggest that 
Treg cells are capable of selfrenewal, as transfer of relatively 
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small numbers of Treg cells afforded a long-lasting protection 
against autoimmunity. In addition, Treg cells are capable of 
robust MHC class II–dependent proliferation in lymphopenic 
conditions, after specific TCR stimulation or after transfer into 
mice genetically deficient in Treg cells (Fisson et al. 2003, 
Gavin et al. 2002, Klein et al. 2003, Walker et al. 2003, 
Annacker et al. 2001, Malek et al. 2002, Fontenot et al. 
2003). Additionally, an in vitro protocol has been developed 
for the expansion of Treg cell populations after TCR and 
CD28 engagement in the presence of very high 
concentrations of IL-2, which could allow for isolation and 
cloning of antigen-specific Treg cells (Tang et al. 2004). Thus, 
despite their apparent in vitro anergy, Treg cell population are 
capable of robust expansion in vivo and their early description 
as anergic cells is misleading. 
The important issue of the mechanisms of suppressive 
action by Treg cells remains unresolved. Although in vitro 
suppression is contact dependent and is insensitive to 
transforming growth factor-beta (TGF-β) or IL-10 blockade, 
both IL-10 and TGF-β have been linked to suppression 
mediated by Treg cells in several in vivo experimental models 
(Shevach 2002, Green et al. 2003, Asseman et al. 1999). 
Reverse signalling through crosslinking of B7 (CD80 and 
CD86) on the cell surface of antigen-presenting cells or 
activated T cells, mediated by cytotoxic T lymphocyte–
associated antigen 4 (CTLA-4) expressed by Treg cells, has 
been proposed as yet another effector mechanism of 
suppression (Paust et al. 2004). However, like IL-10 and 
TGF-β, CTLA-4 does not seem to be a nonredundant 
mechanism of suppression, as Treg cells isolated from mice 
with the targeted deletions of genes encoding each of these 
molecules are suppressive in vitro (Piccirillo et al. 2002, Tang 
et al. 2004). The interplay of these mechanisms in Treg cell 
function in vivo remains to be further defined. In addition, 
after activation, human Treg cells may directly kill activated 
CD4 and CD8 T cells in a perforin- or granzyme-dependent 
way (Grossman et al. 2004). Finally, it has been proposed 
that Treg cells may suppress immune activation by ‘soaking 
up’ T cell growth factors such as IL-2 (Barthlott et al. 2003). It 
is likely the predominant effector mechanism of Treg cell–
mediated suppression may vary depending on the specific 
tissue and inflammation type being studied. Treg cell–specific 
gene targeting may help to elucidate the suppressive 
mechanisms operating in vivo. Other important, unresolved 
issues are whether Treg cells show constitutive suppressive 
activity in vivo and whether this activity requires maintenance 
by ‘tonic’ Treg cell TCR and cytokine signals or whether the 
induction of suppressive mechanisms requires stronger TCR 
and/or cytokine receptor stimuli. Evidence supporting the idea 
of involvement of TCR signals in inducing the suppressive 
function of Treg cells in vivo has begun to emerge from the 
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analysis of Treg cells derived from TCR transgenic mice in 
the presence or absence of cognate ligand. Indirect evidence 
for the involvement of specific TCR stimulation required for 
Treg cell–mediated suppression has come from the finding of 
much more efficient protection against organ-specific 
autoimmunity mediated by Treg cells found in the organ-
draining lymph nodes than by Treg cells found in nondraining 
lymph nodes or spleen (Green et al. 2002). 
As for the involvement of cytokines in affecting suppressive 
properties of Treg cells, early reports indicated that Treg cell–
mediated in vitro suppression could be overridden by 
provision of large amounts of IL-2 (Shevach 2002). However, 
more recent studies have suggested that Treg cells are 
capable of suppressing IL-2 mRNA induction in responder 
cells even in the presence of large amounts of IL-2 (Thornton 
et al. 2004). Moreover, two groups have reported that Treg 
cell suppressive activity in vitro is dependent on IL-2, as it is 
abrogated in the presence of IL-2-neutralizing antibodies 
(Thornton et al. 2004, de la Rosa et al 2004). Those data and 
results, suggesting that the maintenance of CD25 expression 
on Treg cells depends on IL-2 (Curotto de Lafaille 2004), 
envisage the possibility of a relatively simple regulatory 
network whereby the maintenance and suppressive activity of 
Treg cells is conditional on IL-2 production by nonregulatory T 
cells. Furthermore, increased amounts of IL-2 resulting from 
immune activation may fuel the expansion of the Treg cell 
population. 
Although CD25 expression has been useful in defining 
the Treg cell population in nonimmune mice and humans, 
accurate discrimination between Treg cells and recently 
activated nonregulatory T cells, which upregulate CD25, 
during immune activation associated with autoimmune 
pathology or infection is almost impossible. Increased 
expression of CD25, as well as GITR, CTLA-4 and 
lymphocyte activation gene 3, on activated nonregulatory T 
cells suggests that expression of these molecules does not 
functionally define the Treg cell population and raises the 
possibility that not all Treg cells express these molecules. 
Therefore, a principal challenge is to identify a unique 
functional molecular marker of Treg cells. The identification of 
such a molecule should help to resolve a fundamental issue 
regarding the nature of dominant tolerance. Two general 
models for T cell–mediated immunosuppression have been 
considered: that Treg cells represent a dedicated functional 
lineage, or that Treg cells represent a ‘plastic’ phenotype. The 
first model suggests the existence of a factor responsible for 
specifying a Treg cell lineage, which therefore serves as the 
mediator of the genetic mechanism of dominant tolerance. 
The second argues that T cell–mediated immunosuppression 
is not the purview of a dedicated Treg cell lineage but is the 
consequence of a dynamic balance between cells expressing 
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different amounts of cytokine receptors and different cytokine 
production profiles (Stockinger et al. 2001). The identification 
of mutations in the gene encoding Foxp3 as the cause of the 
fatal human autoimmune disorder ‘immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked’ (IPEX) and the 
analogous disease in a spontaneous mutant mouse, scurfy, 
was a breakthrough in the field and led to subsequent studies 
that argue for the idea of Treg cells as a dedicated functional 
lineage (Brunkow et al. 2001, Chatila et al. 2000, Wildin et al. 
2001, Bennet et al. 2001, Sakaguchi 2005). At a very young 
age, human patients with this autoimmune syndrome present 
with massive lymphoproliferation, early-onset insulin 
dependent diabetes mellitus, thyroiditis, eczema, severe 
enteropathy and food allergies preventing normal food intake, 
and additional autoimmune pathologies such as autoimmune 
hemolytic anemia and thrombocytopenia, as well as severe 
infections. Similar sequelae are found in scurfy mutant and 
Foxp3-deficient mice, including severe dermatitis, aggressive 
lymphoproliferation resulting in gross enlargement of 
secondary lymphoid organs, lymphocytic infiltration of 
multiple organs, hypergammaglobulinemia and autoimmune 
haemolytic anemia. Affected males succumb to the IPEX 
syndrome between 3 and 4 weeks of age. Analysis of the 
scurfy mutant before the identification of the causative 
mutation demonstrated that the disease is mediated by T 
cells, with CD4+ T cells being the primary effectors of the 
disease (Godfrey et al. 1994, Godfrey et al. 1991, Blair et al. 
1994). In addition to showing substantially increased 
production of a broad spectrum of proinflammatory cytokines, 
the in vitro responses of T cells isolated from scurfy mice 
show a decreased activation threshold and lesser 
dependence on costimulation (Clark et al. 1999, Kanangat et 
al. 1996) . Furthermore, transgenic overexpression of Foxp3 
results in reduced numbers of peripheral T cells, and the 
remaining T cells show impaired responses to TCR ligation. 
Those studies along with phenotypic similarities to TGF-β– 
and CTLA4-deficient mice led to the proposal that Foxp3 may 
mediate a general mechanism of negative regulation of T cell 
activation. Foxp3 belongs to a large family of functionally 
diverse transcription factors based on its winged helix–
forkhead DNA-binding domain (forkhead box (Fox)). In 
addition to the C-terminal forkhead domain, Foxp3 also  
contains a Cys2His2 zinc finger domain and a coiled-coil–
leucine zipper motif. Homology among full-length human, 
mouse and rat Foxp3 is very high, suggesting a highly 
conserved function. At present there is very little 
understanding of the function of Foxp3 at the molecular level. 
Foxp3 binds DNA, localizes to the nucleus and can act as a 
transcriptional repressor (Schubert et al. 2001). Identification 
of consensus forkhead binding domains adjacent to NFAT 
transcription factor binding sites in the promoters of several 
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cytokine genes, including those encoding IL-2, IL-4 and tumor 
necrosis factor, led to the proposal of a model of Foxp3-
mediated transcriptional inhibition or repression in which 
Foxp3 antagonizes NFAT function by competition for DNA 
binding sites (Schubert et al. 2001). Based on those and 
other studies, it has also been proposed that Foxp3 is 
induced in a variety of cell types as a general mechanism of 
negative immune regulation by repressing production of 
inflammatory cytokines. However, so far there has been no 
characterization of Foxp3 target genes or the transcriptional 
program specified by Foxp3. The devastating 
lymphoproliferative autoimmune disease resulting from Foxp3 
deficiency affects mutant males but not heterozygous female 
carriers for both humans and mice. Those observations and 
the fact that random X-chromosome inactivation is 
maintained in T cells from heterozygous female carriers 
suggest that control of the pathology in heterozygous females 
is mediated by a cell-extrinsic mechanism consistent with the 
idea of dominant tolerance. That consideration and some 
resemblance between the range of target organs affected by 
the disease in Foxp3 mutant mice and that in mice depleted 
of CD25+CD4+ T cells prompted examination of the function 
of Foxp3 in Treg cell biology. Analysis of Foxp3 expression in 
T cells at both the mRNA and protein level has shown high 
expression in CD25+CD4+ Treg cells and low expression of 
Foxp3 in naive and, notably, recently activated CD25–CD4+ 
T cells (Fontenot et al. 2003, Khattri et al. 2003, Hori et al. 
2003). Those results suggest that Foxp3 is a specific 
molecular marker of Treg cells and, unlike CTLA-4, GITR and 
lymphocyte activation gene 3, allows for discrimination 
between Treg cells and activated nonregulatory T cells. 
Analysis of the origin of CD4+CD25+ Treg cells in chimeric 
mice containing a 1:1 mixture of allelically marked bone 
marrow stem cells derived from Foxp3-deficient and wild-type 
mice showed that Foxp3-deficient bone marrow cannot give 
rise to CD4+CD25+ Treg cells, thus demonstrating that 
CD4+CD25+ Treg cell development is critically dependent on 
Foxp3 expression21. In agreement with that finding, 
transgene-driven Foxp3 overexpression in mice results in an 
increase in the CD4+CD25+ Treg cell subset and acquisition 
of suppressive properties by CD4+CD25– and CD8+ T cells, 
although these cells are not as efficient at inhibiting CD25–
CD4+ T cell in vitro responses as are CD4+CD25+ Treg cells 
(Khattri et al. 2003). The essential involvement of Foxp3 in 
programming Treg cell function was further demonstrated by 
the acquisition of regulatory properties by CD4+CD25– T 
cells after retroviral transduction with Foxp3. However, in 
those experiments, only some of the Foxp3-expressing cells 
acquired the characteristics of CD4+CD25+ Treg cells, 
including high expression of CD25 and suppressor activity. 
One possible interpretation of those results is that the 
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acquisition of regulatory properties after expression of Foxp3 
in peripheral nonregulatory T cells is conditional on TCR 
specificity or the expression of additional cofactors either pre-
existing or acquired in the process of activation and 
differentiation. Although Treg cells have high expression of 
Foxp3, low expression of Foxp3 has been detected in 
CD4+CD25– and CD8+ T cells (Fontenot et al. 2001, Furtado 
et al. 2002). Do all T cells have low expression of Foxp3, or 
do subsets of cells with high expression of Foxp3 exists in 
these populations? Along the same lines, the issue of a cell-
intrinsic role for Foxp3 in nonregulatory T cell function has not 
been conclusively resolved. Does low Foxp3 expression 
modulate T cell activation in nonregulatory T cells? Analysis 
of mice expressing a ‘knock-in’ allele encoding a green 
fluorescent protein–Foxp3 fusion protein suggests that Foxp3 
expression is highly restricted to Treg cells and that the low 
expression of Foxp3 detected in CD4+CD25– and CD8+ T 
cells is due to the presence of Foxp3+ Treg cells in these 
populations. 
Another principal issue in the field is the frequency of 
the conversion of mature, nonregulatory T cells to Treg cells 
in the periphery as well as the in vivo conditions necessary 
for such conversion. Does a subset of nonregulatory T cells 
upregulate Foxp3 and acquire Treg cell activity during the 
course of conventional immune responses as part of a 
negative feedback loop? Do experimental manipulations that 
generate increased numbers of Treg cells expand a 
preexisting Treg cell population or convert them from 
nonregulatory T cells? If nonregulatory T cells can acquire 
Treg cell phenotype, is this a transient phenotype or a 
terminal differentiation into Treg cells, and does such 
conversion occur during the course of a conventional immune 
response? Unlike mouse CD25–CD4+ T cells, human CD25–
CD4+ T cells are reported to upregulate Foxp3 after in vitro 
activation (Walker et al. 2003). However, because Foxp3 
expression was analyzed in bulk T cell populations in those 
studies, it is unclear if the observed increase in Foxp3 
expression was due to expansion of a small population of 
Foxp3+ CD25– Treg cells or conversion of nonregulatory T 
cells. Although more work is required to reconcile the data in 
human T cells, one possibility is that the function of Foxp3 is 
different in mice and humans. From a general perspective, 
peripheral upregulation of Foxp3 after activation of human 
CD25–CD4+ T cells would support a model of dominant 
tolerance in which Treg cells are generated de novo from 
nonregulatory T cells as a consequence of immune activation 
and thereby act as negative feedback regulators of 
conventional immune responses. However, the salient 
conservation of Foxp3 at the protein and nucleic acid level, in 
both coding and noncoding sequence, and the notable 
similarity in autoimmune syndrome found in both mice and 
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humans deficient in Foxp3, challenge the idea of such 
scenario. In conclusion, induction of Foxp3 expression in 
developing thymocytes commits these cells to the Treg cell 
lineage. It must be noted that induction of Foxp3 expression 
in peripheral nonregulatory T cells in both humans and mice 
in physiological conditions is a relatively rare process. The 
issue of whether Foxp3 is required only at the commitment 
stage of Treg cell differentiation or is also needed for the 
maintenance of Treg cell function remains to be addressed. 
The devastating lymphoproliferative autoimmune syndrome 
found in both mice and humans deficient in Foxp3, and thus 
Treg cells, demonstrates that Treg cell–mediated dominant 
tolerance is a vital mechanism of immune homeostasis. We 
argue that the early onset of this syndrome indicates that this 
mechanism evolved specifically to control T cell self-reactivity 
and autoimmune inflammation.  
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2. Aims of the study 
 
We believe that there is a strong relationship between 
metabolic state and Treg cells response that controls 
immunological tolerance. We hypothesize that the product of 
the adipose tissue, leptin, acts as a proinflammatory cytokine 
that promotes Th1 responses on one side and inhibits Treg 
cell expansion on the other, setting the basis for exaggerated 
immuno-inflammatory responses to altered self or non-self, 
and leading to autoimmunity in subjects with autoimmunity 
risk factors (ie. genetic predisposition, HLA, environment, 
sex, etc.). Capitalizing our joint effort and trans-disciplinary 
expertise in immunology, metabolism and autoimmune 
diseases, we have used several cellular and molecular 
approaches in animal models and in humans to: 
1) Identify the precise relationship between leptin, metabolic 
state and Treg cells in the context of autoimmune disease 
susceptibility; 
2) Dissect the required milieu for the physiological 
development of Treg cells and the role of leptin in this 
process; 
3) Set-up the cellular and molecular basis for the use of leptin 
antagonists to modulate T cell immune responses in 
autoimmune disorders such as multiple sclerosis;  
4) Investigate the possibility to expand Treg cells with leptin 
antagonists for novel immune therapeutic intervention in 
multiple sclerosis and type 1 diabetes. 
All the above considerations will also help to 
understand how the environment, through the availability of 
nutrients, is able to influence susceptibility to autoimmune 
disorders. Being leptin a unique mediator linking nutritional 
status and immune response, we feel that the understanding 
of the cellular and molecular mechanisms underlying leptin’s 
actions on proinflammatory responses will provide 
fundamental insights to set-up novel strategies for immune 
interventions in autoimmune disorders and chronic 
inflammation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27
3. Materials and Methods 
 
3.1 Purification, cultures and assays with T cells 
Human CD4+CD25+ and CD4+CD25- T cells were 
purified from human healthy donors PBL either by magnetic 
cell separation using the Dynal® CD4+CD25+ Treg Kit (Dynal-
Biotech, Oslo, Norway) or by flow cytometry cell sorting 
(MoFlo™ high-performance cell sorter, Dako, Glostrup, 
Denmark), and rapidly cleaned with the Detach® reagent 
(Dynal-Biotech) from surface bound anti-CD25 mAb. Both 
magnetic beads-based and flow cytometry-based purification 
techniques yielded a highly expressing CD25+ population (95-
98% pure by FACS analysis), 90% of which expressed 
Foxp3. The Treg cells:effector ratio in the suppression 
experiments was 1:1. Cells were cultured (5 x 104 cells/well) 
in round-bottom 96-well plates (Becton-Dikinson Falcon, 
Franklin Lakes, New Jersey) with RPMI medium 
supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin (all from Life Technologies Inc., 
Gaithersburg, Maryland) and 5% AB human serum (Sigma-
Aldrich, St. Louis, Missouri). Cells were stimulated for 3 days 
in the presence of anti-CD3/CD28 Dynabeads® (0.1 
bead/cell) (Dynal-Biotech). On the last day, [3H] thymidine 
(0.5 µCi/well) (Amersham-Pharmacia Biotech, Cologno 
Monzese, Italy) was added to the cultures and cells harvested 
after 12 hrs. Radioactivity was measured with a β-cell-plate 
scintillation counter (Wallac, Gaithersburg, Maryland).  
For suppression experiments in the mouse, Treg cells 
were isolated with the Regulatory T Cell Isolation Kit (Miltenyi 
Biotec, Gladbach, Germany) and stimulated with Dynabeads® 
mouse anti-CD3/CD28 (0.5 bead/cell; 5 x 104 cells/well). The 
Treg cells:effector ratio in the suppression experiments was 
1:2. Purified cells (98% pure by FACS analysis) were cultured 
in round-bottom 96-well plates (Becton-Dikinson Falcon) with 
RPMI medium supplemented with 2 mM L-glutamine, 100 
U/ml penicillin, 100 μg/ml streptomycin (Life Technologies 
Inc.) and 5% FCS or 5% mouse serum (Hyclone-Pierce, 
Rockford, Illinois). Cells were stimulated for 3 days, labelled 
with [3H] thymidine (0.5 μCi/well) for the last 16 hours of 
culture and harvested similarly to what done for human T cell 
cultures. Incorporation of Bromodeoxyuridine (BrdU) and 
FACS analysis were performed in T cell cultures in serum 
free medium (X-VIVO) using the BrdU Flow Kit from BD-
Pharmingen in accordance to the manufacturer’s instructions. 
 
 
 
3.2 IL-2 measurement 
IL-2 measurement was done using the CTLL-2 cell line 
(kindly provided by Dr. Nick Davey, Imperial College London, 
UK) according to a previously described method (Ng et al., 
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2001). Cells were maintained in culture in supplemented 
RPMI medium with 10% FCS (Hyclone-Pierce) and human 
recombinant (rh)–IL-2 (10 U/ml, Boehringer Mannheim, 
Mannheim, Germany). They were subcultured every 2 to 3 
days. Cells were rested in medium without IL-2 overnight 
prior to use in the assays.  
 
 
 
3.3 Reagents, leptin neutralizing antibodies and leptin 
measurement 
For in vitro blocking experiments, human leptin 
neutralizing mAb (R&D Systems, Minneapolis, Minnesota) 
was used at a final concentration of 0.25 to 25 μg/ml; controls 
were irrelevant isotype-matched antibodies (Biovendor 
Laboratory Medicine Inc., Brno, Czech Republic). Human 
recombinant leptin was purchased from R&D Systems. 
Human IL-2 neutralizing mAb (MQ1-17H12) was from BD 
Pharmingen and was utilized at final concentration of 5-10 
μg/ml. FITC-anti-human-CD4 and PE-anti-human-CD25 were 
from BD Pharmingen; the anti-human Foxp3 staining set was 
from eBiosciences (San Diego, California). Recombinant 
mouse GAD65 was purified from GAD65-producing cells that 
were kindly provided by Dr. Roland Tisch, (University of North 
Carolina, Chapel Hill, USA); recombinant GAD65 was tested 
for purity by SDS-PAGE and silver staining before the 
experimental use. The endotoxin content in the preparations 
was below the detection limit (about 10pg of endotoxin/μg of 
protein) of the Limulus amebocyte lysate (LAL) method. The 
9F8 is an anti-human ObR mAb, generated in our laboratory 
in collaboration with dott. Richard Ross, that cross-react with 
mouse ObR with low affinity.  
Human leptin specific ELISA was purchased from R&D 
Systems and measurements were performed according to the 
manufacturer’s instructions (Matarese et al., 2005). Serum 
free media were RPMI (Life Technologies), HyQ-ADCF 
(Animal Derived Component Free, from Hyclone-Pierce) and 
X-VIVO (BioWittaker). 
 
 
 
3.4 Mice and in vivo experiments 
Six weeks-old female leptin-deficient C57BL6/J-ob/ob 
(ob/ob), C57BL6/J, leptin-receptor deficient C57BL/Ks-db/db 
(db/db), C57BL/Ks-db/+ lean controls (db/+) and female 
SJL/J mice were purchased from Harlan Italy s.r.l. 
(Corezzana, Italy); B10.Cg.Tg(TcrAND)53Hed/J (AND-TCR 
Tg) PCC-specific transgenic mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME, USA); NOD/LtJ and 
NOD-Leprdb5J/LtJ mutants were kindly provided by Dr. Ed 
Leiter from The Jackson Laboratory. Experiments were 
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conducted in accordance with the animal welfare guidelines 
under an approved protocol of the Istituto Superiore di Sanità, 
Roma, Italy. Mice were age-matched for individual 
experiments and housed with a 12-hour light/dark cycle in the 
animal facility at the Università di Napoli "Federico II". Ob/ob 
mice were injected intraperitoneally twice daily for 10 days 
with mouse recombinant leptin (R&D Systems) dissolved in 
200 μl of PBS at a dose of 1μg/g of body weight. The mouse 
leptin blocking antibody was produced in our laboratory after 
immunization of C57BL/6J mice with mouse recombinant 
leptin (R&D Systems) emulsified in complete Freund's 
adjuvant (CFA) CFA (Difco Laboratories, Detroit, MI, USA); 
mouse leptin specific antibodies (of the IgM class) were 
affinity purified with recombinant mouse leptin (R&D 
Systems) bound to AminoLink® Plus Immobilization Gel 
(AminoLink® Plus Immobilization Kit from Pierce, Rockford, 
IL, USA) from serum and ascites of immunized mice. Affinity 
purified IgM were used as control (BD-Pharmingen). WT mice 
were treated for three days either with 100 μg of control 
mouse IgM or with mouse leptin Abs intraperitoneally in a 
total volume of 100 μl of PBS. 
Adoptive transfer experiments were performed by labeling 
highly purified (98% pure by FACS analysis) CD4+ T cells 
obtained from C57BL6/J WT mice (cells were purified using 
the mouse CD4+ negative isolation kit from Dynal) with the 
fluorescent dye CFSE (5-, 6-carboxyfluorescein diacetate 
succinimidyl ester) from Molecular Probes Inc., Eugene, 
Oregon, used at 1μg/ml. Briefly, 107 CFSE-labeled CD4+ T 
cells were adoptively transferred into mice intravenously. 
Four and seven days later, spleen cells were harvested from 
mice and stained with PE-anti-Foxp3 (eBioscience) and Cy-
anti-CD4 (BD PharMingen). In experiments of adoptive 
transfer performed with CFSE-labeled AND-TCR Tg CD4+ T 
cells (98% pure), after four and seven days spleen cells were 
harvested from recipient mice and stained with anti-clonotypic 
PE-anti-Vα11.1 (RR8.1), biotynilated-anti-Vβ3 (KJ25) (both 
from BD PharMingen) and APC-anti-Foxp3 (eBioscience). 
Flow cytometric analysis of CFSE dilution was performed by 
gating on CFSE+CD4+Foxp3+ cells (in non-Tg mice) and on 
CFSE+Vα11.1+/Vβ3+Foxp3+ cells (in AND-TCR Tg mice) with 
a FACScalibur™ (Becton-Dickinson, San Diego, California) 
and analyzed by Cell Quest® software (Becton-Dickinson). 
For active induction of EAE, mice (n = 6 per group) were 
immunized s.c. in the flank with 100 µl CFA (Difco; BD 
Diagnostics — Diagnostic Systems) emulsified with 100 µg 
PLP139–151 peptide on day 0 and with 200 ng pertussis 
toxin (Sigma-Aldrich s.r.l.) i.p. on days 0 and 1. Control mice 
(n = 5 per group) were injected with CFA emulsified with PBS 
plus pertussis toxin according to the same schedule. 
Individual mice were observed daily for clinical signs of 
disease for up to 40 days after immunization and after 
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adoptive transfer. Mice were weighed and scored daily in a 
blinded fashion according to clinical severity of symptoms on 
a scale of 0 to 6, with 0.5 points for intermediate clinical 
findings: 0, no abnormality; grade 0.5, partial loss of tail 
tonicity, assessed by inability to curl the distal end of the tail; 
grade 1, reduced tail tone or slightly gait; grade 2, tail atony, 
moderately clumsy gait, impaired righting or any combination; 
grade 3, hind limb weakness or partial paralysis; 4, complete 
hind limb paralysis or fore limb weakness; grade 5, 
tetraplegia or moribund state; grade 6, death. The data were 
plotted as daily mean clinical score for all animals in a 
particular treatment group. Scores of asymptomatic mice (i.e., 
scores of 0) were included in the calculation of the daily mean 
clinical score for each group. A relapse was defined as a 
sustained (more than 2 days) increase in clinical score by at 
least 1 full grade after the animal had improved previously by 
at least 1 full grade and stabilized for at least 2 days. The 
data are plotted as the relapse rate of all the animals of that 
group (total number of relapses per group divided by total 
number of mice in the group; see Table 1). The brains and 
spinal cords were dissected between 15 and 20 days after 
immunization, according to the clinical stage of disease, and 
fixed in 10% formalin. Paraffinembedded sections of 5 µm 
thickness were cut and stained with H&E (Sigma-Aldrich). 
Sections from 4–10 segments per mouse were examined 
blindly for the number of inflammatory foci by using a 
previously published scoring system (7, 8).  
Mice were treated 3 or 4 times with 100 µg control mouse 
IgG1 or with anti ObR specific mAb (9F8) i.p. in a total 
volume of 100 µl of PBS. Treatment was initiated with 
PLP139–151 peptide for 3 consecutive days (days –1, 0, and 
1), during the acute phase of the disease for 4 consecutive 
days (days 8–11) or during disease progression (14–17). 
 
 
  
3.5 Western blots, biochemical analyses and confocal 
microscopy 
Total cell lysates were obtained in 50 mM HEPES (pH 
7.5), 250 mM NaCl, 1 mM EDTA, 1.0% Triton X-100, 10 mM 
sodium fluoride, 1 mM sodium orthovanadate, and 2 μg/ml 
aprotinin, 2 μg/ml leupeptin, and 2 μg/ml pepstatin. 50 μg of 
total proteins were subjected to SDS-PAGE under reducing 
conditions. After electrophoresis, proteins were transferred 
onto a nitrocellulose filter membrane (Protan, Schleicher & 
Schuell) by using a Trans-Blot Cell (Bio-Rad) and transfer 
buffer containing 25 mM Tris, 192 mM glycine, 20% 
methanol. Membranes were placed in 5% non-fat milk in 
phosphate buffered saline, 0.5% Tween 20 (PBST) at 4°C for 
2h to block the non-specific binding sites. Filters were 
incubated with specific antibodies before being washed three 
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times in PBST and then incubated with a peroxidase-
conjugated secondary antibody (Amersham Biosciences). 
After washing with PBST, peroxidase activity was detected by 
using the ECL system (Amersham Biosciences) or Femto 
(Pierce). The antibodies used were the following: anti-p27Kip-1, 
anti-STAT3 and anti-phospho-STAT3 (Y705), anti-STAT1 and 
anti-phospho-STAT1 (Y701) (Cell Signaling Technology, 
Beverly, MA, USA); anti-phospho-ObR (Y1138) (Upstate 
Biotechnology, Lake Placid, NY, USA); anti-leptin, anti-ObR, 
anti-ERK 1/2 and anti-phospho-ERK 1/2 (all from Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA); anti-Foxp3 
(eBioscience); anti-SOCS3 (Serotec Ltd, Kidlington, UK). The 
filters were also probed with an anti-tubulin antibody (Sigma) 
to normalize the amount of loaded protein. Only for the 
human leptin western blots, performed on a 15% SDS-PAGE 
gel to better visualize 16kDa leptin, normalization was 
performed against total ERK1/2. All filters were quantified by 
densitometric analysis of the bands utilizing the program 
ScionImage 1.63 for Mac (Scion Corporation, Frederick, 
Maryland, USA). Confocal microscopy was performed in 
parallel with proliferation and biochemistry at 1h and 36h on 
98% pure Treg cells and CD4+CD25- cells. Cells were 
washed in PBS and 104 cells were seeded on multitest slide 
(ICN Biomedicals Inc., Aurora, Ohio USA) dried on air and 
fixed for 1 minute in methanol, washed in PBS, permealized 
in PBS containing 0.2% Triton X-100 for 3 minutes, and 
incubated in blocking solution (PBS 1% BSA) for one hour. 
Cells were then washed 3 times in PBS and incubated 
overnight at 4°C with primary antibodies (rabbit polyclonal 
anti-leptin and mouse anti-ObR mAb, both from Santa Cruz 
Biotechnology Inc.) diluted 1:100 in blocking solution, washed 
in PBS and incubated with the secondary antibody (goat anti-
rabbit 488 and goat anti-mouse 543, both from Molecular 
Probes Inc.) for 1 hour at room temperature diluted 1:100 in 
blocking solution, washed in PBS and finally mounted in 
PBS/Glycerol 1:1. Immunofluorescence analysis was 
performed with a confocal laser scanner microscope Zeiss 
LSM 510. The wavelength of the Argon ion laser was set at 
488 nm, that of the HeNe laser was set at 543 nm. 
Fluorescence emission was revealed by BP 505-530 band 
pass filter for Alexa Fluor 488 and by BP 560-615 band pass 
filter for Alexa Fluor 543. Double staining 
immunofluorescence images were acquired simultaneously in 
the green and red channels at a resolution of 1024x1024 
pixels. 
 
 
 
3.6 Statistical analysis 
Analyses were performed using the Mann-Whitney U-
test for unrelated two-group analyses and the Kruskal-Wallis 
 32
ANOVA test for three or more group analyses using the 
StatViewTM software (Abacus Concepts Inc., Cary, NC, USA). 
Results are expressed as mean ± SD. P values < 0.05 were 
considered statistically significant. 
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4. Results and Discussion 
 
4.1 Human Treg cells express higher amounts of ObR 
than CD4+CD25- effector T cells 
Previous studies have shown that ObR is expressed 
on CD4+ T cells and that leptin signalling during TCR 
stimulation is able to switch immune responses towards a 
Th1 phenotype (La Cava and Matarese, 2004). To better 
understand the impact of this molecule on the different T cell 
subsets, we sought to analyze the expression of ObR on Treg 
cells and correlate its expression with Foxp3. CD4+CD25+ 
Treg cells and CD4+CD25- effector T cells purified from 
human healthy donors (Figure 1A, left panel) were analyzed 
for Foxp3 expression by FACS analysis and immunoblot 
(Figure1A, right panel and Figure1B, respectively). As 
expected, Treg cells showed high amounts of Foxp3 protein 
whereas CD4+CD25- did not show detectable amount of the 
protein in cell extracts (Figure 1A-B). Instead, ObR was 
expressed on both freshly isolated cellular subsets, although 
at significantly higher amounts (P < 0.001) in Treg cells as 
compared to the CD4+CD25- T cell effectors (Figure 1C).  
 
 
 
4.2 Leptin neutralization results in the proliferation of 
human Treg cells stimulated with anti-CD3 and anti-CD28 
We decided to investigate the ability of leptin to affect 
human Treg cells proliferative and/or suppressive capacity. It 
is well estabilished that human Treg cells were 
hyporesponsive to in vitro anti-CD3 and anti-CD28 stimulation 
(Figure 1D) (Ng et al. 2001). Addition of exogenous 
recombinant leptin to the cultures did not alter Treg cells 
hyporesponsiveness (Figure 1D). However, addition of 
neutralizing leptin monoclonal antibody (mAb) reversed the 
hyporesponsiveness and promoted Treg cells proliferation 
(Figure 1D) (*P < 0.0001) in a dose-dependent fashion 
(Figure 1E). Analogous results were observed using different 
leptin or ObR-blocking antibodies (data not shown). 
Confirming specificity, addition of exogenous recombinant 
leptin to anti-CD3 and anti-CD28-stimulated Treg cells 
antagonized the proliferation induced by leptin mAb (Figure 
1D) (**P < 0.01). Moreover, dose-dependent increase of the 
proliferation of stimulated Treg cells in the presence of leptin 
mAb (Figure 1E) was reversed by addition of increasing 
doses of recombinant leptin (Figure 1F). Interestingly, leptin 
mAb inhibited the proliferation of purified effector CD4+CD25- 
T cells, a phenomenon that was reversed by addition of 
exogenous leptin (Figure 1G) (*P < 0.01 and **P < 0.01, 
respectively). Thus, neutralization of leptin had opposite 
effects on effector CD4+CD25- T cells and Treg cells - it 
inhibited proliferation on the former lymphocyte subset 
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(Figure 1G) whereas it promoted expansion of the latter 
subpopulation (Figure 1D). This effect was also evident 
morphologically, as formation of cell clumps in the cultures of 
Treg cells stimulated with anti-CD3 and anti-CD28 and leptin 
mAb, but not in the cultures of Treg cells stimulated with anti-
CD3 and anti-CD28 in the absence of leptin mAb (data not 
shown). Finally, in co-culture experiments, Treg cells 
efficiently suppressed the proliferation of CD4+CD25- T cells, 
and leptin neutralization reversed the suppression by Treg 
cells (Figure 1H). Data obtained suggest that freshly isolated 
human Treg cells express high amounts of ObR that account 
for an inhibitory loop that constrains the expansion of this 
subset. While leptin neutralization inhibits the proliferation of 
effector CD4+CD25- T cells, this condition leads to an 
expansion of the Treg cells, which maintain their suppressive 
phenotype in the resting phase. The opposite effects of leptin 
blockade on CD4+CD25- T cells and Treg cells associate with 
a differential expression of intracellular leptin and cell-surface 
ObR in the two cell subsets.  
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Figure 1. Human Treg cells express high ObR and leptin 
neutralization reverses their hyporesponsiveness.  
(A) Representative flow cytometry plot of human T cells stained for CD4, 
CD25 and Foxp3.  
(B) and (C) Immunoblot analysis of sorted CD4+ T cells on the basis of 
their CD25 expression. Graphs show quantitation of Foxp3 and ObR with 
respect to tubulin. One representative out of five independent experiments 
is shown. 
(D) Proliferation of CD4+CD25+ Treg cells treated with recombinant human 
leptin (250ng/ml) in the presence or absence of leptin mAb (10μg/ml). The 
data are shown as mean ± SD (n = 5, *P < 0.0001; ** P < 0.01). 
(E) Dose dependency of Treg cells proliferation induced by leptin mAb. 
Proliferation was measured after treatment with indicated doses of leptin 
mAb. The data are shown as mean ± SD (n = 5). 
(F) Proliferation of Treg cells induced by a fixed dose of leptin mAb in the 
presence of increasing concentration of recombinant leptin. The data are 
shown as mean ± SD (n = 5). 
(G) Proliferation of CD4+CD25- effector T cells treated with recombinant 
human leptin (250ng/ml) in the presence or absence of leptin mAb 
(10μg/ml). The data are shown as mean ± SD (n = 5, *P < 0.01; ** P < 
0.01). 
(H) Proliferation of CD4+CD25- effector T cells, Treg cells and of both cell 
types in co-culture in the presence or absence of leptin mAb (10μg/ml). 
The data are shown as mean ± SD (n = 5, *P < 0.01; ** P < 0.0001). 
 
 
 
4.3 Proliferated Treg cells have partial suppressive 
capacity that attains full activity when they enter the 
resting phase  
The suppressive capability of Treg cells in the 
presence of leptin mAb was tested in co-culture experiments 
of Treg cells together with CD4+CD25- T cells. Addition of 
exogenous leptin did not affect suppression of Treg cells on 
CD4+CD25- T cells (Figure 2A). In contrast, suppression of 
proliferation was apparently abrogated in the presence of 
leptin mAb (Figure 2A, grey columns) (*P < 0.0001). 
Concomitant addition of leptin together with the leptin mAb 
partly reduced the anti-leptin-induced reversal of suppression, 
confirming specificity for leptin neutralization in the co-culture 
experiments (Figure 2A, grey columns) (**P < 0.01).  
To understand whether Treg cells during anti-leptin-
induced proliferation could exert suppressive capacity, we 
performed co-culture experiments using CFSE labelled 
CD4+CD25- T cells in the presence of unlabeled Treg cells 
(Figures 2B-E). As expected, Treg cells suppressed the 
expansion of CD4+CD25- effectors (Figure 2D) (*P < 0.0001), 
and suppression was partially maintained in the presence of 
leptin mAb (Figure 2E) (**P < 0.01) - albeit at a lower degree 
when compared with untreated Treg cells (Figure 2D). This 
suggested that Treg cells during anti-leptin-induced 
proliferation are partially functional in terms of suppressive 
capability. Moreover, the co-culture experiments of Treg cells 
with CD4+CD25- T cells, in the presence of leptin mAb, 
indicated that the reversal of suppression (Figure 2A, grey 
 36
columns) was only apparent because CD4+CD25- effectors 
were inhibited in part in their proliferation, as indicated by the 
CFSE dilution (Figure 2E). Thus, the high amount of [3H] 
thymidine incorporation in co-culture of Treg cells with 
CD4+CD25- T cells in the presence of leptin mAb (Figure 2A 
and Figure1H) has to be ascribed to both Treg cells 
proliferation and partly to CD4+CD25- T cells. These 
phenomena were confirmed in terms of expression of the 
activation marker CD25 on CFSE-labelled CD4+CD25- 
effector T cells. The anti-CD3 and anti-CD28 activation 
induced a substantial up-regulation of CD25 on the cell 
surface (Figure 2F) and was significantly inhibited in the 
presence of Treg cells (Figure 2H) (*P < 0.0001). A 
significant reduction of CD25 expression on effector T cells 
was observed in the presence of anti-leptin-expanding Treg 
cells (even if at lower extent when compared with untreated 
Treg cells) (Figure 2I) (**P < 0.01). In any case, the 
suppressive capacity of anti-leptin-expanding Treg cells was 
diminished of about 40% and a certain number of CD4+CD25- 
T cells was still able to proliferate and divide (Figure 2E). 
Next, we performed two-step experiments to address 
whether anti-leptin-proliferated Treg cells in the resting phase 
could retain their suppressive capacity over time. Eight days 
after the first expansion, stimulated Treg cells were still 
suppressive for CD4+CD25- effector T cells in in vitro co-
culture experiments (Figure 2L-N). Although effector 
CD4+CD25- T cells cultured in the presence of leptin mAb 
proliferated upon re-stimulation and did not suppress 
allogeneic CD4+CD25- T cells expansion in co-culture 
experiments (Figure 2M), the anti-leptin-expanded Treg cells 
maintained their hyporesponsiveness after re-stimulation and 
were capable to suppress proliferation of allogeneic 
CD4+CD25- effector T cells (Figure 2N) (*P < 0.0001). Data 
obtained envisage an innovative therapeutic approach of 
Treg cells expansion, as the anti-leptin-expanded Treg cells, 
once in the resting phase, maintain their suppressive capacity 
over time. 
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Figure 2. Human Treg cells exhibit partial suppressive 
capacity upon leptin-mAb-induced proliferation.  
(A) Proliferation of CD4+CD25- effector T cells, Treg cells and of both cell 
types in co-culture treated with recombinant human leptin (250ng/ml) in 
the presence or absence of leptin mAb (10μg/ml). The data are shown as 
mean ± SD (n = 3, *P < 0.0001; **P < 0.01).  
(B-E) and (F-I) Proliferative response and CD25 expression analysis, 
respectively, of CFSE-labelled-CD4+CD25- effector T cells alone or in co-
culture with untreated or leptin-mAb-treated unlabelled Treg cells. The thin 
line represents the isotype matched negative control and the thick line 
represents the CD25 staining. One representative out of three 
independent experiments is shown (*P < 0.0001; **P < 0.01; ***P < 0.05, 
as compared with CD4+CD25-CFSE+).  
(L) Proliferation of CD4+CD25- effector T cells, Treg cells and of both cell 
types in co-culture stimulated with anti-CD3 and anti-CD28 in the 
presence or absence of leptin mAb (10µg/ml). The data are shown as 
mean ± SD (n = 5, *P < 0.01; **P < 0.0001). 
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(M) and (N) Suppressive activity of either CD4+CD25- or CD4+CD25+ 
Treg cells, treated with leptin mAb, eight days after anti-CD3 and anti-
CD28 activation. The data are shown as mean ± SD (n = 5, *P < 0.0001; 
NS, Not significant). 
 
 
 
4.4 Leptin production from human Treg cells 
 Leptin is present in media supplemented with human 
serum, such as the medium used in our experiments (see 
Methods). To test whether human Treg cells could expand in 
the absence of leptin, we stimulated Treg cells with anti-CD3 
and anti-CD28 in three different types of serum- and leptin-
free media (Figure 3A). Under these conditions, Treg cells 
maintained hyporesponsiveness even in the absence of 
exogenous leptin. Surprisingly, addition of leptin mAb to the 
cultures resulted in Treg cells proliferation (Figure 3A). This 
finding was also confirmed by BrdU incorporation in serum-
free medium cultures (Figure 3B). This finding suggests the 
possibility that leptin may be produced by Treg cells, in a 
fashion similar to the production of leptin by CD4+ T cells and 
monocytes in multiple sclerosis (Sanna et al. 2003; Matarese 
et al. 2005). To test this possibility, we examined leptin and 
ObR expression, on Treg cells and CD4+CD25- T cells. Both 
freshly isolated Treg cells and CD4+CD25- T cells stained 
positive for leptin and ObR, with different intensity patterns 
(Figure 3C). Moreover, after 1h culture, Treg cells showed 
higher leptin production than CD4+CD25- T cells, and this 
tendency was maintained during anti-CD3 and anti-CD28 
stimulation, both in the presence or in the absence of leptin 
mAb (Figure 3C). Parallel quantitation by immunoblotting 
analysis for leptin on cell lysates confirmed the difference 
(Figure 3D). Indeed, the presence of a basal production of 
leptin increased significantly after anti-CD3 and anti-CD28 
stimulation (Figure 3D), and Treg cells always produced 
more leptin than CD4+CD25- T cells (Figure 3D) (P < 0.05). 
Interestingly, leptin neutralization induced a compensatory 
leptin production and ObR upregulation in both Treg cells and 
CD4+CD25- T cells, and again, to a higher amount in the Treg 
cells (Figure 3C-D). Additionally, to address the capacity of 
Treg cells and CD4+CD25- T cells to secrete leptin, we 
performed a human leptin specific ELISA (see Methods) and 
confocal microscope analysis at different time points (12h and 
36h) on culture supernatants (Figure 3E). At 12h the 
secretion of leptin was similar in both Treg cells and 
CD4+CD25- T cells, whereas at 36h the amount of leptin 
secreted was significantly higher in the Treg cells, either 
unstimulated (*P < 0.03) or treated with anti-CD3 and anti-
CD28 plus leptin mAb (**P < 0.05) (Figure 3E). The finding 
was confirmed by the observation of a reduced content of 
leptin in Treg cells at 36h (Figure 3E) in confocal microscopy 
and immunoblotting studies on cell lysates. Finally, these 
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results on leptin secretion were also confirmed by 
immunoblotting for leptin on culture supernatants (data not 
shown). It must be noted that in our experimental system, the 
culture media supplemented with human serum contained 
low - albeit significant - concentrations of human leptin (0.5-
1ng/ml in the 5% human serum [HS]/95% RPMI). The 
contribution of HS-derived leptin versus Treg cells-derived 
leptin was analyzed in cultures with three different serum free 
media - all tested for the absence of leptin. The anti-leptin-
induced expansion of the Treg cells in serum free conditions 
indicated that the Treg cells -derived leptin was sufficient to 
act as negative signal for the expansion of the Treg cells. It is 
possible to speculate that a leptin-mediated negative 
autocrine loop may operate on Treg cells, as both freshly 
isolated and cultured Treg cells stain positive for and secrete 
leptin. On the other hand, the leptin present in the culture 
medium and secreted by the CD4+CD25- T cells could act as 
a positive signal for T cell proliferation. These differential 
effects induced by leptin could rely upon the different ObR 
levels and leptin secretory capacity, which would ultimately 
affect the intracellular signalling differentially.  
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Figure 3. Treg cells produce leptin and express high 
amounts of ObR.  
(A) Proliferation of CD4+CD25- effector T cells, Treg cells and of both cell 
types in co-culture in three different serum- and leptin-free media in the 
presence or absence of leptin mAb. The data are shown as mean ± SD (n 
= 6, *P < 0.01; **P < 0.001). 
(B) Flow cytometry plot of BrdU incorporation of CD4+CD25- effector T 
cells, Treg cells and of both cell types in co-culture in serum free medium 
(X-VIVO), in the presence or absence of leptin mAb during anti-CD3 and 
anti-CD28 stimulation. One representative out of three independent 
experiments is shown (*P < 0.05; **P < 0.001).  
(C) Confocal microscopy of freshly isolated and 1h-stimulated Treg cells 
and CD4+CD25- effectors stained for leptin (in green) and leptin receptor 
(ObR) (in red). One representative out of three independent experiments 
is shown.  
(D) Immunoblot for leptin on cell lysates from Treg cells and CD4+CD25- 
effectors. The graph shows quantitation of leptin with respect to total 
ERK1/2. One representative out of three independent experiments is 
shown.  
(E) Confocal microscopy for leptin and ObR at 36h after anti-CD3 and 
anti-CD28 stimulation, and human leptin specific ELISA performed on cell 
culture media at 12h and 36h after stimulation (right column). The data 
are shown as mean ± SD (n = 3, *P < 0.03 and **P < 0.05). 
 
 
 
4.5 Leptin-mAb-induced proliferation of Treg cells is IL-2 
dependent, and IL-2-supported expansion of Treg cells is 
not affected by leptin 
To test whether the leptin-mAb-induced proliferation of 
Treg cells was IL-2 dependent, we evaluated the effects of IL-
2 neutralization on the Treg cells proliferative responses and 
IL-2 production. Addition of human IL-2 neutralizing mAb 
enhanced the inhibitory effects of leptin mAb treatment on the 
CD4+CD25- T cell proliferation and IL-2 secretion (Figures 
4A-B, white columns) (*P < 0.01 and **P < 0.05). IL-2 mAb 
reduced both Treg cells proliferation and IL-2 production 
induced by the neutralization of leptin (Figures 4A-B, black 
columns) (*P < 0.001). Moreover, the apparent reversal of 
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suppression in co-culture experiments due to anti-leptin-
induced Treg cells proliferation was inhibited by anti-IL-2  
(Figures 4A-B, grey columns) (*P < 0.01). IL-2 secretion was 
evaluated via CTLL-2 proliferation (Figure 4B).  
Next we compared IL-2-induced proliferation versus 
anti-leptin induced proliferation on Treg cells. Addition of 
exogenous IL-2 reversed Treg cells unresponsiveness upon 
anti-CD3 and anti-CD28 stimulation (Figure 4C, left panel, *P 
< 0.01), as expected. Of interest, IL-2-induced proliferation 
was less than that observed upon leptin blockade (Figure 4C, 
left panel, **P < 0.05). To also address whether anti-leptin 
treatment affected the ability of Treg cells to proliferate in the 
presence of IL-2 but in the absence of TCR stimulation, we 
measured the proliferation of unstimulated Treg cells cultured 
with leptin mAb or IL-2 and anti-leptin plus IL-2. No 
proliferation was observed in the absence of TCR 
engagement in all the above conditions (Figure 4C, left 
panel). Finally, we tested whether leptin could inhibit IL-2-
induced expansion of Treg cells. The anti-proliferative effect 
of increasing doses of recombinant leptin on Treg cells 
proliferation induced by IL-2 was not significant (Figure 4C, 
right panel), suggesting that IL-2 signalling may be 
independent and dominant on the leptin-mediated inhibitory 
effects on the cell proliferation. Previous experimental 
evidence suggests that the growth, homeostasis and function 
of the Treg cells is dependent on IL-2 in vitro and in vivo 
(Setoguchi et al. 2005; Fontenot et al. 2005). Our data also 
indicated that leptin neutralization could induce IL-2 secretion 
by Treg cells and that leptin mAb-induced-proliferation was 
IL-2-dependent. When comparing the efficiency of leptin 
neutralization and IL-2 to expand Treg cells in vitro, we 
observed that leptin mAb had a better efficiency than 
recombinant IL-2 (as indicated by Treg cells proliferation and 
number after eight days culture). Conversely, addition of 
increasing doses of recombinant leptin to the cell cultures did 
not affect the IL-2-mediated proliferation of the Treg cells, 
suggesting that the control of leptin on the expansion of the 
Treg cells was independent and not overcome by IL-2 
signalling. McHugh et al. (McHugh et al. 2002) demonstrated 
that cultures of Treg cells with neutralizing glucocorticoid-
induced TNF receptor (GITR) mAb allowed the Treg cells to 
respond to exogenous IL-2 in the absence of TCR-
stimulation. We also tried to induce Treg cells proliferation in 
the absence of TCR-stimulation by adding high concentration 
of IL-2 and anti-leptin, but found lack of proliferation, 
indicating that anti-leptin-induced proliferation of the Treg 
cells needs concomitant TCR-engagement. 
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Figure 4. Leptin-mAb-induced proliferation of human Treg 
cells is IL-2-dependent and Foxp3 expression is 
increased during proliferation.  
(A) Proliferation of CD4+CD25- effector T cells, Treg cells and of both cell 
types in co-culture in the presence or absence of leptin mAb and IL-2 
neutralizing mAb. The data are shown as mean ± SD (n = 5, *P < 0.01; 
**P < 0.05, white columns; *P < 0.001 black columns and *P < 0.01 grey 
columns, respectively). 
(B) IL-2 secretion of CD4+CD25- effector T cells, Treg cells and of both cell 
types in co-culture in the presence or absence of leptin mAb and IL-2 
neutralizing mAb. The data are shown as mean ± SD (n = 5, *P < 0.01 
and **P < 0.05, white columns; *P < 0.001 black columns and *P < 0.01 
grey columns, respectively). 
(C) Proliferation of Treg cells in the presence of either leptin mAb or 
recombinant IL-2 (left), stimulated or not with anti-CD3 and anti-CD28. 
The data are shown as mean ± SD (n = 5, *P < 0.0001; **P < 0.01; ***P < 
0.05). Addition of scalar doses of recombinant leptin to proliferating Treg 
cells (right) stimulated with anti-CD3 and anti-CD28 in the presence of 
recombinant IL-2. The data are shown as mean ± SD (n = 5, NS = Not 
significant). 
(D) Immunoblot analysis of CD4+CD25- effector T cells and Treg cells in 
the presence or absence of leptin mAb, at 1h stimulation with anti-CD3 
and anti-CD28. The graph shows quantitation of Foxp3 with respect to 
tubulin. One representative out of five independent experiments is shown. 
(E) Immunoblot analysis and flow cytometry plot of CD4+CD25- effector T 
cells and Treg cells in the presence or absence of leptin mAb, at 12h 
stimulation with anti-CD3 and anti-CD28. The graph shows quantitation of 
Foxp3 with respect to tubulin. One representative out of five independent 
experiments is shown (*P < 0.01, as compared with anti-CD3 and anti-
CD28). 
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4.6 Treg cells expanded with leptin mAb have increased 
expression of Foxp3  
 We next addressed whether leptin neutralization could 
affect the amount of Foxp3 in Treg cells. Foxp3 expression 
was evaluated after leptin neutralization at 1h and 12h during 
anti-CD3 and anti-CD28 stimulation. As shown in Figure 4D, 
Foxp3 expression was increased at early time points after 
anti-CD3 and anti-CD28 stimulation (P < 0.01) and leptin 
mAb treatment did not alter Foxp3 protein amounts. 
Conversely, at 12 hours, Treg cells that proliferated after 
leptin mAb showed increased Foxp3 amounts when 
compared to those activated with anti-CD3 and anti-CD28 
alone (P < 0.01) (Figure 4E). As expected, Foxp3 was 
undetectable in CD4+CD25- T effectors after 1h of stimulation 
in all the experimental conditions (Figure 4D), whereas at 
12h there was a little expression of Foxp3 after anti-CD3 and 
anti-CD28 stimulation either in the presence or in the 
absence of leptin mAb that did not reach statistical 
significance (Figure 4E). Foxp3 - the master gene for Treg 
cells development and function (Sakaguchi et al. 2005) - was 
induced in leptin-neutralized Treg cells at late time points 
(12h), supporting the evidence that removal of leptin from 
cultures medium not only expanded the Treg cells but also 
allowed the maintenance of their phenotype. The 
phenomenon might possibly be ascribed to the increased IL-2 
secretion induced by leptin neutralization, as others have 
shown that IL-2 is capable to upregulate Foxp3 expression in 
human Treg cells (Zorn et al. 2006). 
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Figure 5. Molecular effects of leptin neutralization on 
human Treg cells.  
(A) and (B) Immunoblot for ObR, STAT3 and SOCS3 on CD4+CD25- T 
cells and Treg cells in the presence or absence of leptin mAb stimulated 
with anti-CD3 and anti-CD28 at 1h and 12h, respectively. Graphs show 
quantitation of each specific protein. One representative out of five 
independent experiments is shown. 
(C) and (D) Immunoblot for ERK1/2, STAT1 and p27kip1. Graphs show 
quantitation of each specific protein. One representative out of five 
independent experiments is shown. 
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4.7 The effect of leptin neutralization on ObR and STAT3 
activation pathway  
The molecular effects of leptin mAb were studied at 
early (1h) or late time points (12h) on highly purified human 
Treg cells or effector CD4+CD25- T cells, activated or not with 
anti-CD3 anti-CD28. We first analyzed the leptin-ObR-STAT3 
biochemical pathway: 1h and 12h cultures confirmed that in 
unstimulated cells the ObR was expressed at higher amounts 
in Treg cells than in CD4+CD25- T cells (Figure 5A-B and 
Figure 3C). In vitro stimulation with anti-CD3 and anti-CD28 
induced an upregulation of the ObR expression on both cell 
types and was more evident at 1h than at 12h (Figure 5A-B 
and Figure 3C). Leptin neutralization on both Treg cells and 
CD4+CD25- T cells further upregulated the expression of ObR 
particularly at 1h, suggesting that leptin blockade might 
induce a compensatory upregulation of its receptor.  
As readout of ObR activity, we measured phospho-
STAT3 (P-STAT3) amounts, because STAT3 is known to 
participate in the intracellular signalling pathways of ObR (La 
Cava and Matarese, 2004). Activation of CD4+CD25- T cells 
induced strong STAT3 phosphorylation at 1h and 12h and 
anti-leptin treatment reduced the P-STAT3 amounts, 
particularly at 1h (Figure 5A-B). Conversely, stimulation of 
Treg cells was not associated with a marked increase of P-
STAT3, whereas anti-leptin induced amounts of P-STAT3 at 
1h and 12h comparable to those observed in proliferating 
CD4+CD25- T cells (Figure 5A-B). Of note, at 1h, CD4+CD25- 
T cells expressed both STAT3 spliced isoforms (Maritano et 
al. 2004) - STAT3α and STAT3β - whereas Treg cells mainly 
expressed the STAT3α isoform. This phenomenon was not 
as evident after 12h when the two spliced isoforms were 
similar in both cell subsets, suggesting that the tissue culture 
conditions could induce STAT3β in Treg cells, independently 
on the different type of stimulation. Finally, in unstimulated or 
anti-CD3 and anti-CD28-stimulated Treg cells, at both 1h and 
12h, the amounts of P-STAT3 were higher than those 
observed in unstimulated CD4+CD25- cells, suggesting an 
increased “basal” leptin-mediated signalling in Treg cells. This 
result could be secondary to higher basal expression of ObR 
on Treg cells (Figure 5A-B, Figure 1C and Figure 3C). No 
induction of P-STAT3 was observed in Treg cells treated with 
leptin mAb alone without TCR stimulation. 
We also investigated in our system the expression of 
suppressor of cytokine signalling 3 (SOCS3), a key negative 
regulator of cytokine signalling, including leptin (Kinjyo et al. 
2006; La Cava and Matarese, 2004). SOCS3 in anti-CD3 and 
anti-CD28 stimulated CD4+CD25- T cells increased markedly 
and was further increased by leptin neutralization at 1h 
(Figure 5A). This finding inversely correlated with the 
corresponding P-STAT3 expression. At a later time point 
(12h), SOCS3 was undetectable and could be found at low 
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amounts upon leptin neutralization (Figure 5B). At 1h, 
SOCS3 in Treg cells was markedly higher than in CD4+CD25- 
cells in all the experimental conditions. Specifically, SOCS3 
expression was high in unstimulated Treg cells and increased 
after anti-CD3 and anti-CD28 stimulation despite little STAT3 
activation. Treatment with anti-leptin, which induced P-
STAT3, did not alter the SOCS3 amounts (Figure 5A). At 
12h, basal SOCS3 expression was higher in the Treg cells 
than in CD4+CD25- cells, and was markedly reduced after 
anti-CD3 and anti-CD28 stimulation. In conclusion, leptin 
mAb treatment - which associates with STAT3 activation in 
Treg cells – also induced SOCS3 expression (Figure 5B).  
 
 
 
4.8 The effect of leptin neutralization on biochemical 
pathways involved in T cell activation and anergy 
To evaluate whether leptin neutralization could affect 
T cell activation and anergy, we studied tyrosine-
phosphorilation of the extracellular-signal regulated kinases 1 
and ERK2 (ERK1/2). Leptin neutralization in the presence of 
anti-CD3 and anti-CD28 in CD4+CD25- T cells, increased 
ERK1/2 phosphorylation as compared to anti-CD3 and anti-
CD28 stimulation alone, particularly at 12h (Figure 5C-D). 
Treatment of Treg cells with anti-CD3 and anti-CD28 did not 
induce phospho-ERK1/2 (P-ERK1/2), confirming their anergic 
state. However, leptin mAb induced high amounts of ERK1/2 
tyrosine-phosphorylation at both 1h and 12h, concomitantly 
with the induction of Treg cells proliferation and a reversal of 
their hyporesponsiveness (Figure 5C-D). Moreover, we 
investigated whether leptin neutralization could alter STAT1, 
another transcription factor whose activity is required for the 
development and function of Treg cells (Nishibori et al. 2004). 
We found that leptin neutralization did not affect STAT1 
phosphorylation (P-STAT1) in CD4+CD25- effectors at both 
time points. In contrast, P-STAT1 was markedly induced in 
the leptin-neutralized Treg cells (Figure 5C-D). The fact that 
leptin neutralization in CD4+CD25- T cells reduced the levels 
of STAT3 phosphorylation and had little effect on STAT1 
needs an explanation. This partial effect on the ObR-STAT3-
mediated signalling could be ascribed to the fact that also 
other cytokines activate STAT3 (Doganci et al. 2005). As 
such, removal of leptin could only inhibit in part STAT3 
phosphorylation. In this context, it is interesting to note that 
also SOCS3, a key negative regulator of STAT3-activating 
cytokines (Kinjyo et al. 2006) was differentially expressed in 
the Treg cells and in the CD4+CD25- T cells. The regulation of 
STAT3 signalling by SOCS3 in CD4+CD25- effectors was bi-
phasic, with a first peak at 1h and a rapid degradation at 12h, 
as previously described (Wormald et al. 2006). Leptin 
neutralization increased SOCS3 amounts concomitantly with 
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a reduced phosphorylation of STAT3. This is also consistent 
with the SOCS3 inhibition of IL-2 production and T cell 
proliferation which we observed in our work (Matsumoto et al. 
2003). In Treg cells, SOCS3 was highly expressed in basal 
conditions and markedly induced during acute stimulation, in 
agreement with the anergic state of the Treg cells and their 
reduced IL-2 secretion.  
Last, we studied the modulation of the cyclin-
dependent kinase inhibitor p27 (p27kip1), a molecule  involved 
in the control of cell-cycle, T cell anergy and known to block 
the cell-cycle progression in Treg cells (Li et al. 2005, Wells et 
al. 2001). p27kip1 was down-modulated by anti-CD3 and anti-
CD28 stimulation in CD4+CD25- effectors whereas anti-leptin 
did not down-modulate p27kip1 expression at 1h and markedly 
increased its expression at 12h (Figure 5C-D), explaining, at 
least in part, the inhibition of CD4+CD25- T cells proliferation 
induced by leptin neutralization. In contrast, Treg cells 
showed elevated amounts of p27kip1 before and after anti-
CD3 and anti-CD28 stimulation, confirming their anergic state 
associated with cell-cycle arrest. Leptin mAb treatment 
induced degradation of this molecule at both 1h and 12h, 
which could explain reversal of their anergic state and 
subsequent proliferation (Figure 5C-D). Taken together these 
data suggest that, at the molecular level, Treg cells 
expressed high levels of ObR and of p27kip1 but no 
phosphorylation of ERK1/2, STAT1, and little phosphorylation 
of STAT3. In contrast, leptin neutralization upon anti-CD3 and 
anti-CD28 stimulation and Treg cells expansion associated 
with a rapid degradation of p27kip1 as well as a marked 
phosphorylation of ERK1/2, STAT1 and STAT3 
(phosphorylation of STAT3 in Treg cells could be partly 
explained by both the induction of the ERK1/2, which is 
known to phosphorylate STAT3 independently of ObR 
(Quadros et al. 2004, Barboza et al. 2004), as well as by the 
secretion of STAT3-activating cytokines, ie. IL-2 and IL-6 
(Dogangi et al. 2005). Recently, Zorn and collegues (Zorn et 
al. 2006) showed that IL-2 upregulates Foxp3 expression in 
human Treg cells through a STAT3-dependent mechanism, 
confirming that induction of Foxp3 (in our case, during leptin 
neutralization) may occur via a STAT3-dependent 
mechanism. Intriguingly, CD4+CD25- T cells, after leptin 
neutralization, showed an increase of p27kip1 associated with 
sustained ERK1/2 phosphorilation - a phenotype often 
observed in anergic T cells (Wells et al. 2001, Chen et al. 
1999, Waiczies et al. 2005) and in effector T cells from mice 
treated with anti-leptin antibodies during autoimmune 
encephalomyelitis (De Rosa et al. 2006). Our results indicate 
that leptin neutralization can “unlock” the hyporesponsiveness 
of Treg cells via a rapid degradation of the cell-cycle inhibitor 
p27kip1, associated with the phosphorylation of ERK1/2. 
These biochemical events would allow the Treg cells to enter 
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the G1/S phase of the cell-cycle, induce IL-2 gene 
transcription and, consequently, reverse their anergic state (Li 
et al. 2005). Our data also indicate that these changes 
associate with the activation of STAT1 and STAT3, two 
transcription factors related with cytokine signalling and 
proliferation of the Treg cells (Doganci et al. 2005, Nishibori, 
et al. 2004). 
 
 
 
4.9 Leptin deficiency promotes proliferation of Treg cells 
in mice 
Treg cells, despite their in vitro hyporesponsiveness, 
can expand in vivo in normal, non-lymphopenic hosts 
(Trenado et al. 2003, Gavin et al. 2002). We used non-
irradiated, non-lymphopenic recipient mice to avoid a 
homeostatic expansion of the Treg cells which would occur in 
lymphopenic hosts (Trenado et al. 2003, Gavin et al. 2002). 
The in vivo proliferative capacity of Treg cells in anti-leptin-
treated wild-type (WT) mice versus control-Ig-treated mice 
was tested using CFSE-labelled-CD4+ T cells from normal 
WT mice and measuring the CFSE dilution in the 
CD4+Foxp3+ cells (Figure 6A). Mouse Treg cells expanded in 
vivo more robustly and earlier (day 4 and day 7 post transfer) 
when adoptively transferred into leptin-neutralized WT mice 
(Figure 6A) (*P < 0.01; **P < 0.001). This result was 
confirmed by adoptive transfer of CFSE-labelled-CD4+ T cells 
from normal WT mice into leptin-deficient ob/ob mice, in 
which the Treg cells expanded more robustly and earlier (day 
4 and day 7 after transfer) when compared with cells 
transferred into normal WT mice (Figure 6B) (**P < 0.001 
and *P < 0.01, respectively). We also confirmed our data in a 
transgenic antigen-specific system utilizing donor mice 
carrying the (TcrAND)53Hed transgene (AND-TCR Tg mice) 
expressing the clonotypic Vα11.1/Vβ3 TCR chains, specific 
for the carboxy-terminal fragment of pigeon cytochrome c 
(PCC) (Kaye et al. 1989). Assessment 4 and 7 days after 
adoptive transfer revealed that transferred CFSE-labelled 
clonotypic AND-TCR Treg cells proliferated more vigorously 
in ob/ob mice as compared with normal WT controls (Figure 
6C) (**P < 0.001 and *P < 0.01, respectively). This 
phenomenon was reversed by recombinant leptin 
administration to leptin-deficient ob/ob mice (Figure 6C). To 
avoid interference of CD4+ T cell lymphopenia on the Treg 
cells expansion in vivo, in the adoptive transfer experiments 
in ob/ob mice, we utilized 6 weeks-old mice (in which the 
leptin deficiency has not yet determined significant reduction 
of the CD4+ T cell number). The in vivo results were also 
confirmed by CFSE dilution experiments gating on the 
CD4+CD25+ Treg cells in both leptin neutralized WT and 
leptin-deficient ob/ob mice, respectively (Figure 6D and F, 
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respectively). Foxp3 expression was increased in the Treg 
cells of the leptin neutralized WT mice (Figure 6E).  
Taken together, in vivo studies in leptin-deficient ob/ob 
mice show higher percentage and absolute number of 
circulating Treg cells. They can expand up to 90% in vivo in 
normal non-lymphopenic hosts by day 28 post transfer 
(Trenado et al. 2003). Adoptive transfer experiments of 
CFSE-labelled Treg cells from WT mice into leptin-deficient 
ob/ob mice showed a significant in vivo expansion of Treg 
cells. It is also noteworthy that chronic leptin deficiency allows 
higher expansion of Treg cells when compared with acute 
leptin neutralization induced by leptin mAb (the percentage of 
proliferating Treg cells in ob/ob mice was always higher than 
that observed in leptin neutralized WT mice). Importantly, in 
vivo leptin neutralization also determined an increased Foxp3 
expression in the Treg cells, suggesting maintenance of their 
suppressive phenotype after expansion in vivo. Taken 
together, our data suggest that the presence of ObR may be 
crucial in the control of the expansion of Treg cells because 
stimulated Treg cells from db/db mice proliferated better than 
Treg cells from controls in vitro, whereas the suppressive 
capability of Treg cells from db/db mice was similar to that of 
control mice. 
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Figure 6. In vivo leptin neutralization or congenital leptin 
deficiency associate with proliferation of Treg cells.  
(A) Proliferation measured as CFSE dilution of CFSE-labelled-Treg cells 
obtained from WT mice and transferred into control (CTR)-Ig or mouse 
leptin neutralizing Ab-treated WT mice. The histogram shows the percent 
of CFSE+ Treg cells (gated on CD4+Foxp3+ cells) that had divided 4 and 7 
days after transfer. One representative out of three independent 
experiments with 3 mice per group is shown (*P < 0.01; **P < 0.001). 
(B) CFSE dilution profile of CFSE-labelled-Treg cells (gated on 
CD4+Foxp3+ cells) obtained from WT mice and transferred into WT or 
leptin-deficient ob/ob mice, 4 and 7 days after transfer. One 
representative out of three independent experiments with 3 mice per 
group is shown (**P < 0.001; *P < 0.01). 
(C) CFSE dilution profile of PCC-specific CFSE-labelled AND-TCR Treg 
cells (gated on Va11.1+/Vb3+Foxp3+ cells) adoptively transferred into WT, 
ob/ob and ob/ob treated with recombinant leptin, 4 and 7 days after 
transfer. One representative out of two independent experiments with 4 
mice per group is shown (**P < 0.001; *P < 0.01).  
 
 
 
4.10 Proliferative potential and functional capacity of Treg 
cells from leptin receptor-deficient mice 
We studied the in vitro proliferation and suppressive 
capacity of CD4+CD25- effectors and Treg cells from 
congenitally leptin-receptor-deficient db/db mice and normal 
db/+ heterozygous controls (Figure 7A-C). Stimulation with 
anti-CD3 and anti-CD28 of CD4+CD25- effector T cells from 
db/db mice was less effective in inducing proliferation than 
stimulation on CD4+CD25- from db/+ mice (Figure 7A) (*P < 
0.001). Conversely, in vitro stimulation of Treg cells from 
db/db mice induced significantly higher proliferation than that 
of Treg cells from db/+ heterozygous controls (Figure 7B) 
(**P < 0.01). These data suggested that the absence of the 
ObR impaired the expansion of CD4+CD25- effectors and 
enhanced the proliferative potential of Treg cells. The ObR-
deficiency seemed to affect the proliferative potential of the 
Treg cells rather than their qualitative or functional activity, as 
Treg cells from db/db mice suppressed the proliferation of 
CD4+CD25- T cells in a fashion similar to that of Treg cells 
from db/+ control mice (Figure 7C), confirming the finding 
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that addition of exogenous leptin did not alter the suppressive 
capacity of Treg cells in vitro (Figure 2A). 
Subsequent studies were performed analyzing 
antigen-specific responses in an autoimmune disease model: 
the in vitro proliferative capacity of Treg cells against the 
pancreatic autoantigen glutamic acid decarboxylase (GAD)65 
was evaluated in autoimmune diabetes nonobese diabetic 
(NOD/LtJ) mice versus leptin-receptor-mutant NOD-
Leprdb5J/LtJ mice (Lee et al. 2005) (Figure 7D). These 
recently-isolated ObR mutant mice display obesity, 
hyperphagia, and resistance to the development of pancreatic 
β-islets infiltration (Lee et al. 2005). We found that after five 
days of splenocyte cultures, Treg cells from NOD-Leprdb5J/LtJ 
proliferated more robustly against mouse GAD65 than Treg 
cells from NOD/LtJ females, suggesting an increased 
autoantigen-specific proliferative potential of the Treg cells 
from mice with impaired ObR signalling (Figure 7D) (*P < 
0.01).  
 
 
 
4.11 Leptin-deficient mice have increased numbers of 
Treg cells that can be reduced by administration of leptin
 Mice with genetic deficiency of leptin (ob/ob) or leptin-
receptor (db/db) have reduced susceptibility to autoimmunity 
(Matarese et al. 2001, Sanna et al., 2003, Siegmund et al. 
2004, Faggioni et al. 2000, Lee et al. 2005). Since Treg cells 
play a central role in regulating autoimmunity (Shevach 2002, 
Sakaguchi, 2005), we tested whether genetic deficiency of 
leptin associated with effects on Treg cells. A significant 
increase of the percentage of peripheral Treg cells was 
observed in ob/ob as compared to WT (Figure 7E-F, 
respectively) (*P < 0.02). Administration of leptin reduced the 
elevated number of Treg cells in the ob/ob mice to a number 
comparable to that found in the WT mice (Figure 7E-F) (*P < 
0.02).  
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Figure 7. ObR deficiency increases Treg cells proliferative 
potential, does not alter their suppressive capacity and 
impairs CD4+CD25- proliferation. 
(A) Proliferation of CD4+CD25- effector T cells from db/+ and leptin 
receptor-deficient db/db mice stimulated with anti-CD3 and anti-CD28. 
The data are shown as mean ± SD (n = 5, *P < 0.001).  
(B) Proliferation of Treg cells from db/+ and db/db mice stimulated with 
anti-CD3 and anti-CD28. The data are shown as mean ± SD (n= 5, **P < 
0.01).  
(C) Proliferation of CD4+CD25- effector T cells from db/+ mice in the 
presence of increasing number of either db/+ or db/db Treg cells, 
stimulated with anti-CD3 and anti-CD28. The data are shown as mean ± 
SD (n = 5). 
(D) CFSE dilution of Treg cells (gated on CD4+Foxp3+ cells) from leptin 
receptor mutant NOD-Leprdb-5J/LtJ mice stimulated with mouse 
recombinant GAD65, after five days culture. One representative out of five 
independent experiments is shown (*P > 0.01).  
(E) Percentage numbers of peripheral CD4+CD25+ Treg cells in WT, 
leptin deficient ob/ob mice, and recombinant leptin-treated ob/ob mice. 
One representative out of three independent experiments with 8 mice per 
group is shown (*P < 0.02). 
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(F) Percentage numbers of peripheral CD4+Foxp3+ Treg cells in WT and 
leptin deficient ob/ob mice. One representative out of three independent 
experiments with 7 mice per group is shown (**P < 0.02). 
 
 
 
4.12 In vivo leptin-receptor neutralization improves EAE 
clinical score and delays disease progression  
To test whether interference with the leptin axis could 
modify the in vivo generation and/or the expansion of Treg 
cells, we evaluated the absolute number and the percentage 
of Treg cells during EAE in mice treated or not with a leptin-
receptor blocking antibody (9F8 mAb).  
We first analyzed the capacity of 9F8 to affect induction and 
progression of EAE after immunization with proteolipid protein 
139–151 (PLP139–151) myelin peptide. Treatment with 9F8 was 
initiated prior to immunization (from day –1 to day 1 relative to 
immunization), during the acute phase of the disease (days 
8–11), or during the disease course (days 14-17) for 3 and 4 
consecutive days, respectively (Figure 8A; see Methods for 
details). In all the conditions leptin-receptor neutralization led 
to a statistically significant reduction in EAE clinical score and 
percentage of initial body weight loss). These effects led to 
significant clinical improvement and delayed disease 
progression during the following 40 days of observation 
(Figure 8A), indicating that leptin-receptor blockade inhibited 
both development and progression of EAE. Moreover, 
observation of animals over a longer period of time (90–120 
days) revealed a significant reduction in relapse rate, 
suggesting that this protection was long lasting. 
Surprisingly, when we compared the percentage of Treg 
cells from spleen and lymphnodes of EAE affected mice, 
treated or not with 9F8, we did not find increased number of 
Treg cells after in vivo leptin-receptor neutralization (data not 
presented). Starting from these preliminary results, we 
hypothesized that alteration of the leptin axis did not modify 
the in vivo generation and/or expansion of Treg cells, and that 
amelioration of disease clinical signs observed after leptin-
receptor neutralization was not to be ascribed to an in vivo 
induction of tolerance. However, a more detailed analysis of 
the in vitro expansion of Treg cells during a specific PLP139–
151 T cell activation, showed that the percentage of these cells 
increased when lymphocytes derived from EAE affected CTR 
mice, that did not receive in vivo treatment with leptin-
receptor neutralizing mAb, were cultured in vitro in the 
presence of 9F8 (Figure 9A-B). On the contrary, no 
statistically significant difference was observed when 
lymphocytes derived from EAE affected 9F8 treated mice (in 
all the experimental conditions) were cultured in vitro with 
PLP139–151, in the presence or in the absence of 9F8 mAb.  
The evidence that disturbances in the leptin axis 
determinate an increased in vitro expansion of Treg cells after 
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a PLP139–151 specific T cell activation, led us to suppose that 
also in vivo, after leptin-receptor neutralization, there was an 
increased expansion of Treg cells that, together with a 
reduced activation of autoreactive T cells and with a decrease 
of pro-inflammatory cytokines, could explain the amelioration 
of EAE clinical signs and disease progression. Probably, by 
analyzing the percentage of peripheral Treg cells in EAE 
affected mice, treated or not with 9F8, we did not evaluate 
whether an increased expansion of this subset was 
accompanied with a robust migration of Treg cells into CNS. 
This possible explanation needs further characterization and 
will be confirmed by future immunohistochemical analyses of 
the CNS sections derived from the different groups of mice. 
 
 
 
 
 
 
 
 
 
Figure 8. 9F8 treatment during active EAE reduces 
clinical severity of the disease 
(A) Mean clinical score of SJL/J female mice treated with  9F8 mAb, 
injected either from day –1 to day 1, from days 8-11 or from days 14-17 
(100 µg/d i.p.). Leptin-receptor blockade significantly reduced clinical 
score and body weight loss. Data are from 1 representative experiment 
out of 3. 
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Figure 9. In vitro 9F8 treatment of lymphocytes derived 
from EAE affected mice, during a a specific PLP139–151 T 
cell activation, lead to an increase of Treg cells 
percentage. 
Flow cytometry plots of CD4+Foxp3+ cells after 8 days of a specific 
PLP139–151 T cell activation, in the absence (A) or in the presence (B) of 
9F8 in the culture medium. One representative out of three independent 
experiments is shown (*P < 0.05; **P < 0.001). 
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5. Conclusions 
In this study we establish a unique link between Treg 
cells and leptin by showing that leptin can modulate the 
hyporesponsiveness and proliferation of Treg cells both in 
vitro and in vivo. Our results indicate that leptin neutralization 
can “unlock” the hyporesponsiveness of Treg cells via a rapid 
degradation of the cell-cycle inhibitor p27kip1, associated with 
the phosphorylation of ERK1/2. These biochemical events 
would allow the Treg cells to enter the G1/S phase of the cell-
cycle, induce IL-2 gene transcription and, consequently, 
reverse their in vitro anergic state (Li et al. 2005).  
Incidentally, this study also describes a novel 
strategy to expand human peripheral Treg cells, via leptin 
neutralization, although this approach needs to be further 
investigated. Current strategies to expand Treg cells employ 
ex vivo addition of cytokines to cultured cells during TCR-
stimulation (Tang et al., 2004; Jiang et al., 2003). Since 
neutralization of the leptin present in human serum of tissue 
cultures and of leptin produced by Treg cells may be sufficient 
to determine an expansion of the Treg cells, it might be 
possible that leptin neutralization, in addition with exogenous 
IL-2, may improve the protocols of expansion for Treg cells. 
We are currently investigating this possibility. The find that 
leptin can act as a negative signal for the proliferation of Treg 
cells envisions new possibilities of anti-leptin-based 
approaches for the immunotherapy of conditions 
characterized by low numbers of Treg cells. Leptin might act 
as an endogenous “sensing” factor linking the environment 
(availability of nutrients) to circulating Treg cells number. 
Since nutritional deprivation increases susceptibility to 
infection and associates with amelioration of clinical 
manifestations of autoimmunity (Kuchroo et al. 2003, Payne 
2001), it will be important to address how this relates to the 
influence of leptin on Treg cells and whether anti-leptin-based 
intervention can be applied to tune cognate T cell responses 
in immune regulation.  
We are currently performing experiments of Treg 
cells expansion from naïve to treatment MS patients; our 
future goal is to expand in vitro myelin-specific Treg cells and 
reinfuse them in MS patients with the aim to induce long-term 
self-tolerance and ameliorate the disease progression.  
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We analyzed the serum and cerebrospinal fluid (CSF) leptin secre-
tion and the interaction between serum leptin and CD4CD25
regulatory T cells (TRegs) in naı¨ve-to-therapy relapsing-remitting
multiple sclerosis (RRMS) patients. Leptin production was signifi-
cantly increased in both serum and CSF of RRMS patients and
correlated with IFN- secretion in the CSF. T cell lines against
human myelin basic protein (hMBP) produced immunoreactive
leptin and up-regulated the expression of the leptin receptor (ObR)
after activation with hMBP. Treatment with either anti-leptin or
anti-leptin-receptor neutralizing antibodies inhibited in vitro pro-
liferation in response to hMBP. Interestingly, in the RRMS patients,
an inverse correlation between serum leptin and percentage of
circulating TRegs was also observed. To better analyze the finding,
we enumerated TRegs in leptin-deficient (obob) and leptin-recep-
tor-deficient (dbdb) mice and observed the significant increase in
TRegs. Moreover, treatment of WT mice with soluble ObR fusion
protein (ObR:Fc) increased the percentage of TRegs and ameliorated
the clinical course and progression of disease in proteolipid protein
peptide (PLP139–151)-induced relapsing-experimental autoimmune
encephalomyelitis (R-EAE), an animal model of RRMS. These find-
ings show an inverse relationship between leptin secretion and the
frequency of TRegs in RRMS and may have implications for the
pathogenesis of and therapy for multiple sclerosis.
autoimmunity  tolerance  metabolism  hormones
I t has recently been shown that leptin, a cytokine-like hormonemainly secreted by adipocytes, can play a significant role in the
pathogenesis of several autoimmune diseases, such as experimental
autoimmune encephalomyelitis (EAE), antigen-induced arthritis,
and experimentally induced colitis (1–6). EAE is an animal model
for the human demyelinating disease multiple sclerosis (MS) (7, 8).
EAE can be induced in susceptible strains of mice through immu-
nization with myelin antigens or by adoptive transfer of myelin-
specific T helper 1 (Th-1) cells (7, 8). Genetically leptin-deficient
(obob) mice are resistant to the induction and progression of EAE,
and WT EAE-susceptible mice show an increase in serum leptin
preceding the clinical onset of the disease that correlates with
inflammatory anorexia and disease susceptibility (2, 3). In addition,
pathogenic Th-1 cells and macrophages in active EAE brain lesions
secrete consistent amounts of leptin (3). These data account for an
involvement of leptin in CNS autoimmunity, at least in the EAE
model. Despite this finding, in humans, the role of leptin in the
pathogenesis of MS is not yet fully elucidated. In this study, we
analyzed the secretion of leptin in the cerebrospinal fluid (CSF) and
serum of naı¨ve-to-treatment relapsing–remitting MS (RRMS) pa-
tients and leptin’s interaction with the CD4CD25 regulatory T
cells (TRegs). TRegs are known to dampen autoreactive responses
mediated by CD4CD25 T cells and may influence the onset and
progression of autoimmunity (9). In mice, depletion of TRegs is
associated with autoimmunity, and defects of TRegs have been
described in nonobese diabetic mice and in humans with type 1
diabetes (9, 10). Also, reduced frequency of TRegs andor defective
suppressor function have been observed in humans with systemic
lupus erythematosus, juvenile idiopathic arthritis, autoimmune
polyglandular syndrome type II, and RRMS (11–15). TRegs are
anergic in vitro but can expand in vivo (9). Although the mechanisms
operated by TRegs in suppression are not fully delineated, the
forkhead transcription factor FoxP-3 seems to be required for
suppression to occur (9).
Here, we report increased leptin levels in CSF and serum of
naı¨ve-to-therapy RRMS patients and an inverse correlation with
TRegs frequency. These findings may be relevant in better
understanding the disease pathogenesis and may have therapeu-
tic implications.
Materials and Methods
Subjects. All MS patients and controls were recruited at the
Universita` di Napoli ‘‘Federico II.’’ For serum and CSF leptin
measurement, we included in the study 126 individuals (Table 1)
with MS defined according to the criteria of McDonald et al. (16)
and 117 age-, gender-, and body mass index (BMI)-matched
controls with other noninf lammatory neurologic disorders
(NIND). All MS patients had RRMS and an expanded disability
status scale score of 3.5 and were naı¨ve to treatment. The
inclusion criteria for RRMS patients were (i) onset of relapse within
4 weeks of serumCSF collection, (ii) a history of at least two
clinical relapses during the preceding 2 years, and (iii) the presence
of one or more enhancing lesions on MRI at the time of entry into
the study. NIND included Parkinson’s disease, spinocerebellar
degeneration, amyotrophic lateral sclerosis, brain tumors, cranial
trauma, nonspecific headache, and hydrocephalus. We additionally
included, for only serum leptin measurement and the immune-
phenotypic analysis, 27 donors who were healthy age-, sex-, and
BMI-matched with the RRMS and NIND populations. None of the
NIND and healthy controls had a history of autoimmune disorders,
infection, or endocrine disease. The study was approved by the
institutional ethics committee and all individuals gave written
informed consent.
Leptin and IFN- Measurement. All serum and CSF samples were
collected at 8:30 a.m. after overnight fast and stored at80°C. For
leptin measurement, a human leptin ELISA kit (R & D Systems)
was used according to the manufacturer’s instructions. Human
IFN- and IL-4 were measured in the CSF, in parallel with leptin,
with ELISA kits (Endogen, Cambridge, MA).
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Flow Cytometry. Immunophenotypic analysis of peripheral blood
from RRMS patients and healthy controls was performed with an
EPICS XL flow cytometer (Beckman Coulter) using the Beckman
Coulter software program XL SYSTEM II. Triple combinations of
various anti-human mAbs were used (Coulter Immunotech, Mar-
seille, France). All samples were analyzed within 3–4 h of sampling,
and staining was performed according to standard procedures as
described in ref. 17.
CD4CD25 TRegs in various mouse strains were analyzed by
flow cytometry with a FACSCalibur flow cytometer (Becton
Dickinson) and the Becton Dickinson software program
CELLQUEST. mAbs were added to single cell suspensions of lym-
phocytes obtained from spleens and lymph nodes after lysis with the
ACK buffer [0.15 M NH4Cl10 mM KHCO30.1 mM Na2EDTA
(pH 7.4)]. The analysis and quantification of the TRegs population
was obtained by gating on CD4 T cells.
Human Myelin Basic Protein (hMBP) T Cell Lines. hMBP-specific
short-term T cells lines were generated according to a method
reported in ref. 18. The T cell lines were derived from peripheral
blood lymphocytes of three naı¨ve-to-treatment RRMS patients.
Proliferation and Suppression Assays. For in vitro blocking experi-
ments, Abs against human leptin provided by Radek Sokol (Bio-
Vendor, Brno, Czech Republic) and mAb against the human leptin
receptor (R & D Systems) were used at a final concentration of
10–25 gml; the control was irrelevant IgG Ab (BioVendor).
The in vitro suppressive capacity of TRegs isolated from RRMS
patients and healthy controls was measured after magnetic cell
sorting by using the Dynal CD4CD25 TReg kit (Dynal, Oslo).
Briefly, CD4CD25 T cells (5  104 cells per well) were cocul-
tured with CD4CD25 (5 104 cells per well) in a 1:1 ratio (both
98% pure) and stimulated for 3 d in the presence of anti-CD3
CD28 Dynabeads (0.1 bead per cell) (Dynal). In mice, TRegs were
isolated with the Regulatory T Cell Isolation kit (Miltenyi Biotec,
Gladbach, Germany) and stimulated with anti-CD3 antibody (2C11
hybridoma) at 200 ngml final concentration and irradiated (30 Gy)
T cell-depleted syngeneic splenocytes (1:1 ratio, 5  104 cells per
well).
Immunocytochemistry. T cells cultured, or not, with hMBP were
washed twice with PBS on d 5 of culture, spotted onto glass slides,
and fixed with methanol for 2 min. Leptin and ObR were detected
with polyclonal Abs (Santa Cruz Biotechnology) (3).
Mice. Female obob (C57BL6J-obob), WT controls (C57BL6J-
WT), female leptin-receptor-deficient (dbdb) mice (C57BL-Ks-
dbdb), C57BL-Ks-db controls (db), and SJLJ mice (all 6–8
weeks old) were obtained from Harlan Italy (Corezzana, Italy).
Experiments were performed following the guidelines of the Isti-
tuto Superiore di Sanita`, Rome.
EAE Induction and Treatment with the Fusion Protein of ObR and the
Fc Fragment of IgG (ObR:Fc). The peptide used for EAE induction
in SJLJ female mice was the proteolipid protein peptide
(PLP)139–151) (HSLGKWLGHPDKF). The peptide was synthe-
sized by INBIOS (Pozzuoli, Italy), purity was assessed by HPLC
(97% pure), and amino acid composition was verified by mass
spectrometry. For EAE induction, mice were immunized s.c. in the
flank with 100l of complete Freund’s adjuvant (Difco) emulsified
with 100g of PLP139–151 peptide on d 0 and with 200 ng of pertussis
toxin (Sigma) i.p. on d 0 and d 1. Mice were scored for clinical
symptoms and weighed daily according to a system described in refs.
2 and 3. Brains and spinal cords were dissected 15–20 d after
immunization and fixed in 10% formalin. Paraffin-embedded sec-
tions of 5 m thickness were stained with hematoxylineosin, and
sections from 4–10 segments per mouse were examined blindly for
the number of inflammatory foci by using a scoring system de-
scribed in ref. 3.
The chimeric fusion protein ObR:Fc (R & D Systems) in 200 l
of PBS was injected i.p. at a dose of 100 g per mouse per day for
three consecutive days. Thus, treatment with ObR:Fc of SJLJ mice
was performed on d 1, d 0, and d 1 both before and after
PLP139–151 immunization. The same amount of control IgG was
injected i.p. in the control SJLJ mice.
Real-Time Quantitative PCR. mRNA was extracted from purified
CD4CD25 cells (98% pure by FACS analysis) by using the
MicroFastTrack 2.0 kit followed by cDNA synthesis with
the SuperScript System (Invitrogen). Expression levels of the
transcription factor FoxP3 were analyzed by real-time quan-
titative PCR (TaqMan gene expression assay) by using an ABI
PRISM 7700 thermal cycler (Applied Biosystems). TaqMan
primers and probes for FoxP3 and for the housekeeping gene
GAPDH were purchased as premade kits (Applied Biosys-
tems). For relative quantitation of gene expression to the
endogenous control, the comparative CT method was used in
accordance with the manufacturer’s guidelines. Results are
expressed as the percentage of FoxP3 increase compared with
CD4CD25 effector T cells.
Statistical Analysis. Nonparametric analyses were performed by
using the Mann–Whitney U test for unrelated two-group analyses.
The ANOVA test was used to assess differences between groups.
Table 1. Anthropometric parameters, leptin, and IFN- measurements in RRMS patients and
NIND controls
Parameter measured RRMS patients NIND controls P
No. of patients 126 117
Sex (malefemale) 5868 5265
Age, yr 36.5  9.5 38.2  15.5 0.30
Height, m 1.65  0.07 1.66  0.07 0.52
Mass, kg 65.9  9.6 65.4  10.7 0.65
BMI, kgm2 24.1  3.3 23.4  3.2 0.12
Serum leptin, pgml 21,517.0  15,676.0 11,727.0  13,057.0 0.0001
Serum leptinBMI 900.0  650.0 488.6  482.0 0.0001
CSF leptin, pgml 1,143.1  1,389.5 205.3  222.5 0.0001
CSF leptinBMI 47.7  57.3 8.2  8.7 0.0001
CSF leptinserum leptin 0.09  0.18 0.03  0.06 0.001
CSF leptinCSF albumin 5.7  6.5  106 1.2  2.1  106 0.0001
CSF leptin index* 20.7  53.4 7.0  12.2 0.008
CSF IFN-, pgml 3.9  3.1 0.45  1.3 0.0001
*The CSF leptin index is a measure of in situ synthesis of leptin in the CNS, calculated with the following formula:
(CSF leptinCSF albumin)(serum leptinserum albumin).
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Simple regression analysis and the Pearson’s correlation coeffi-
cients were adopted to study the relationship between different
variables. The program used was STATVIEW (Abacus Concepts,
Cary, NC). Results are expressed as mean  SD; P  0.05 was
considered statistically significant.
Results
Increased Serum and CSF Leptin in Naı¨ve-to-Treatment RRMS Patients
Correlates with IFN- Production in CSF.
We found that leptin was increased in both serum and CSF of
naı¨ve-to-therapy RRMS patients (Table 1 and Fig. 1 a–d). These
differences were maintained even when serum and CSF leptin
were normalized for BMI (Table 1 and Fig. 1 a–d). In addition,
as expected, serum and CSF leptin secretion positively corre-
lated with BMI in NIND controls (Fig. 1 b and d). This
correlation was lost in RRMS patients (Fig. 1 a and c). Con-
versely, the correlation between serum leptin and CSF leptin was
maintained in both RRMS patients and NIND controls; how-
ever, this correlation was stronger in NIND controls than in
RRMS patients (Fig. 1 e and f ). We also compared the CSF-
leptinserum-leptin ratio and observed a statistically significant
increase of this value in RRMS (Table 1). This evidence was
further supported by the lack of increase of albumin in the CSF
of RRMS patients, a marker of blood–brain-barrier (BBB)
damage. In addition, we calculated the CSF-leptinCSF-albumin
ratio as a further indicator of BBB integrity and the CSF leptin
index, calculated as the (CSF leptinCSF albumin)(serum
leptinserum albumin), to evaluate the in situ production of
leptin by CNS. As shown in Table 1, the CSF-leptinCSF-
albumin ratio and the CSF leptin index were higher in RRMS
patients (Table 1), suggesting the production of leptin by CNS in
RRMS.
Finally, we measured the amount of IFN- and IL-4 in CSF and
observed a significant increase in IFN- (Table 1) and a positive
correlation with CSF leptin secretion in RRMS patients only (Fig.
1 g and h). IL-4 did not show any significant increase in CSF, and
the concentration of IL-4 was always below the detection limit of the
assay in both RRMS and NIND controls (data not shown).
RRMS Patient-Derived T Cell Lines Activated with hMBP Produce
Immunoreactive Leptin and Up-Regulate the ObR. To investigate
whether leptin could be secreted by hMBP-activated autoreactive T
cells present in the CNS, we generated short-term T cell lines from
RRMS patients and stained them with leptin- and ObR-specific
antibodies. As shown in Fig. 2 a–f, hMBP-activated T cells from
three naı¨ve-to-therapy RRMS patients produced consistent
amounts of leptin and up-regulated the ObR. The production of
leptin was also confirmed with the measurement of immunoreac-
tive leptin in the culture medium by a human-leptin-specific ELISA
(Fig. 2g).
Neutralization of Leptin or Its Receptor Inhibits T Cell Activation of
hMBP-Specific T Cell Lines Derived from RRMS Patients. We measured
the proliferative response against hMBP on T cells from three
naı¨ve-to-treatment RRMS patients and added either an anti-leptin
or an anti-leptin-receptor blocking antibody to the culture medium
(Fig. 2h). We observed a significant reduction in the proliferative
response of all three patients tested, ranging from 45% to 60%
inhibition of proliferation (Fig. 2h).
Inverse Correlation Between Serum Leptin and Circulating TRegs in
Naı¨ve-to-Treatment RRMS Patients. The analysis of the immune
phenotype was also performed on the peripheral blood of 31
individuals from the naı¨ve-to-therapy RRMS patient population,
selected on the basis of increase in serum leptin concentration (a
serum leptin increase to 2.5-fold higher than the mean serum
leptin observed in NIND and healthy controls). We compared these
phenotypes with the immune phenotype of 27 healthy controls
matched for age, sex, and BMI. The relative percentage and the
absolute cell count per mm3 of the CD3, CD4, CD8, CD19,
CD3CD16CD56, and CD4CD25TRegs subpopulations were
performed (see Table 3, which is published as supporting informa-
tion on the PNAS web site). Interestingly, naı¨ve-to-therapy RRMS
patients, selected on the basis of their serum leptin increase, showed
a significant reduction in the percentage and absolute number of
TRegs in the peripheral blood (Fig. 3a and Table 3), whereas no
difference was observed in the frequency of the other cell sub-
populations (Table 3). TRegs measurement in healthy controls was
in agreement with that found in other studies (14). Regression
Fig. 1. Naı¨ve-to-therapy RRMS patients show an increased secretion of leptin in
serum and CSF that correlates with IFN-production in CSF. Statistical analyses of
these data are summarized in Table 1. (a and b) Simple regression analysis
between serum leptin and BMI in RRMS patients (n126) and NIND controls (n
117). The correlation was lost in RRMS patients, whereas correlation was main-
tained inNINDcontrols. (candd) ThecorrelationbetweenCSF leptinandBMIwas
lost inRRMSpatientswhereascorrelationwasvery strong inNINDcontrols. (eand
f ) Significant correlation between serum and CSF leptin in both RRMS patients
and NIND controls; the correlation was stronger in patients than in controls. (g
and h) Simple regression analysis between the CSF leptin and the IFN- levels in
CSF in both RRMS patients and NIND controls. Only in RRMS patients was there a
statistically significant positive correlation between the CSF leptin and the IFN-
levels in CSF. In NIND controls, the IFN- average levels were very low (see Table
1), and no correlation was observed with CSF leptin.
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analysis between serum leptin and the percentage of TRegs showed
an inverse correlation in RRMS patients (Fig. 3b) but not in the
controls (Fig. 3c). In vitro analysis of TRegs-mediated suppression in
RRMS patients indicated a reduced ability to suppress T cell
proliferation as compared with healthy controls (Fig. 3d), as
reported in ref. 15. Moreover, the addition of leptin (100 ngml) to
human TRegs alone, or during coculture with CD4CD25 effec-
tors, did not alter significantly either proliferation or the suppressive
capacity of TRegs (see Fig. 5 a and b, which is published as supporting
information on the PNAS web site).
obob and dbdb Mice Have Increased TRegs. To analyze in more
detail the effect of leptin on the generation of TRegs in the
periphery, we measured the effect of chronic leptin deficiency on
the number of TRegs in obobmice. These mice showed an increased
frequency of TRegs in lymphoid organs when compared with normal
WT mice (10.4  3.7% vs. 4.7  1.7%, respectively; P  0.02). In
addition, we counted TRegs in the lymphoid organs of dbdb mice
and, again, observed an increased percentage of TRegs when com-
pared with db heterozygote controls (13.9  1.9 vs. 7.9  0.9,
respectively; P  0.01). Finally, the suppressive capacity and phe-
notype of TRegs from dbdb mice were evaluated. No significant
differences were observed in terms of either suppressive capacity or
hyporesponsiveness of TRegs (see Fig. 6 a–c, which is published as
supporting information on the PNAS web site). In addition, ex-
pression levels of FoxP3 in TRegs of obob and dbdb mice were
comparable to those in normal control mice (Fig. 6d).
ObR:Fc Soluble Chimera Increases the Number of TRegs and Amelio-
rates Clinical Course and Progression of Relapsing EAE (R-EAE). Treat-
ment of normal R-EAE-susceptible SJLJ mice with anti-leptin
Fig. 2. T cell lines against hMBP derived from naı¨ve-to-treatment RRMS
patients produce immunoreactive leptin, up-regulate the ObR, and are inhib-
ited in their proliferation by anti-leptin or anti-leptin-receptor blocking an-
tibodies. (a–c) Expression of leptin in T cells from a naı¨ve-to-treatment RRMS
patient in the presence of medium alone (a) or after activation with hMBP (b
and c). Leptin was detectable only after activation in the cytoplasm of T cells.
(d–f ) Expression of ObR on T cells in the presence of medium only (d) or after
activation with hMBP (e and f ). The ObR was expressed at very low levels
before activation and was significantly up-regulated on the cell membrane
after activation with hMBP (e and f ). All photos show immunoperoxidase
staining with diaminobenzidine chromogen (brown) and hematoxylin coun-
terstaining (violet). The open squares in b and e represent the zone of higher
magnification shown in c and f, respectively. (Magnification: a, b, d, and e,
100; c and f, 400.) (g) Anti-hMBP short-term T cell lines secrete immuno-
reactive leptin. (h) The anti-hMBP proliferative response of T cells is inhibited
by the addition to cell cultures of either of the anti-Ob or anti-ObR antibodies.
The data shown are from one representative experiment of three.
Fig. 3. Inverse correlation between serum leptin and circulating TRegs in
RRMS patients. (a) The immune phenotype of circulating lymphocytes in RRMS
patients selected on the basis of their increase in serum leptin (RRMS patients
with a serum leptin increase to2.5-fold higher than the mean of serum leptin
observed in NIND and healthy controls) revealed a significant reduction in the
percentage and the absolute number of circulating TRegs. (*, P 0.0001 and *,
P 0.0001, respectively). (b and c) A statistically significant inverse correlation
was observed between serum leptin and circulating TRegs in RRMS patients (b),
whereas no correlation was observed in healthy controls (c). (d) Functional
analysis of CD4CD25 TRegs of two RRMS patients selected on the basis of an
increase in serum leptin. The proliferative response was inhibited upon addi-
tion of CD4CD25 cells to the CD4CD25 responder population at a 1:1 ratio
in normal controls (black bars). CD4CD25 cells from two naı¨ve-to-therapy
patients with RRMS exhibited significantly less suppressor activity (white and
gray bars). *, P  0.03. CD4CD25 cells alone were unresponsive upon
stimulation as reported in ref. 9. The numbers above the bars represent the
percent of inhibition of proliferation in the experiment. The data shown are
from one representative experiment of five.
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blocking ObR:Fc soluble chimera induced an increase of the
percentage of TRegs in the periphery (Fig. 4a). To test whether this
treatment could also modify the inductionprogression of R-EAE,
we pretreated SJLJ female mice with ObR:Fc chimera before
immunization with the encephalitogenic peptide PLP139–151. The
treatment was performed from d 1 to d 1 with i.p. injection of
100g per day per mouse of ObR:Fc chimera dissolved in PBS (Fig.
4b). ObR:Fc-treated mice showed a reduced peak clinical score, an
improvement in disease relapses and progression, and a reduction
in the percentage of body weight loss (Fig. 4b and Table 2).
Moreover, a significant increase in body weight beforeduring the
early phases of disease in ObR:Fc-treated mice (on d 9, the
percentage of initial body weight in ObR:Fc-treated mice was
112.4 0.9% vs. 100.6 0.7% in control (CTR)-Ab-treated mice,
P 0.01) was observed, compared with a classical reduction in body
weight preceding the onset of clinical symptoms in CTR-Ab-treated
mice. In addition, ObR:Fc-treated mice showed very rapid reduc-
tion of body weight after d 10 and a rapid recovery after d 13 of
disease to a weight that was significantly higher than that of
CTR-Ab-treated mice (Fig. 4b and Table 2). On the contrary,
control mice showed a more stable body weight loss that was
maintained over the disease course (Fig. 4b and Table 2). Finally,
CNS inflammatory lesions were also significantly reduced in Ob-
R:Fc-treated mice (Table 2). A significant increase in TRegs was
observed on d 15 of the disease course in mice pretreated with
ObR:Fc (Table 2).
Discussion
In this report, we analyze the secretion of leptin in serum and CSF
of naı¨ve-to-treatment RRMS patients in correlation with the se-
cretion of IFN- in CSF and the percentage of circulating TRegs. The
data presented here provide evidence that a significant increase of
leptin secretion occurs in the acute phase of MS and that this event
positively correlates with the CSF production of IFN-. Increased
secretion is present in both the serum and CSF of RRMS patients
and determines the loss of correlation between leptin and BMI (Fig.
1 a and c). Moreover, the increase of leptin in the CSF is higher than
that in the serum (a 5.6-fold increase in CSF leptin vs. a 1.8-fold
increase in serum leptin, P  0.0001, Table 1), possibly secondary
to in situ synthesis of leptin in the CNS andor an increased
transport across the blood–brain barrier, upon enhanced systemic
production. Indeed, the CSF-leptinserum-leptin ratio, the CSF-
leptinserum-albumin ratio, and the CSF leptin index all signifi-
cantly increase in RRMS patients when compared with NIND
controls (Table 1).
Recently, gene-microarray analysis of Th-1 lymphocytes and
active MS lesions in humans revealed elevated transcripts of many
genes of the neuroimmunoendocrine axis, including leptin (19, 20).
Leptin’s transcript was also abundant in the gene-expression profile
of human Th-1 clones, demonstrating that the leptin gene is induced
in and associated with polarization toward Th-1 responses, com-
monly involved in T cell-mediated autoimmune diseases such as MS
(19, 20). We previously reported in situ leptin secretion by inflam-
matory T cells and macrophages in active EAE lesions (3). Here, we
show that autoreactive hMBP-specific T cells from RRMS patients
can produce immunoreactive leptin and up-regulate the leptin
receptor after activation (Fig. 2 a–f), possibly explaining, in part, the
increased in situ CSF leptin levels in RRMS patients. Interestingly,
both anti-leptin and anti-leptin-receptor blocking antibodies re-
duced the proliferative responses of hMBP-specific T cell lines (Fig.
2 h, j, and l), underscoring the possibilities of leptin-based inter-
vention on this autocrine loop.
Many questions need to be answered about whether and how
TRegs can regulate autoimmunity in humans. In animal models of
autoimmune diseases, the role of TRegs has been demonstrated (21).
More recently, a reduced function andor generation of TRegs in
human autoimmune diseases such as systemic lupus erythematosus,
type 1 diabetes, autoimmune polyglandular syndrome type II,
Fig. 4. Neutralization of leptin with ObR:Fc increases the number of TRegs
and ameliorates the clinical course of R-EAE. (a) Treatment of R-EAE-
susceptible SJLJ female mice with ObR:Fc induced a significant increase in the
circulating TRegs. *, P  0.01. (b) Mean clinical score (bars) and body weight
(curves) of SJLJ female mice pretreated with the ObR:Fc (white bars and
squares) or the CTR-Ab (black bars and squares) on d 1, d 0, and d 1 and
immunized with the PLP139–151 on d 0. Statistical analyses of these data are
summarized in Table 2. The data shown are from one representative experi-
ment of two (n  6 mice per group). *, P  0.01; **, P  0.002.
Table 2. Effect of pretreatment with soluble ObR:Fc chimera on neurological impairment and percentage of CD4CD25 during active
R-EAE induction with the PLP139-151 encephalitogenic peptide in SJLJ female mice
Group of mice Antigen
Incidence,
no.total (%)
Day of onset
(range)
Peak clinical
score
Average
CDI*
Percentage of initial
body weight at
disease peak
No. of
inflammatory
foci
Percentage of
CD4CD25
after
treatment
SJLJ CTR-Ab (d 1 to d1) PLP139–151 66 (100.0) 8.1  0.4 (8–9) 2.8  0.7 42.7  7.9 89.4  0.5 30.8  1.8 4.5  0.7
SJLJ ObR:Fc (d 1 to d1) PLP139–151 66 (100.0) 10.6  2.0 (8–13) 1.9  0.7† 21.8  5.3‡ 108.2  0.7‡ 15.0  1.5‡ 11.3  4.3†
The data shown are from one representative of two independent experiments shown in Fig. 4b. CTR-Ab, control Ab.
*Cumulative disease index, sum of daily scores determined for each mouse of that group and averaged.
†P  0.01.
‡P  0.002.
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juvenile idiopathic arthritis, and MS has been described in refs.
10–15. Recently, this reduction has been shown, in RRMS, to be a
functional defect of TRegs rather than a reduced number of TRegs in
the periphery (15). To address whether leptin secretion could have
an effect on TRegs in RRMS patients, we measured the TRegs
frequency in the peripheral blood of naı¨ve-to-treatment RRMS
patients selected on the basis of an increase in serum leptin to
2.5-fold higher than levels measured in NIND and healthy
controls. Here, we show that the average percentage and the
absolute number of TRegs in these RRMS patients were significantly
lower than those of healthy controls (Fig. 3a and Table 3). No
significant differences in CD3, CD4, CD8, CD19, and
CD3CD16CD56 cells were observed in either study group
(Table 3). In addition, our functional data confirmed that, in our
experimental conditions, RRMS patients showed a functional TRegs
defect, confirming findings previously reported in ref. 15 (Fig. 3d).
Administration of exogenous leptin to human TRegs or to suppres-
sion assays did not alter hyporesponsiveness and suppressive ca-
pacity (Fig. 5 a and b), suggesting that in vitro leptin is not
responsible for impaired TRegs function. Simple regression analysis
showed an inverse correlation between systemic leptin concentra-
tions and TRegs in the naı¨ve-to-treatment RRMS population (Fig. 3
b and c). These data demonstrate an inverse relationship between
leptin and TRegs in MS and may account for a reduced generation
of TRegs, at least early in the disease, in naı¨ve-to-treatment patients.
Indeed, we hypothesize that, after therapy, these phenomena may
be masked and overcome by therapy-induced effects. In fact, in the
case of chronic leptin deficiency, such as in obob mice, we found
an increased number of circulating TRegs, and similar results were
observed in dbdb mice. This finding was also confirmed by
experiments showing a higher recovery and percentage of TRegs
from R-EAE-susceptible SJLJ female mice treated with leptin-
blocking ObR:Fc (Fig. 4a). Also, this pretreatment subsequently
ameliorated R-EAE onset and progression (Fig. 4b and Table 2).
The fact that TRegs from dbdb mice had a similar suppressive
capacity and phenotype compared with TRegs from normal controls
(Fig. 6 a–d) suggests that leptin does not affect in vitro suppressive
function but, rather, in vivo expansionproliferation of TRegs. Fur-
ther studies need to address this point. Recent reports have shown
increased secretion of serum leptin before relapses in RRMS
patients during treatment with IFN- and the capacity of leptin to
enhance in vitro secretion of TNF-, IL-6, and IL-10 by peripheral
blood mononuclear cells of RRMS patients in the acute phase of
the disease but not in patients in the stable phase (22, 23). In view
of the above considerations, we suggest that, in MS, leptin may be
part of a wider scenario in which several proinflammatory soluble
factors may act in concert in driving the pathogenic (autoreactive)
Th-1 responses targeting neuroantigens (24). Recently, Hafler et al.
(15) reported a decrease in the effector function and cloning
frequency of TRegs from the peripheral blood of patients with MS.
We show here that, in naı¨ve-to-therapy MS patients, not only the
function but also the number of TRegs is affected, and, more
importantly, the finding inversely correlates with the concentration
of serum leptin. It appears therefore that, early in the disease, the
effects on TRegs in MS may be different from the effect observed
after therapy has been initiated. Regarding the correlation with
leptin, it is worth mentioning that strains of mice prone to the
spontaneous development of autoimmune diseases, such as nono-
bese-diabetic (NOD) and IL-2-deficient (IL-2/) mice, show re-
duced frequency of TRegs in the periphery (9) associated with
abnormal leptin responses due to increased serum leptin concen-
trations (disproportionate to fat mass) (25, 26). NOD mice have
higher basal serum leptin levels than normal age-, sex-, and
fat-matched controls (25). IL-2/ mice are prone to spontaneous
development of inflammatory bowel disease and other autoim-
mune disorders (26). Whereas in normal mice, serum leptin de-
creases with fat-mass loss, in IL-2/mice there is a paradoxical rise
in serum leptin compared with control mice, even after starvation,
which reduces serum leptin (26). These data support the hypothesis
that a disproportionate response in leptin secretion can correlate
with a reduction in the periphery of the TRegs compartment in these
two models.
Because of the influence of leptin on food intake and metabo-
lism, the findings reported here underscore the role of molecules at
the interface between metabolism and immunity in the control of
not only inflammation but also autoimmune reactivity (24, 27).
Recently, molecules with orexigenic activity, such as ghrelin and
neuropeptide Y (NPY), have been shown to mediate not only
effects opposite to those of leptin on the hypothalamic control of
food intake but also on peripheral immune responses (28, 29).
Indeed, ghrelin blocks the leptin-induced secretion of proinflam-
matory cytokines by human T cells (28), and NPY ameliorates the
clinical course and progression of EAE (29). Given these consid-
erations, we may envisage a situation in which the influences
exerted by several metabolic regulators, including leptin, might
broadly influence vital functions not limited to caloric tuning but,
rather, affecting immune responses and the interaction of the
individual with the environment. Although additional studies are
needed, our data provide direct evidence of a negative association
between leptin secretion and TRegs in the early stages of an
autoimmune disease characterized by Th-1 autoreactivity, such
as MS.
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To elucidate whether the role of leptin in regulating neuroendo-
crine and immune function during short-term starvation in healthy
humans is permissive, i.e., occurs only when circulating leptin
levels are below a critical threshold level, we studied seven
normal-weight women during a normoleptinemic-fed state and
two states of relative hypoleptinemia induced by 72-h fasting
during which we administered either placebo or recombinant
methionyl human leptin (r-metHuLeptin) in replacement doses.
Fasting for 72 h decreased leptin levels by 80% from a midphysi-
ologic (14.7  2.6 ngml) to a low-physiologic (2.8  0.3 ngml)
level. Administration of r-metHuLeptin during fasting fully re-
stored leptin to physiologic levels (28.8  2.0 ngml) and reversed
the fasting-associated decrease in overnight luteinizing hormone
pulse frequency but had no effect on fasting-induced changes in
thyroid-stimulating hormone pulsatility, thyroid and IGF-1 hor-
mone levels, hypothalamic–pituitary–adrenal and renin–aldoste-
rone activity. FSH and sex steroid levels were not altered. Short-
term reduction of leptin levels decreased the number of circulating
cells of the adaptive immune response, but r-metHuLeptin did not
have major effects on their number or in vitro function. Thus,
changes of leptin levels within the physiologic range have no major
physiologic effects in leptin-replete humans. Studies involving
more severe andor chronic leptin deficiency are needed to pre-
cisely define the lower limit of normal leptin levels for each of
leptin’s physiologic targets.
fasting  reproductive
Deficiency of the adipocyte-secreted hormone leptin (1) isassociated with distinct abnormalities in energy-demanding
processes such as neuroendocrine and immune function. Leptin-
deficient obob mice and humans with congenital complete leptin
deficiency have abnormal neuroendocrine function, including hy-
pogonadotropic hypogonadism, hypothalamic hypothyroidism,
andor growth-hormone-axis abnormalities (2–6) and impaired
cell-mediated immunity (4, 7), which are improved with leptin
replacement (4, 8). Similarly, starvation-induced decline of circu-
lating leptin to very low levels in normal mice (9) and lean men (10)
causes comparable neuroendocrine (9, 10) and immune defects (11,
12) that are significantly blunted or reversed with exogenous leptin.
We have shown that an 80% decline of leptin levels from 2 to
0.3 ngml in men mediates the fasting-induced suppression of
gonadotropin and thyroid-stimulating hormone (TSH) pulsatility as
well as sex steroid, insulin-like growth factor-1 (IGF-1), and thyroid
hormone levels (10). Importantly, although observational studies
have proposed that leptin regulates the hypothalamic–pituitary–
gonadal axis only when serum leptin levels fall below a ‘‘threshold’’
of 2 ngml (13), the role of decreasing leptin levels to approxi-
mately, but not below, this threshold in leptin-replete humans with
higher baseline leptin levels (e.g., normal-weight women) has not
yet been directly studied.
To elucidate whether such a threshold exists, below which leptin
has a ‘‘permissive’’ effect to regulate neuroendocrine and immune
function [including peripheral blood mononuclear cell (PBMC)
subpopulations, T cell proliferation, and cytokine production], we
assessed pituitary hormone pulsatility and hormone levels of sev-
eral neuroendocrine axes and markers of immune function in
normal-weight women during a normoleptinemic-fed condition
and two hypoleptinemic 72-h fasting states, with administration of
either placebo (to achieve a low leptin level close to the proposed
threshold) or recombinant methionyl human leptin (r-metHuLep-
tin) (to replace leptin to physiologic levels). To further investigate
the question of a threshold leptin level in regulating immune
function, we studied the effect of a range of leptin levels on T cell
proliferation in vitro.
Results
Seventy-Two-Hour Fasting Suppresses Serum Leptin Levels out of
Proportion to Changes in Body Weight and Fat Mass, and r-metHuLep-
tin Replacement Restores Leptin Levels Without Affecting Metabolic
Parameters. In the baseline fed state, body weight increased slightly
without significant changes in percent or total fat mass or fat-free
mass, whereas serum leptin levels and insulin levels increased, and
free fatty acid (FFA) levels decreased (Table 1). Complete fasting
for 72 h significantly decreased serum leptin levels to 20% of
baseline, out of proportion to the slight decreases in body weight
and fat mass (Table 1). Leptin pulsatility on the third day of fasting
was markedly suppressed (Fig. 1a) with loss of normal diurnal
variation and decreased 24-h mean levels (20.5  1.6 to 2.8  0.2
ngml), peak height (23.8  2.1 to 3.4  0.3 ngml), valley mean
(20.2 1.6 to 7.8 0.2 ngml), integrated area (29,286 2,354 to
3,997 277), and pulse mass (2.6 0.8 to 0.5 0.1) (all P 0.05
vs. fed) but not pulse frequency or interpulse interval. r-
metHuLeptin during fasting fully corrected the fasting-induced
suppression of leptin to levels that were higher than baseline but
within the physiological range for women (24-h mean: 42.4  4.0
ngml vs. trough level on day 4 at 8 a.m. in Table 1) (Fig. 1a). Similar
decreases in body weight and fat mass were observed as during
fasting alone, with a slightly greater decrease in fat-free mass with
r-metHuLeptin (Table 1). Resting metabolic rate was not affected
by fasting or r-metHuLeptin, and r-metHuLeptin did not alter
fasting-induced changes in insulin, respiratory quotient, or FFA
(Table 1).
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r-metHuLeptin Restores the Fasting-Induced Decline in Overnight
Luteinizing Hormone (LH) Pulse Frequency but Does Not Alter the
Suppression of TSH Pulsatility and IGF-1 Levels or Mild Activation of
the HPA Axis. Overnight LH peak frequency decreased significantly
during fasting (7.3 0.4 vs. 4.5 1.1 peaks per 12 h, P 0.05) and
was fully corrected with r-metHuLeptin (6.4  0.5 peaks per 12 h,
P  0.04 by ANOVA) (Table 2 and Fig. 1b). A similar trend that
did not reach statistical significance was observed for 24 h (see
Table 4, which is published as supporting information on the PNAS
web site) but not daytime (data not shown) LH pulsatility. There
were no changes in estradiol, follicle-stimulating hormone (FSH),
or testosterone with fasting or r-metHuLeptin (Table 1).
Thyroid hormones were stable at baseline (Table 1), and fre-
quently sampled TSH levels showed typical diurnal variation and
pulsatility (Fig. 3, which is published as supporting information on
the PNAS web site). Seventy-two-hour fasting significantly de-
creased free triiodothyronine (T3), increased reverse T3, and
markedly suppressed several parameters of TSH pulsatility,
whereas free thyroxine remained stable. r-metHuLeptin did not
alter these fasting-induced changes of the thyroid axis (Fig. 3 and
Tables 1 and 2).
IGF-1 decreased by 40% after 72-h fasting alone and with
r-metHuLeptin, with similar findings in IGF-binding protein 3
(IGF-BP3) (Table 1). Neither serum cortisol levels nor adrenocor-
ticotropic hormone (ACTH) pulsatility were altered by fasting or
r-metHuLeptin (Tables 1 and 2). However, there was an overall
significant difference in 24-h urine cortisol, with higher levels in
both fasting states vs. the fed state (P  0.03 for fed vs. fasting).
Plasma renin activity (PRA) and aldosterone tended to increase
with fasting but with no effect of r-metHuLeptin (Table 1). There
was an overall significant change for PRA and aldosterone but no
significance by post hoc tests or change from days 1 to 4. Twenty-
four-hour urine sodium (Table 1), nitrogen, and volume (data not
shown) were not affected by fasting or r-metHuLeptin.
Seventy-Two-Hour Fasting Reduces the Number of Cells of the Adap-
tive Immune Response, but r-metHuLeptin Has Minimal Effects to
Restore Their Number with No Effect on Innate Immunity or in Vitro
T Cell Function. Acute starvation resulted in a decline of total CD3
T lymphocytes by 838  268 cells per mm3 (461  344 after
adjustment for controls) (P 0.04 for days 1 vs. 4). r-metHuLeptin
during fasting blunted this decline to 302  185 cells per mm3
Table 1. Weight, body composition, resting metabolic rate (RMR), and hormone levels at the beginning (Day 1) and end (Day 4) of a
fed state (n  7), 72-h fasting with placebo (n  6), and 72-h fasting with r-metHuLeptin (n  7) mean  SE
Baseline fed state (n  7) Fasting  placebo (n  6) Fasting  leptin (n  7)
Overall
P
Baseline
PDay 1 Day 4 Day 1 Day 4 Day 1 Day 4
Weight, kg 57.0  2.3 58.0  2.2* 56.9  3.1 55.4  2.8* 56.2  2.2 54.1  2.0* 0.01†‡§ 0.61
Fat mass, % 29.9  1.5 30.0  1.4 31.2  1.9 29.3  2.2* 30.0  1.6 29.1  1.9 0.07†‡ 0.85
Fat mass, kg 17.2  1.3 17.3  1.2 18.0  1.9 16.4  1.8* 17.0  1.4 15.9  1.5* 0.01†‡§ 0.45
Fat-free mass, kg 39.9  1.4 40.7  1.7 38.9  1.6 39.0  1.6 39.2  1.3 38.2  1.3* 0.03†‡¶ 0.68
RMR, kcald 1,267  40 1,259  36 1,285  82 1,352  43 1,330  52 1,344  34 0.26 0.12
Respiratory quotient 0.87  0.03 0.91  0.01 0.88  0.02 0.74  0.01* 0.88  0.03 0.72  0.01* 0.01†‡§ 0.83
Leptin, ngml 11.4  1.6 16.7  1.2* 14.7  2.6 2.8  0.3* 12.2  1.6 28.8  2.0* 0.002†‡§¶ 0.85
Insulin, IUml 6.72  1.21 9.28  1.51* 6.06  0.81 1.22  0.24* 7.91  1.54 1.23  0.30* 0.01†‡§ 0.85
FFA, mmoll 0.07  0.01 0.04  0.00* 0.05  0.01 0.94  0.16* 0.04  0.01 0.83  0.08* 0.01†‡§ 0.08
Estradiol, pgml 57.0  12.1 64.5  11.3 60.9  13.1 66.1  27.2 61.2  11.1 52.8  10.2 0.31 0.61
FSH, mIUml 6.00  0.61 5.39  0.90 5.83  0.47 4.92  0.51 5.81  0.44 5.66  0.69 0.22 0.85
Testosterone, ngdl 74.6  11.8 74.2  10.9 78.5  11.9 68.5  9.8 66.4  8.1 67.6  7.1 0.85 0.61
fT3, pgml 2.81  0.10 2.60  0.08 2.98  0.17 1.66  0.11* 2.78  0.16 1.69  0.08* 0.01†‡§ 0.68
Reverse T3, ngdl 15.0  0.7 12.4  1.0* 16.9  2.3 33.5  3.7* 15.8  0.9 34.1  2.0* 0.01†‡§ 0.61
Free T4, ngdl 1.19  0.07 1.12  0.06 1.22  0.09 1.18  0.08 1.17  0.08 1.17  0.08 0.83 0.54
IGF-1, ngml 265.3  17.1 346.9  24.5* 260.8  19.5 162.2  12.5* 239.3  25.3 147.6  10.7* 0.01†‡§ 0.31
IGF-BP3, gml 4.78  0.11 5.11  0.22* 4.94  0.14 4.22  0.33 4.66  0.25 4.06  0.21* 0.04†‡§ 0.51
Cortisol, gdl 16.9  3.4 16.7  3.1 17.5  0.9 17.6  3.0 16.9  1.9 14.5  2.1 0.51 0.85
PRA, ngmlhr 4.16  0.71 2.28  0.75 2.45  0.80 6.03  2.42 6.50  3.18 9.42  2.52 0.03 0.22
Aldosterone, pgml 60.0  11.7 38.4  3.0 66.0  12.8 112.1  23.5 66.1  11.7 132.6  27.0 0.01†‡§ 1.0
24-hr urine cortisol, g 19.6  1.9 28.6  3.3 25.0  2.5 0.03‡ —
24-hr urine sodium, mEq 195.4  26.4 167.8  9.9 153.2  24.6 0.51 —
Overall P value for comparison of change from day 1 to day 4 and baseline P value for comparison of day 1 values across the three conditions by nonparametric
ANOVA *, P  0.05 vs. Day 1; †, P  0.05 by one-way ANOVA; ‡, P  0.05 for fed vs. fasting  placebo; §, P  0.05 for fed vs. fasting  r-metHuLeptin; ¶, P 
0.05 for fasting  placebo vs. fasting  r-metHuLeptin.
Fig. 1. Twenty-four-hour profile (8 a.m.–8 p.m.) of average (n 7) leptin (a)
and representative LH (b) levels on day 3 of a baseline fed state (Top), 72-h
fasting with placebo (Middle), or 72-h fasting with replacement-dose r-
metHuLeptin (Bottom).
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(201  350 adjusted) (P  0.14 for days 1 vs. 4). The decline in
CD3 T lymphocytes was greater during 72-h fasting alone vs. with
r-metHuLeptin (P 0.04) although not different after adjustment
for controls (P  0.50). We found similar findings in CD4 and
CD8 T lymphocytes and CD19 B lymphocytes, with greater
declines during 72-h fasting alone vs. with r-metHuLeptin, although
the differences were not statistically significant (Table 3 and Table
5, which is published as supporting information on the PNAS web
site). Naı¨ve and memory CD3, CD4, and CD8 subpopulations
decreased more with fasting than with r-metHuLeptin during
fasting, although these differences were not significant after ad-
justment for controls, except an increase in naı¨ve CD8CD45RA
cells with r-metHuLeptin vs. decrease during fasting (Tables 3 and
5). Decreases in PBMCS were not due to nonspecific factors,
because CD3CD16CD56 natural killer (NK) cells, represent-
ing innate immunity, increased slightly with fasting. The prolifer-
ative response of T cells to several polyclonal stimuli decreased after
72-h fasting but was not significantly different from fasting with
r-metHuLeptin (OKT3,19,246 5,251 vs.8,217 14,773 cpm,
P 0.47; PHA,36,214 11,808 vs.25,823 10,362 cpm, P
0.72; PMAIono,31,545 20,328 vs.4,829 18,050 cpm, P
0.47; PPD, 445  4,620 vs. 4,125  4,843 cpm, P  0.72).
Stimulated cytokine (IFN-, IL-10, and IL-4) production by PB-
MCs did not change with 72-h fasting or r-metHuLeptin, nor did
serum glucose levels (data not shown).
Changes in IGF-1 Correlate with Changes in Several PBMC Subpopu-
lations in Response to 72-h Fasting Alone and with r-metHuLeptin. To
evaluate whether changes in PBMC subpopulations are related to
changes in hormones known to be affected by fasting andor leptin,
we analyzed the correlation between changes in PBMC subpopu-
lations with changes in hormones relevant to immune function,
including leptin, insulin, FFA, estradiol, FSH, testosterone, free T3,
free thyroxine, IGF-1, IGF-BP3, and cortisol. The most significant
correlations were observed for IGF-1, and borderline significant
correlations were noted for free T3 (see Table 6, which is published
as supporting information on the PNAS web site). Correlations with
other hormones were not significant after adjustment for controls
(data not shown).
Complete Leptin Depletion from Human Serum or Neutralization in
Culture Medium Significantly Impairs in Vitro T Cell Proliferation and
Is Reversible with Leptin Replacement. We then investigated whether
the lack of major changes in PBMC proliferation and cytokine
production may have been due to the continued presence of leptin
at physiological levels despite being suppressed to20% of baseline
(2.8 0.3 ngml), i.e., above a putative threshold level for immune
function. T cells were first stimulated with OKT3, PHA, or PMA
Iono in 5% human serum, which corresponds to a leptin level of1
ngml. In contrast to the lack of effect of 72-h fasting (with leptin
level 2.8 ngml) on T cell function, complete removal of leptin
from serum with anti-human leptin Ab dramatically suppressed the
proliferative response to essentially no proliferation (Fig. 2 a–c).
Specificity of the system was confirmed by adding recombinant
human leptin back to leptin-depleted serum, which restored pro-
liferation to a level comparable with that in the basal state. The
restoration of proliferation was less efficient with PMAIono
compared with OKT3 and PHA and was reachable in all conditions
only with high doses of leptin (ranging from 50 to 100 ngml). To
further dissect the role of leptin present in culture medium on T cell
proliferation, we added anti-leptin neutralizing Abs to culture
medium during mixed lymphocyte reactions, which inhibited T cell
proliferation between 45% and 60% compared with medium alone
or control Ab, suggesting that leptin levels above a certain threshold
are necessary for sustaining in vitro T cell proliferation (Fig. 2d).
Discussion
Maintenance of normal neuroendocrine and immune function
depends critically on the availability of adequate energy stores.
Evidence from animal and human models supports a central role
for leptin as a signal of energy sufficiency and mediator of the
adaptation to starvation (9, 10, 14). Congenital complete leptin
deficiency (3–5) or acute hypoleptinemia to 1 ngml in leptin-
replete humans induces changes in reproductive, thyroid, and IGF
axes (10) and immune function (12), whereas increasing serum
Table 2. Pulsatility characteristics (mean  SE) of frequently
sampled (every 15 minutes) overnight LH (8 p.m.–8 a.m.) and
24-h TSH and ACTH (8 a.m.–8 a.m.) on day 3 of a baseline fed
state (n  7), 72-h fasting with placebo (P) (n  6), or 72-h
fasting with r-metHuLeptin (RL) (n  7)
Fed Fast  P Fast  RL P
Overnight LH,
IUliter
Mean level 10.57  2.59 7.61  0.58 11.51  2.76 0.31
Peak frequency 7.29  0.42 4.50  1.06 6.43  0.48 0.04*†
Peak interval 80.86  6.94 119.51  20.54 95.91  12.18 0.07
Peak width 50.15  3.98 91.20  28.61 66.96  11.09 0.35
Peak height 13.31  3.21 10.44  1.00 15.00  3.48 0.82
Valley frequency 8.00  0.31 5.50  1.06 7.14  0.59 0.047†
Valley mean level 9.37  2.24 6.28  0.84 10.30  2.69 0.31
Integrated area 7,462  1830 5,358  428 8,101  1940 0.31
Pulse mass 1.35  0.37 4.01  2.15 2.35  0.49 0.07
TSH, IUml
Mean level 1.42  0.20 0.35  0.08 0.51  0.07 0.006*†‡
Peak frequency 8.29  0.68 11.33  0.92 9.57  0.87 0.048†
Peak interval 151.1  11.4 114.8  10.8 141.4  12.6 0.006†
Peak width 105.25  11.5 68.18  4.16 86.49  11.26 0.042†
Peak height 1.75  0.28 0.41  0.08 0.59  0.08 0.006*†‡
Valley frequency 9.14  0.70 11.67  0.88 9.71  0.87 0.013†
Valley mean level 1.25  0.20 0.32  0.07 0.46  0.06 0.006*†‡
Integrated area 2,005  283 495  109 728  98 0.006*†‡
Pulse mass 0.65  0.14 0.04  0.02 0.13  0.04 0.050*†‡
ACTH, pgml
Mean level 10.48  1.28 9.89  2.01 9.33  1.23 0.31
Peak frequency 9.57  1.07 12.17  0.87 10.14  0.70 0.17
Peak interval 139.6  15.2 105.3  5.4 123.7  5.6 0.51
Peak width 88.87  11.13 67.63  4.92 83.39  6.35 0.61
Peak height 13.52  1.74 13.51  3.09 12.70  1.92 0.14
Valley frequency 10.14  1.06 12.50  0.67 10.57  0.75 0.54
Valley mean level 8.71  1.12 8.74  1.75 7.79  0.93 0.07
Integrated area 14,703  1856 14,029  2846 12,915  1,760 0.07
Pulse mass 6.17  0.86 4.22  2.82 2.85  0.76 0.25
P value for nonparametric ANOVA across the three conditions. *, P  0.05
by one-way ANOVA; †, P  0.05 for fed vs. fasting  placebo; ‡, P  0.05 for
fed vs. fasting  r-metHuLeptin.
Table 3. Change in PBMC subpopulations (mean  SE) from days
1 to 4 of 72-h fasting with placebo or replacement-dose
r-metHuLeptin (n  5)
PBMC
subpopulation
Actual Adjusted for controls
Fasting
 placebo
Fasting
 leptin
Fasting
 placebo
Fasting
 leptin
CD3 838  268† 302  185* 461  344 201  350
CD4 534  184† 247  138 327  246 139  273
CD8 257  77† 57  52 128  93 43  88
CD3CD45RA 443  124† 134  134 197  188 14  243
CD3CD45RO 396  177 168  85 274  175 215  152
CD4CD45RA 234  76† 149  72 126  104 71  151
CD4CD45RO 300  119† 98  74* 201  143 68  129
CD8CD45RA 209  78† 15  72 71  98 85  104*
CD8CD45RO 96  111 70  6 73  74 147  67
CD19 152  51† 82  24 86  69 71  70
CD3CD16CD56 80  27 91  34† 27  26 56  53
*, P  0.05 vs. fasting alone; †, P  0.05 vs. day 1.
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leptin levels to 2–3 ngml with r-metHuLeptin corrects, fully or
in part, these abnormalities (4, 10). However, whether a critical
leptin threshold of3 ngml exists, above which leptin has no major
additional physiological effect on neuroendocrine andor immune
function, has been proposed based on observational studies (13) but
not yet tested in an interventional fashion.
We studied women who have substantially higher baseline leptin
levels than lean men. Although 72-h fasting results in a similar
percent decline of leptin levels as in men (15–20% of baseline),
the absolute levels achieved are 10-fold higher (2.8 ngml) (13).
Leptin levels after r-metHuLeptin (28.8 ngml) were higher than
baseline, but remained well within the physiologic range and below
levels (400–4,000 ngml) achieved with pharmacologic dosing
(15, 16). Decreasing serum leptin levels to 2.8 ngml and increasing
leptin back to a high physiologic range had only modest effects on
LH pulsatility and did not substantially alter any other neuroen-
docrine or immune parameter. This alteration in levels also had no
statistically significant effect on metabolic variables. Larger, longer-
term studies are needed to more fully elucidate this finding.
The unique aspect of this study lies in the in vivo exploration of
decreasing leptin from mid- to low-physiologic levels but not to the
extremely low levels of severe leptin deficiency (10). Previous leptin
administration data in congenital (4) and lipoatrophic (17) leptin-
deficient subjects and leptin-replete subjects with short-term rela-
tive leptin deficiency (10) or 10% reduced body weight (18) suggest
that a leptin level of 2–3 ngml appears to be necessary for the
regulation of neuroendocrine axes (particularly the hypothalamic–
pituitary–gonadal axis). Importantly, these data provide insight
into the ‘‘normal range’’ of leptin levels, an issue of considerable
diagnostic and therapeutic importance when r-metHuLeptin gains
a place in the therapeutic armamentarium. Our findings are
consistent with the existence of a threshold leptin level for regu-
lation of neuroendocrine and immune function, whereas an upper
limit to leptin’s effect on metabolic parameters may exist (i.e., leptin
resistance). Given the pleiotropic nature of leptin and the com-
plexity of the leptin system, it remains to be determined whether
different thresholds exist for other physiological functions influ-
enced by leptin andor whether differences in populations with
varying degrees or duration of leptin deficiency exist.
We studied women in the midfollicular phase of their menstrual
cycles, an important time for development of dominant follicles.
Decreasing leptin to low-physiologic levels decreased overnight LH
pulse frequency only modestly by 40% but not other pulsatility
parameters, FSH, or sex steroid levels. This finding stands in distinct
contrast to r-metHuLeptin’s ability to (i) restore several LH pul-
satility parameters and the 40% decline in testosterone with the
same duration but greater magnitude of fasting-induced hypolep-
tinemia in lean men (10) and (ii) normalize LH pulsatility and
ovulatory cycles in women with hypothalamic amenorrhea and
chronic leptin deficiency (14). Although follicle development was
not directly evaluated, the maintenance of normal menstrual cycles
argues against substantial disruption of follicular growth and ovu-
lation. Interestingly, normal-weight women have decreased LH
pulse frequency during short-term starvation despite maintaining
ovulatory cycles in several (19, 20) but not all (21–23) studies. Partial
restoration of leptin levels with r-metHuLeptin during 4-day fasting
was associated with a decrease in overnight LH pulses in normal-
weight women, but fed-state leptin levels were not reached (23).
Potential effects of r-metHuLeptin may have been obscured by
interindividual differences, which our study and others (19, 20, 24,
25) have minimized by studying the same subjects under different
conditions at the same times of their menstrual cycles.
It has been suggested that LH pulsatility is disrupted at a
threshold of energy availability deep in negative energy balance
(26). Low energy availability, but not the stress of exercise alone,
suppressed leptin rhythm (27) and altered LH pulsatility (26) in
eumenorrheic, sedentary women. Similarly, 72-h fasting disrupted
follicle growth and lengthened the follicular phase in lean women
with body fat 20% (24), but not in normal-weight women with
body fat similar to that of our subjects (27%) (25). Taken
together, these studies suggest that lean women with lower leptin
levels may be more vulnerable to energy deficit than normal-weight
women. Thus, evaluation of very lean women during short-term
starvation may provide insights into the relative contribution of a
critical leptin level vs. duration of hypoleptinemia.
In this study, 72-h fasting caused marked suppression of TSH
pulsatility, decrease in free T3, and increase in reverse T3. Humans
with complete functional leptin deficiency due to defects in the
leptin or leptin-receptor gene have altered TSH pulsatility (28) or
central hypothyroidism (6). In small, uncontrolled studies, r-
metHuLeptin increased free thyroxine and free T3 levels in leptin-
deficient children (4) and reversed the decrease in thyroid hor-
mones in subjects during weight loss (18). Although normalizing
leptin from very low levels (0.2 ngml) blunted the fasting-
induced suppression of TSH pulsatility in lean men (10), increasing
leptin from 2.8 to 28.8 ngml had no effect on TSH pulsatility
in women. We propose that these differences in TSH pulsatility may
be related to a threshold leptin level similar to that for the
hypothalamic–pituitary–gonadal axis.
Short-term fasting decreased IGF-1 levels with no effect of
r-metHuLeptin and no major alterations in IGF-BP3. We have
shown that r-metHuLeptin in fasting men modestly blunted the
starvation-induced decrease in IGF-1 levels (10) and increased
IGF-1 and IGF-BP3 levels over 2–3 mo in leptin-deficient women
with hypothalamic amenorrhea (14). In congenital leptin-deficient
humans, r-metHuLeptin for 18 mo increased IGF-BP1 and IGF-
BP2 but not IGF-1 or IGF-BP3 (5). Thus, although the role of leptin
in regulating IGF-1 requires further study, the above observations
suggest that leptin may need to decrease below a certain level for
IGF-1 to decrease because of leptin deficiency.
We found mild activation of the HPA axis with 72-h fasting but
no effect of r-metHuLeptin. Leptin-deficient humans have elevated
basal cortisol and ACTH levels and disturbed diurnal rhythm (3),
and long-term r-metHuLeptin in three leptin-deficient adults in-
Fig. 2. Leptin depletion or neutralization inhibits polyclonal T cell prolifer-
ation and mixed lymphocyte reactions (MLR), respectively. (a–c)The prolifer-
ative response of T lymphocytes to polyclonal stimuli (OKT3, PHA, and PMA
Iono) from controls is completely inhibited in medium with human serum
depleted of leptin. Addition of recombinant human leptin (at 100 ngml final
concentration) completely reverses this phenomenon. (d) Anti-leptin blocking
Abs partially inhibit the antigen-specific proliferative response of T cells
during MLR. HS, human serum.
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creased cortisol levels, but these studies were uncontrolled (5). In
healthy humans, regulation of the HPA axis appears to be inde-
pendent of leptin (10) in contrast to leptin’s reversal of starvation-
induced HPA activation in mice (9). We report herein a lack of
change in ACTH pulsatility in response to r-metHuLeptin. Al-
though observational human studies have shown an inverse rela-
tionship between pulsatility of ACTH and cortisol with that of
leptin (29), our interventional studies do not support a direct role
for leptin in regulating the HPA axis; whether pulsatile or longer
duration of r-metHuLeptin is required remains to be studied.
Consistent with our prior findings (10), fasting-induced changes in
PRA and aldosterone appear to be independent of leptin.
In this study, acute starvation in leptin-replete humans deter-
mines a specific change in peripheral lymphocyte distribution that
differentially affects the number of circulating cells of the adaptive
and innate immune response. Restoration of leptin levels had no
major effect on fasting-induced changes in immunophenotypes,
except for naı¨ve CD8CD45RA cells, indicating that decreasing
leptin levels to2.8 ngml has a minor role in mediating the effects
of short-term starvation on PBMCs. Similarly, the in vitro prolif-
erative and cytokine-producing capacity of T cells was not affected,
suggesting that this degree of short-term leptin deficiency disrupts
immune function only minimally, i.e., induces partial changes in
immune cell distribution but no impairment of T cell proliferation
against classical polyclonal and recall antigens.
Leptin reverses the immunosuppression associated with 48-h
starvation in normal mice (8, 11), increases thymic or splenic
cellularity in leptin-deficient obob mice (8), and, by using a similar
protocol for acquiring PBMCs and analyzing immune function,
improves severely impaired T cell function in children with con-
genital leptin deficiency (4). Thus, our findings highlight the
contrast between short-term mild and long-term severe leptin
deficiency on immune function. Relative leptin deficiency after
leptin withdrawal in mice depleted of fat after high-dose leptin
administration reduces thymic and splenic cellularity (30). The
bioequivalence of 48-h starvation in mice is likely closer to a few
weeks in humans, and, thus, 72-h fasting in humans may be
insufficient for substantial alterations in immune function to occur,
but further studies are needed to clarify this role of leptin over a
wider range of leptin levels. This robustness of the immune system
is consistent with evidence that acute starvation does not affect
susceptibility to infectious diseases, whereas more long-term star-
vation profoundly alters inflammatory immune responses and
infectious disease susceptibility in mice and humans (31). Indeed,
both anorexic and malnourished subjects (particularly those with
protein energy malnutrition) have impaired T cell-mediated im-
mune responses and very low leptin levels (31).
We studied T cell function in vitro to differentiate between
insufficient duration vs. degree of hypoleptinemia and found a
striking reduction of T cell proliferation to polyclonal stimuli when
leptin was absent from culture medium that was fully restored when
leptin was added back at low doses. Importantly, the use of
autologous serum in the in vivo immune studies preserves the
existing environment of the cells and avoids introducing exogenous,
confounding factors. The lack of change in serum glucose levels,
verified viability of immune cells, and observed proliferative re-
sponse argue against a substantial change in metabolic environment
due to shipment, because T cells become anergic in low-glucose
settings (32).
The simultaneous assessment of neuroendocrine and immune
function in this paradigm provides a unique opportunity to inves-
tigate whether leptin regulation of immune function may be me-
diated in part by leptin-associated changes of hormones that
influence immune function. We observed a significant correlation
between IGF-1 and PBMC subpopulations. The IGF-1 receptor is
expressed on immune cell types including activated T cells, B cells,
NK cells, and monocytes and exerts effects on T cells and antigen-
presenting cells (33), supporting the notion that IGF-1 may have
immunomodulatory effects. Importantly, we did not find any
correlation with cortisol, similar to the mouse model of acute leptin
deficiency after leptin withdrawal (30). Correlations cannot prove
causality and must be interpreted with caution in cross-sectional
analysis. Further clinical and mechanistic investigations into the
role of these hormones acting alone or in concert with leptin to
affect immune function are needed.
In summary, our findings suggest that leptin serves a permis-
sive role in regulating neuroendocrine and immune function.
Given the beneficial effect of leptin replacement in ameliorating
these defects in more severe andor chronic leptin deficiency, we
propose that, similar to other hormone deficiency syndromes, a
leptin-deficiency syndrome exists. The lower limit of normal
leptin levels appears to be3 ngml (by using the assay reported
herein), but the exact normal range remains to be defined
precisely. Neuroendocrine alterations during more chronic rel-
ative hypoleptinemia in the setting of obesity (e.g., during weight
loss) may involve different physiological mechanisms and adap-
tations. Whether changes of another putative factor are respon-
sible for leptin-independent changes that occur when leptin
remains above this threshold, andor whether duration or an
interaction of degree and duration of hypoleptinemia are im-
portant remains to be studied.
Methods
Study Design. This protocol was approved by our Institutional
Review Board, and clinical quality r-metHuLeptin (Amgen, Thou-
sand Oaks, CA) was administered under an Investigational New
Drug application to the Food and Drug Administration. All sub-
jects were healthy without immunologic or endocrine disease based
on examination and routine blood tests. Seven women (age 
22.4  1.2 yr) with body mass index 25 kgm2 and regular
menstrual cycles (length 26–32 days) not on oral contraceptives for
at least 6 mo participated in three separate studies in our General
Clinical Research Center: a baseline isocaloric fed state as de-
scribed in ref. 10 and two 72-h fasting studies scheduled in random
order in double-blind fashion with administration of r-metHuLep-
tin (dose 0.08 mgkgday on day 1, increased to 0.2 mgkgday on
days 2–3 to account for declining leptin levels with additional
fasting, divided into 4 equal doses given s.c. every 6 h, starting at
8 a.m. on day 1), during one fasting study, or placebo (same
schedule and volume as the corresponding r-metHuLeptin dose),
during the other fasting study. Each subject completed three
studies, separated by at least 8 wk to permit recovery of hematocrit,
leptin levels, and weight to baseline, except one subject for the
fastingplacebo study. For each subject, the frequent sampling was
matched to a cycle day within 2 days of the cycle day of the other
two frequent sampling studies and within menstrual cycle days
6–11. During fasting studies, subjects ate a snack the night before
day 1 and then had only calorie-free liquids and daily multivitamin,
NaCl (500 mg), and KCl (40 meq) until 10 a.m. on day 4. Leptin,
insulin, FFA, estradiol, FSH, testosterone, free T3, reverse T3, free
thyroxine, IGF-1, IGF-BP3, cortisol, PRA, and aldosterone were
measured at 8 a.m. on days 1 and 4 and 24-h urine cortisol, sodium,
and urea nitrogen on day 3. Starting at 8 a.m. on day 3, blood
samples for leptin, LH, TSH, and ACTH were drawn every 15 min
for 24 h through an indwelling peripheral i.v. line. At 8–9 a.m. on
days 1 and 4, resting metabolic rate (DeltaTrac II Metabolic
Monitor; SensorMedics) and body composition (bioelectric imped-
ance analysis; RJL Systems, Clinton Township, MI) were measured.
For five consecutive subjects completing both fasting studies, a
blood sample obtained at 8 a.m. on days 1 and 4 of the fasting
studies was shipped to Naples, Italy, by express courier to be
processed within 48–72 h for immune assays along with a blood
sample from a matched healthy, nonsmoker, fed control to account
for any potential external effects. Processing of PBMCs within this
time frame assures their viability, according to standard immunol-
ogy procedures (34) and verified by our extensive studies in healthy
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controls and leptin-deficient subjects using a similar shipment
protocol (4). As described in ref. 10, hormone levels were run in
duplicate by using standard immunoassays and within the same run
for a given subject, and the program CLUSTER 8.0 was used to
characterize leptin, LH, TSH, and ACTH pulsatility.
Immunophenotypic Analysis, T Cell Proliferation, and Cytokine Pro-
duction. Viability of cells was verified at 85–95% by using trypan
blue staining and annexin-5 binding during flow cytometry, and
serum glucose levels were measured as a marker of metabolic
activity. Immunophenotypic analysis of peripheral blood (see Sup-
porting Materials and Methods, which is published as supporting
information on the PNAS web site) and T cell cultures in medium
supplemented with 5% (volvol) autologous serum were per-
formed as described (4). Cell culture supernatants (100 l) were
removed 48–60 h after stimulation and frozen at 80°C until
assayed for IFN-, IL-4, and IL-10 (PharMingen).
In Vitro Leptin Neutralization and Depletion of Leptin from Human
Serum. Mixed lymphocyte reactions were performed on isolated
PBMCs (stimulator cells) and their corresponding HLA-
mismatched irradiated (30-Gy) stimulators in the absence and
presence of purified polyclonal rabbit anti-human leptin Ab (anti-
hOb, 10–20 gml; provided by Radek Sokol, BioVendor, Brno,
Czech Republic) with affinity-purified rabbit polyclonal IgG as a
control. Responder and stimulator cells were cultured for 5 days in
RPMI medium 1640, supplemented with 5% human AB serum
(Sigma) at a 1:1 ratio. For leptin depletion from serum, a protein
G-Sepharose affinity column (Amersham Pharmacia) was used
after adhesion on G protein of a polyclonal rabbit anti-human leptin
Ab (BioVendor). Human AB serum was passed through the
columns three times and collected. Anti-human leptin-specific
ELISA and Western blotting to measure the serum content of
leptin indicated that the amount of leptin was below the assay
detection limit after depletion. Human recombinant leptin (R & D
System) was used to verify specificity.
Statistical Analysis. Data (mean SE) were analyzed by using SPSS
8.0 (SPSS, Chicago). Changes of variables from days 1 to 4 were
compared by using Wilcoxon signed-rank paired tests or with
nonparametric ANOVA with post hoc tests by least-significant
difference across the three conditions. Immune data were adjusted
for controls by subtracting the change in a parameter for the
matched control from that for the subject, and data were analyzed
by absolute values as well as adjusted for controls. P  0.05 was
considered significant. Bivariate Spearman correlation analyses
were performed on changes in hormone levels and PBMC sub-
populations from days 1 to 4, and P  0.01 was considered
significant to correct for multiple comparisons.
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Abstract: The white adipose tissue (WAT) represents the most important structure of the organism able to provide energy
stores and heat insulation. Recently, its has been postulated that the adipose tissue can be considered as a complex, essen-
tial, and highly active metabolic and endocrine organ. Indeed, it is able to respond to different signals from the endocrine
organs and from the nervous the immune systems. More recently, the adipose tissue has also been hypothesised to repre-
sent an “extension” of the immune system, for its capacity to contain immune cells, lymph nodes, thymus, but above all,
for its ability to produce a series of cytokines and chemokines typical of the immune system (generally named adipoki-
nes). A better understanding of the immune and endocrine function of the adipose tissue will lead to the development of
innovative therapeutic strategies in inflammatory disorders.
INTRODUCTION
The classical view of the adipose tissue as a static reser-
voir of lipids necessary in time of reduced food availability
in the environment, is no longer valid. Today, adipocytes
have been shown to be able to secrete hormones and cytoki-
nes both necessary for the endocrine and immune function
[1]. This has induced a series of novel hypothesis on the role
of the adipose tissue as a key regulator of the immune func-
tion and to consider as a secondary “immune organ” [2].
Indeed, it is well-known that immune cells such as lympho-
cytes and monocytes/macrophages are present in the adipose
tissue and also, the capacity of adipocytes to secrete a huge
number of cytokines, chemokines, and factors classically
considered of immune origin [1, 2]. Here, is presented an
overview of the immune functions of adipose tissue. These
functions may be divided into two broad categories: 1) se-
creted products that have a classical metabolic effects on
important immune functions; 2) homing of the immune cells
in classical sites embedded in abundant adipose tissues such
as the bone marrow, thymus and lymph nodes.
LEPTIN, ADIPOSE TISSUE AND IMMUNITY
Several recent observations show that leptin is a hor-
mone/cytokine that is involved in the immune-
neuroendocrine crosstalk and functions as a key signal, cou-
pling the metabolic axis to the immune system [3]. Leptin,
the product of the obese gene, is a 167-aminoacid peptide
hormone mainly synthesised by adipocytes, that regulates-
body weight by stimulating energy expenditure through in-
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creased thermogenesis and by suppressing food intake [4]. In
addition, leptin is sexually dimorphic, its serum concentra-
tion being higher in females than in males with similar body
fat mass. Leptin belongs structurally to the family of long-
chain helical cytokines and has a similarity with interleukin-
6 (IL-6), IL-12, IL-15, granulocyte colony-stimulating factor
(G-CSF), oncostatin M (OSM), prolactin and growth hor-
mone [4]. The similarity of both functions, as a hormone and
as a cytokine, reinforces the concept that leptin links the en-
docrine to the immune system [3, 4]. The effects of leptin are
mediated by the long form receptor, known as OBRb, that is
a member of the class I cytokine receptor family. This form
is expressed by hypothalamus in areas that are responsible
for secretion of neuropeptides and neurotransmitters regu-
lating appetite. In addition to the long form of OBRb, there
are alternatively spliced forms, named short forms, that seem
to mediate the transport and degradation of leptin [3, 4]. The
wide tissue distribution of OBRb, expressed by the ovary,
pancreatic b cells, endothelial cells, CD34+ haematopoietic
bone-marrow precursors, monocytes/macrophages, T and B
cells, suggests a pleiotropic effect of leptin on the nutritional
status, metabolism and neuroimmunoendocrine axis [3, 4].
In recent years, a number of studies has investigated the
effect of leptin on innate and adaptive immune responses;
specifically, leptin can promote the activation of mono-
cytes/macrophages, chemotaxis and activation of neutrophils
as well as the development and activation of natural killer
cells, regulating in this way the innate immune response [3].
The modulation of adaptive immune response by leptin is
shown by increasing the expression of adhesion molecules
on CD4+T cells, promoting proliferation and secretion of IL-
2 by naïve CD4+T cells, increasing the production of inter-
feron-g (IFN-g) by memory T cells, with little effect on pro-
liferation. Similarly to other pro-inflammatory cytokines, it
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has been shown that leptin promotes T helper 1 (Th1)–cell
differentiation, and can modulate the onset and progression
of autoimmune responses in several animal models of dis-
ease [3]. These effects of leptin on the immune response
modulation have been shown in leptin-deficient (ob/ob) mice
and humans, with congenital deficiency of leptin, in which
both metabolic disturbances and immune abnormalities, in-
cluding decreasing inflammatory cytokine secretion and
thymic hypotrophy have been observed. These abnormalities
are reversed by the administration of recombinant leptin in
both mice and humans. Also, the possible involvement of
leptin in autoimmunity has been shown in studies on ob/ob
mice protected against several experimental autoimmune
diseases and the administration of exogenous leptin to
autoimmune disease genotypically susceptible mice, antici-
pates the onset and accelerates the progression of autoim-
mune responses [3]. The functional inhibition of the leptin
axis could be considered as a possible novel therapeutic ap-
proach in conditions of increased leptin secretion such as
autoimmune disorders and chronic inflammation. In this
context, it is important to note that leptin could contribute to
atherosclerosis and to increased risk of cardiovascular disor-
ders in overweight and obese individuals. Indeed, leptin be-
ing secreted in proportion to body fat, its high concentrations
in overweight individuals could, at least in part, contribute to
the low-grade chronic inflammatory condition observed in
obese subjects [5]. Obese subjects show also higher c-
reactive protein (CRP), IL-6, IL-8, and TNF-a , all cytokines
promoting inflammation [5]. These factors in conjunction
with increased leptin may contribute to the increased endo-
thelial activation and secretion of inflammatory mediators
and cardiovascular disorders in obese subjects. Approaches
aimed at reducing leptin secretion (i.e. diet low caloric diet)
are already employed in the treatment of atherosclerosis.
Future strategies able to neutralise leptin action with mono-
clonal antibodies could be also considered as novel thera-
peutic approaches [5].
CLASSICAL CYTOKINES, CHEMOKINES AND
HORMONES IN ADIPOSE TISSUE
Cytokines are proteic messengers important in the ho-
meostasis and function of immune cells [6]. They are classi-
cally secreted by lymphocytes, macrophages and antigen
presenting cells (APCs) such as dendritic cells (DCs). Re-
cently, it has been shown that also other tissues such as liver,
epithelial cells, and neural cells are also an important source
of cytokines responsible of the acute phase response. More
Fig. (1). Adipose tissue as immune and endocrine organ.
Adipocytes are able to secrete cytokines and hormones that participate of the immune response and metabolism.
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recently, it has been shown that adipocytes are also impor-
tant producers of cytokines such as: IFN- g , TNF-a , trans-
forming growth factor- b  (TGF- b ), leukaemia inhibiting fac-
tor (LIF), IL-1, IL-6, IL-8, and chemokines, such as mono-
cyte chemotactic protein-1 (MCP-1) and macrophage in-
flammatory protein-1 (MIP-1) [1].
In addition to adipokines, several cytokines exert their
action in both immune and metabolic pathways. One of such
cytokines is IL-1, which consists of two molecular forms -
IL-1a  and IL-1b,  and is produced by mono-
cytes/macrophages, epithelial, endothelial, and glial cells [7].
IL-1 is a major mediator of inflammation induced in the
brain during fever. IL-1 effects on metabolism include in-
duction of anorexia, and also inhibition of the synthesis of
fatty acids and adipocytes differentiation [7]. Moreover, IL-1
can act as a hypoglycaemic agent, suggesting an anti-diabetic
role for IL-1. Interestingly, IL-1 also promotes release of
neuropeptides important in both energy homeostasis and
immune function such as the corticotropin releasing hormone
(CRH), melanocortins, and a -melanocyte stimulating hor-
mone (a -MSH). Within the IL-1 gene family, is also in-
cluded the IL-1 receptor antagonist (IL-1Ra), which binds
IL-1 receptors without agonistic activity [7, 8]. IL-1Ra-
deficient mice show growth retardation, are lean, resistant to
high-fat-diet-induced obesity, and have reduced lipoprotein
lipase (LPL) activity and low serum insulin [7, 8].
IL-6 is another important cytokine involved in the regu-
lation of energy status and innate and adaptive immunity.
Structurally, IL-6 belongs to the long-helical cytokine family
and mainly regulates B cell development, antibody produc-
tion, haematopoiesis and adipocyte/metabolic function. In
non-inflammatory conditions, IL-6 is largely produced by
the adipose tissue and the circulating levels of IL-6 correlate
with body mass index (similarly to leptin), insulin sensitivity
and glucose tolerance [9]. Both IL-6 and leptin can exert
inhibitory feedback on the body fat mass by acting directly
on hypothalamic nuclei that express their respective recep-
tors, and high doses of IL-6 increase triglycerides and glu-
cose levels. Interestingly, IL-6-deficient mice develop ma-
ture onset obesity and decreased glucose tolerance, produce
reduced amounts of inflammatory cytokines, and are resis-
tant to autoimmune diseases such as EAE and arthritis [10,
11].
TNF- a  and IFN-g are two cytokines pivotal for the host
defence from infections and for the development of Th1 re-
sponses, and are involved as well in the pathogenesis of
autoimmune diseases such as multiple sclerosis, rheumatoid
arthritis and type-1 diabetes [6, 12-15]. TNF- a  is secreted by
activated macrophages and by adipocytes and can affect adi-
pogenesis via its action on the phosphorylation (and func-
tional inhibition) of the peroxisome proliferator-activated
receptor-g  (PPAR- g ) [12, 13]. TNF- a  can also augment
lipolysis and adipocyte apoptosis. A role of TNF- a  in the
insulin resistance in obesity is suggested by the finding that
patients with insulin resistance have increased levels of
TNF- a,  and by the observation that TNF-a -deficient mice
are protected from obesity-induced insulin resistance [12,
13]. Regarding IFN-g , it seems that, in addition to its im-
mune functions, this cytokine may play a central role during
hypermetabolic and anorectic responses associated with in-
flammation, as IFN-g -receptor-deficient mice are protected
from LPS-induced anorexia [14, 15].
Another adipokine capable to significantly influence en-
ergy balance and T cell immunity is the proteic hormone
insulin [16]. Insulin enhances uptake of nutrients - thus rais-
ing the levels of intermediary cellular metabolism, while
promoting lymphocyte activation, T cell responsiveness and
cytokines action. Since insulin increases energy requirements
and protein synthesis, which are necessary for appropriate T
cell function, defects of insulin action (in conditions such as
insulin resistance, type 1 and type 2 diabetes) result in inap-
propriate immune responses [16]. Moreover, during hyper-
glycaemia and ketoacidosis, insulin promotes secretion of
inflammatory cytokines and favours T cell activation. Al-
though resting T cells are devoid of insulin receptors, these
receptors become expressed on T cells after activation with
antigens or mitogens. After binding to its receptor on acti-
vated T cells, insulin exerts its classical effects such as
stimulation of glucose uptake and oxidation, amino acid
transport, lipid metabolism, and protein synthesis [16].
GLUCOSE, AMINO ACID, LIPID METABOLISM
AND IMMUNE RESPONSE
Recently it has been shown that not simply the secretion
of common mediators at the interface between metabolism
and immune response are able to affect T cell function but
also the glycidic, amino acidic and lipid metabolic response
within T cells and APCs is able to profoundly affect the out-
come of the immune response [2].
Indeed, a rapid and sustained increase of metabolism is
required to support proliferation, differentiation, and effector
functions of T cells. Access to nutrients via increased ex-
pression of glucose transporters (GLUTs) and activation of
glycolysis is an important means by which costimulatory
receptors can stimulate T cell growth [2, 17]. Not surpris-
ingly, several glycidic and amino acid intracellular pathways
have recently been found crucial for T cell function and for
the induction of tolerance/anergy. More specifically, it has
been found that glucose metabolism has important implica-
tions on T cell activation and proliferation through the CD28
costimulation. It is well documented that T cells increase
glucose uptake and glycolysis during an immune response
via the CD28 costimulatory molecule, which recruits
phosphstidylinositol-3’-kinase (PI3K) and Akt, suggesting
that CD28 favours the glycolytic flux, thus providing T cells
with their energetic, biosynthetic and metabolic needs [2,
17]. Similarities exist between the signalling pathways
downstream of the insulin receptor and CD28. In particular,
stimulation of CD28 promotes glucose uptake, glycolysis,
and expression of glucose transporters (GLUT1), which de-
pend on PI3K activity [2, 17]. These findings suggest that
CD28 may be associated with regulation of glucose utilisa-
tion as well, and that CD28 might influence T cell activation
and metabolism similarly to the insulin receptor.
Another metabolic event that significantly affects T cell
responses and tolerance is the catabolism of the essential
aminoacid tryptophan. Mammals have an intracellular heme-
containing enzyme - indoleamine 2,3-dioxygenase (IDO),
which catalyses the oxidative catabolism of tryptophan. IDO
is expressed at basal levels in the thymus, gut, lung, and the
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maternal-foetal interface, and becomes upregulated during
infection and inflammation [18]. The role of IDO in the sup-
pression of microbial infections has long been acknowledged
for the ability of this enzyme to reduce availability of trypto-
phan to infected tissues, with resulting deprivation of an es-
sential aminoacid to cells and thus resolution of inflamma-
tion. More recently, IDO has been shown capable to induce
T cell hyporesponsiveness, by reducing available free tryp-
tophan to T cells. T cells are sensitive to tryptophan depriva-
tion specifically during the G0-S transition phase of the cell
cycle. T cell cycle arrest clearly prevents clonal expansion
and may determine cell death by apoptosis and/or tolerance
(ignorance, anergy, immune deviation, and/or generation of
regulatory T cells) [18]. Interesting work by Munn and
Mellor has suggested that cells expressing IDO during preg-
nancy can regulate T cell immunity during pregnancy and
that placental cells synthesising IDO may protect the foetus
from maternal immune alloreactivity. Indeed, blockade of
tryptophan catabolism during pregnancy enables maternal T
cells to reject the foetus as an allograft. The effects of the
IDO could be relevant in a myriad of other conditions. IDO-
induced depletion of tryptophan could determine reduced
growth of viruses, bacteria and parasites but also of prolif-
eration of T cells. Tryptophan catabolism and IDO upregula-
tion could consume anion superoxide, thus clearing inflam-
matory sites from free radicals, while degradation of tryp-
tamine, serotonin and melatonin would induce changes in the
neuroendocrine function. Moreover, tryptophan is the pre-
cursor of kynurenines, which are produced by IDO for the
transcriptional control of IFN-g  [18]. These molecules could
be relevant in immune homeostasis because of the central
role of IFN- g  and its regulation in cell-mediated immunity
and in the resolution of infections. Immunoac-
tive/neuroactive kynurenines also affect immune and neu-
ronal homeostasis by controlling apoptosis of T cells and
neurotoxicity, respectively. In addition to tryptophan, also
arginine metabolism is crucial for a correct immune response
particularly in protection from infections and the control of
the immune response [19, 20]. More specifically, it has been
shown that L-arginine is metabolised by immune cells by
two enzymes: the nitric oxide synthase (NOS), which oxi-
dises L-arginine in two steps that generate nitric oxide (NO)
and citrulline; and arginase, which converts L-arginine into
urea and L-ornithine [19, 20]. Separate genes encode three
different isoforms of NOS in mammalian cells: NOS1 and
NOS3 are constitutively expressed in neuronal tissue and
endothelium, respectively, and NOS2, the inducible form of
NOS, is expressed in multiple tissues and cell types, includ-
ing vascular endothelium, DCs and macrophages [19, 20].
Induction of NOS2 is controlled mainly by Th1 cytokines,
such as IFN- g  and TNF- a . The enzymatic activity of NOS2
is sustained over a long period of time, enabling the produc-
tion of 1000-fold higher amounts of NO than those produced
by NOS1 and NOS3. Two distinct isoforms of arginase, en-
coded by two genes, are found in mammalian cells: type I
arginase (Arg1), a cytosolic enzyme expressed at high levels
in the liver as a component of the urea cycle, and type II ar-
ginase (Arg2), a mitochondrial enzyme expressed at lower
levels in kidney, brain, small intestine and mammary gland,
with limited expression in liver [19, 20]. Both isoforms are
expressed in murine macrophages: Arg1 is induced by Th2
cytokines including IL-4, IL-13, TGF-b  and IL-10, whereas
Arg2 is induced by lipopolysaccharide (LPS), and intact
bacteria. Discrepancies have been reported on the ability of
LPS to induce Arg1, which probably reflect the use of either
macrophage-like cell lines or primary cultured macrophages.
The activity of NOS is regulated by cytokines and microbial
products [19, 20]. It is important in protection from infec-
tions on one side and for the induction of tolerance on the
other. Indeed, NO secretion is important for protection from
mycobacterium tuberculosis infection; and depletion of ar-
ginine from the milieu together with induction of peroxyni-
trites generated by NOS2 cause activated T cells to undergo
apoptosis. Therefore, metabolism of arginine is crucial also
in the control of T cell tolerance, particularly for the myeloid
suppressor cells (MSCs), able to control and block T cell
activation [19, 20].
Finally, as previously mentioned, also lipid metabolism
plays a relevant role in the control of the immune response
and resistance to infections [21]. Of particular interest are the
liver X receptors (LXRs). More specifically, the nuclear re-
ceptors LXRa and LXRb are important regulators of the bile
acid synthesis in the liver and regulate the cholesterol ab-
sorption in the intestine. The physiological activators for the
LXRs include oxysterols and intermediates in the cholesterol
biosynthetic pathway [21]. In the monocyte/macrophage cell
lineage, the scavenger receptor-mediated uptake of oxidised
lipoproteins leads to the transcriptional activation of LXRs
and induction of genes such as apoE, that enhances choles-
terol removal form cells. Both forms of LXRs are expressed
at high levels in macrophages, and their activation activates
cholesterol efflux, indicating that the function in lipid me-
tabolism is crucial. Macrophages are key cells of the innate
and adaptive immune response. The function of LXRs in this
context is not very clear. More recently, it has been shown
that the LXR-dependent gene expression profile impacts
macrophage function in setting of bacterial infection. Indeed,
mice lacking the LXRs are highly susceptible to bacterial
infection such as Listeria Monocytogenes (LM) [21]. Par-
ticularly, LXR-null macrophages undergo accelerated apop-
tosis when challenged with LM and exhibit reduced bacterial
clearance in vivo. These data suggest that the LXR-
dependent gene expression plays an unexpected role in in-
nate immunity and suggest that common nuclear receptor
pathways mediate macrophage responses to modified lipo-
proteins and intracellular pathogens. Together with previous
work, these results position LXRs at the crossroads of lipid
metabolism and innate immunity. These observations have
implications for the pharmaceutical control of inflammation
and the pathogenesis of atherosclerosis; however, the role of
such crosstalk in normal physiology remains to be clarified.
Therefore, drug compounds able to interfere with such bio-
chemical pathways may have a large impact on both inflam-
mation and infection susceptibility [21].
HIV INFECTION AND HAART AS MODEL FOR
BIDIRECTIONAL COMMUNICATION BETWEEN
IMMUNITY AND METABOLISM
HIV infection is associated with qualitative and quantita-
tive defects of CD4+ T cells. AIDS patients show a progres-
sive decline in the CD4+ T cell subset with a marked reduc-
tion of naïve T cells in peripheral blood. In addition, the re-
duction of CD4+ T cells is associated with a progressive dis-
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ruption of the T cell receptor (TCR)-Vb  repertoire. Several
hypotheses have been proposed to explain these phenomena,
such as the reduced thymic output of T lymphocytes, clonal
anergy, increase of T cell apoptosis and trapping of activated
cells in lymphoid tissues [22].
Highly active antiretroviral therapy (HAART) represents
the most effective current approach to control HIV infection.
A decrease of viral load with an improvement in immu-
nological parameters and a decrease of opportunistic infec-
tions are well documented [22]. Despite these effects,
HAART is still unable to fully reconstitute the immune sys-
tem or to reduce drastically the HIV reservoir. Indeed, it is
possible to observe a significant reduction in the viral load
not associated with an optimal immune-reconstitution char-
acterised by a significant increase in the CD4+ T cell count.
These patients are defined as “discordants”, and represent a
relevant clinical problem due to their increased susceptibility
to opportunistic infections.
Leptin, the adipocyte-derived hormone, represents a key
factor for the regulation of food intake, reproduction and
basal metabolism [3, 4]. It is also an acute-phase reactant
raised during infections and reduced by starvation. Recently,
it has been shown that leptin can modulate T cell function in
vitro and in vivo . In vitro it increases proliferation and IL-2
secretion by CD4+ naive (CD45RA+) T cells and enhances
IFN- g  production by CD4+ memory (CD45RO+) T lympho-
cytes. The leptin-induced pattern of cytokines is classical of
the T helper 1 (Th1) pro-inflammatory immune response
with consequent suppression of the Th2 regulatory cytokines
such as IL-4 [3, 4]. Furthermore, leptin is also able to reverse
the immunodepression associated with acute starvation and
provides protection from starvation-induced lymphoid and
thymic atrophy. HIV-induced lymphoid atrophy resembles
that observed in malnourished individuals with reduced adi-
pose tissue and leptin levels. HIV patients show low adipos-
ity with consequent low leptin levels. The failure of increase
in production of leptin during the infections suggests that an
impairment of the leptin response is present during the early
phases of the HIV infection [3, 4]. More recently, it has been
shown that in a group of HIV+ children there is an increase
in serum leptin during HAART [23]. Interestingly, the leptin
levels were increased only in the patient s with a significant
increase in CD4+ T cells. Conversely, in patients in which
leptin did not change during HAART, low number of CD4+
T lymphocytes was observed [23]. The effects of leptin on
the secretion of pro-inflammatory cytokines by memory T
cells, its ability to expand naive T cells and its capacity to
restore thymic function during starvation make leptin an at-
tractive candidate for augmenting the immune-reconstitution
in patients during HAART [23].
HAART has been associated with the development of
lipodystrophy, changes in fat distribution, dyslipidaemia,
insulin resistance and diabetes. These effects have been for
long considered side-effects of HAART being associated
with and increased cardiovascular risk. It is clear that
HAART has important effects on adipose tissue metabolism
and function. Considering adipose tissue as an important
metabolic and immune organ, which plays a role in synthe-
sizing and secreting a number of hormones and cytokines, it
is important to understand whether or not the therapeutic
action of HAART is only to be ascribed to the anti-HIV rep-
licative capacity or also to the metabolic action on secretion
of hormones and cytokines from the adipose tissue. The
study of this specific aspect of the HIV infection will be of
impact to understand the bidirectional communication be-
tween immunity and metabolism.
CONCLUDING REMARKS
There are still many questions concerning the role of sev-
eral molecules at the interface between metabolism and im-
mune regulation [2]. Significant leaps of knowledge have
been done in the recent years; thanks to the expanding re-
search on such molecules. While new information is unveil-
ing complex networks that intimately connect metabolism
and immunity, further research is needed. Nonetheless, these
new acquisitions have prompted us to no longer regard the
adipose tissue as a mere store of body fat but rather as an
active participant in the regulation of essential body proc-
esses such as the immune homeostasis. From this evidence,
the development of novel therapeutic targets is sure to
emerge in the near future.
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BACKGROUND
A single family has been described in which obesity results from a mutation in the 
leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-
onset obesity has not been systematically examined.
METHODS
We sequenced LEPR in 300 subjects with hyperphagia and severe early-onset obesity, 
including 90 probands from consanguineous families, and investigated the extent to 
which mutations cosegregated with obesity and affected receptor function. We evalu-
ated metabolic, endocrine, and immune function in probands and affected relatives.
RESULTS
Of the 300 subjects, 8 (3%) had nonsense or missense LEPR mutations — 7 were ho-
mozygotes, and 1 was a compound heterozygote. All missense mutations resulted in 
impaired receptor signaling. Affected subjects were characterized by hyperphagia, 
severe obesity, alterations in immune function, and delayed puberty due to hypogo-
nadotropic hypogonadism. Serum leptin levels were within the range predicted by 
the elevated fat mass in these subjects. Their clinical features were less severe than 
those of subjects with congenital leptin deficiency.
CONCLUSIONS
The prevalence of pathogenic LEPR mutations in a cohort of subjects with severe, early-
onset obesity was 3%. Circulating levels of leptin were not disproportionately elevat-
ed, suggesting that serum leptin cannot be used as a marker for leptin-receptor defi-
ciency. Congenital leptin-receptor deficiency should be considered in the differential 
diagnosis in any child with hyperphagia and severe obesity in the absence of devel-
opmental delay or dysmorphism.
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T he assessment of patients with se-vere early-onset obesity conventionally in-cludes screening for potentially treatable 
neurologic and endocrine conditions and identi-
fying known genetic conditions so that appropri-
ate genetic counseling and, in some cases, treat-
ment can be instituted.1 Classically, patients with 
genetic obesity syndromes have been identified in 
childhood as a result of associated mental retarda-
tion and developmental abnormalities.2 However, 
several monogenic disorders have been identified 
in which obesity itself is the predominant present-
ing feature. These disorders result from disruption 
of the hypothalamic leptin–melanocortin signaling 
pathway.3-8
Twelve subjects with congenital leptin defi-
ciency due to loss-of-function mutations in the 
gene encoding leptin have been identified3,4,9,10 
(and unpublished data). Characteristic features in-
clude hyperphagia, obesity, hypogonadism, and 
impaired T-cell–mediated immunity. Treatment 
with recombinant human leptin reverses all as-
pects of the phenotype.9,11,12 So far, only one mu-
tation in the leptin-receptor gene (LEPR) has been 
reported, in three severely obese adult siblings 
from a consanguineous family of Algerian origin.5 
This mutation results in abnormal splicing of 
leptin-receptor transcripts and generates a mutant 
leptin receptor that lacks both transmembrane and 
intracellular domains. The mutant receptor circu-
lates at high concentrations, binding leptin and 
resulting in very elevated serum leptin levels.13 To 
determine the prevalence of pathogenic mutations 
in LEPR in severely obese patients, we studied 300 
subjects with severe, early-onset obesity.
Me thods
Subjects
When we began the study, the Genetics of Obesity 
Study (GOOS) cohort consisted of 2100 unrelated 
probands with severe obesity of early onset (before 
10 years of age); severe obesity was defined as a 
standard-deviation score for the body-mass index 
(BMI) (the weight in kilograms divided by the 
square of the height in meters) of more than 3. We 
calculated BMI standard-deviation scores using ref-
erence data from the U.K. population.14 The mean 
(±SD) score in the GOOS cohort is 4.2±0.8. Of the 
2100 subjects, 1800 were reported to have a history 
of hyperphagia. Of these 1800 subjects, 300 were 
selected to determine the prevalence of leptin-
receptor mutations: all 90 subjects in the GOOS 
cohort from consanguineous families, as well as 
210 additional subjects who were impartially se-
lected. The mean BMI standard-deviation score 
for the group screened was 4.5±1.2. Mutations in 
known obesity genes were ruled out with the use 
of biochemical analysis (mutant leptin and prohor-
mone convertase 1 genes) and direct nucleotide 
sequencing (of the genes encoding pro-opiomela-
nocortin and the melanocortin 4 receptor [MC4R]); 
there were no mutations in additional candidate 
genes for obesity (SIM1, NHLH2, CPE, MCHR1, and 
MCHR2).
Subjects with mutations in LEPR and their rela-
tives were invited to participate in clinical studies 
at the Wellcome Trust Clinical Research Facility at 
Addenbrooke’s Hospital, Cambridge, United King-
dom. All studies were approved by the Anglia and 
Oxford multiregional ethics committee and the 
local–regional ethics committee of Cambridge. 
Each subject, or his or her parent if the subject was 
a child younger than 16 years, provided written 
informed consent; the minors provided oral con-
sent. All clinical studies were conducted in accor-
dance with the principles of the Declaration of 
Helsinki.
In adults, overweight and obesity were defined 
according to the World Health Organization cri-
teria: a BMI of 25.0 to 29.9 and a BMI of 30.0 or 
higher, respectively. Because there are no interna-
tionally recognized definitions of overweight and 
obesity in persons under 18 years of age, we used 
criteria proposed by the International Obesity Task 
Force and supported by a recent International Con-
sensus on Childhood Obesity15: an age-adjusted 
BMI above the 91st percentile and an age-adjusted 
BMI above the 99th percentile, respectively.
Detection of Mutations and Genotyping
Genomic DNA was isolated from leukocytes de-
rived from whole blood, and the coding region of 
the LEPR gene was amplified with the use of the 
polymerase chain reaction and was then sequenced 
(see the Supplementary Appendix, available with 
the full text of this article at www.nejm.org). We 
also sequenced LEPR in impartially selected non-
obese control subjects: 100 alleles from each of 
three population-derived cohorts — of white Eu-
ropean origin,16 of South Asian origin,17 and of 
Turkish origin.18 (See the Supplementary Appen-
dix for details of our studies of mutant-receptor 
function.)
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Body Composition, Growth,  
and Energy Balance
We used anthropometric methods and whole-body 
dual-energy x-ray absorptiometry (DPX software, 
Lunar) to determine body composition, as previ-
ously described.8,11 We measured resting metabolic 
rate using indirect calorimetry after a 12-hour over-
night fast and using an open-circuit, ventilated, 
canopy measurement system (Europa Gas Exchange 
Monitor, Nutren Technology). After adjustment for 
body composition, the resting metabolic rate was 
compared with that predicted by age- and sex-spe-
cific equations.19,20 Semiquantitative assessment of 
eating behavior was undertaken in subjects young-
er than 18 years, as previously described.8,9
Metabolic and Endocrine Studies
Fasting blood samples were analyzed for levels of 
leptin, glucose, insulin, thyrotropin, free thyroxine, 
insulin-like growth factor 1 (IGF-1), follicle-stim-
ulating hormone, luteinizing hormone, estradi-
ol, and testosterone, with the use of standard as-
says.11
Lymphocyte Count and Function
Lymphocytes were isolated from fresh whole blood, 
and cell phenotypes were measured by cytofluo-
rometric (fluorescence-activated cell-sorting) analy-
sis, as reported previously.9 Proliferative responses 
to antigenic stimuli were measured.9 Lymphocyte 
counts and proliferative responses in subjects with 
leptin-receptor deficiency were compared with 
those in 46 control subjects matched for age (from 
8 years to adult).
Statistical Analysis
Clinical data are expressed as means ±SD. Differ-
ences between groups were compared with use of 
the unpaired Student’s t-test. All reported P values 
are from two-sided tests, and P values of less than 
0.05 were considered to indicate statistical signif-
icance.
R esult s
Detection of Mutations and Family Studies
We identified five nonsense and four missense mu-
tations in 8 of the 300 probands (Table 1 and Fig. 
1A). Seven probands were homozygous for such 
mutations, and one proband (Subject 1 in Family 
8) was a compound heterozygote for a missense 
mutation (R612H) and a nonsense mutation. None 
of these mutations were found in alleles from con-
trol subjects. Six of the probands were from con-
sanguineous families (Fig. 2A). In three pedigrees 
(Families 1, 2, and 4), additional homozygous fam-
ily members were identified, all of whom had se-
vere, early-onset obesity (Fig. 2A).
Functional Analysis of Mutant Receptors
All frame-shift mutations occurred in the N-termi-
nal domain of the leptin receptor and were pre-
Table 1. Leptin-Receptor Mutations in Subjects with Severe Early-Onset Obesity.
Mutation
Family  
No.
No. of  
Affected Subjects Race or Ethnic Group*
Homozygous frame-shift
4-bp deletion in codon 22 1 3 (1 deceased) Bangladeshi
11-bp deletion in codon 70 2 2 Turkish
66-bp deletion in codon 514 3 1 (deceased) Iranian
Homozygous nonsense
W31X 4 3 Southern European
Homozygous missense
A409E 5 1 Turkish
W664R 6 1 Norwegian
H684P 7 1 White (United Kingdom)
Compound heterozygous
1-bp deletion in codon 15 and R612H 8 1 White (United Kingdom)
* Race or ethnic group was assigned by the physician.
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dicted to result in the loss of all leptin-receptor iso-
forms. We examined the signaling properties of 
receptors with missense mutations (Fig. 1B). Three 
of the missense mutations (A409E, W664R, and 
H684P) resulted in a complete loss of signaling, as 
measured by leptin-stimulated phosphorylation of 
signal transducer and activator of transcription 3 
(STAT3). The other missense mutation, R612H, en-
codes receptors with some residual ability to phos-
phorylate STAT3 in response to leptin (Fig. 1B).
Clinical Phenotype of Leptin-Receptor 
Deficiency
We studied the clinical phenotype of leptin-recep-
tor deficiency in 10 subjects (6 probands and 4 af-
fected relatives) with early-onset obesity who were 
homozygous for complete loss-of-function muta-
tions in LEPR. All 10 had become obese in early 
childhood; at the time of study, 4 were adults and 
6 were children. We compared their phenotype 
with that of five subjects with congenital leptin de-
ficiency and with that of five subjects who were 
homozygous for complete loss-of-function muta-
tions in MC4R, whom we had studied previously 
using identical protocols8,9 (and unpublished data).
Body Composition and Energy Balance
In all cases, the body weight of subjects with LEPR 
mutations deviated from predicted percentiles 
within the first year of life (data not shown). The 
mean BMI standard-deviation score for these sub-
jects was 5.1±1.6, as compared with 6.8±2.1 for 
subjects with congenital leptin deficiency (P = 0.005) 
and 5.0±1.5 for MC4R-deficient subjects. The mean 
percentage of body fat among homozygous car-
riers of LEPR mutations was high (52.8±3.2; nor-
mal range, 15 to 25) and was similar to that in the 
subjects with congenital leptin deficiency (mean, 
58.0±3.5) but higher than that in the subjects lack-
ing MC4R (45.2±3.3; P<0.001) (Fig. 3B). The per-
centage of lean mass was lower in subjects with 
Figure 1. Mutations in the Leptin-Receptor Gene  
(Panel A) and in Vitro Function of the Leptin-Receptor 
Mutant Constructs (Panel B).
Panel A shows the positions of the identified muta-
tions in the leptin receptor. We observed homozygous 
mutations in seven severely obese probands; in an 
eighth (Subject 1 in Family 8, a compound heterozy-
gote), we observed a nonsense mutation and a mis-
sense mutation (asterisks). Amino acid numbers are 
shown on the left-hand side. Panel B shows the induc-
tion of the phosphorylation of signal transducer and 
activator of transcription 3 (STAT3) by wild-type and 
mutant leptin receptors in the absence (minus signs) 
and presence (plus signs) of recombinant human 
leptin. The control construct was an empty pcDNA3 
vector.
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LEPR mutations than in equally obese subjects 
without such mutations, although the actual 
amount of lean mass in kilograms for each sub-
ject was within the age-related normal range21,22 
(data not shown).
All subjects had a history of increased food-
seeking behavior in childhood, which continued 
into later life in the adult subjects. During an ad 
libitum test meal, the probands with LEPR muta-
tions consumed almost three times the amount of 
energy that control subjects consumed (Fig. 3C). 
This increased intake was similar to that of sub-
jects lacking MC4R but considerably less than that 
of subjects with congenital leptin deficiency. The 
basal metabolic rate was greater in leptin-recep-
tor–deficient, obese subjects than in subjects of 
normal weight, as one would expect. However, the 
basal metabolic rate is usually adjusted for lean 
mass (in kilograms) to allow for differences in 
body weight (and thus lean mass) among subjects. 
The adjusted basal metabolic rate per kilogram of 
lean mass in the subjects with LEPR mutations was 
similar to that predicted for persons with this body 
composition on the basis of accepted age- and sex-
specific calculations23 (see Fig. 1A in the Supple-
mentary Appendix).
Metabolic and Endocrine Function
Most of the subjects with LEPR mutations had nor-
mal glucose concentrations (Table 2), although the 
two oldest adults (Subjects 1 and 2 in Family 4) had 
type 2 diabetes, which was managed with oral hy-
poglycemic medication. All subjects had hyperin-
sulinemia (Table 2) to a degree consistent with the 
degree of obesity (see Fig. 1B in the Supplementary 
Appendix).
In childhood, linear growth was normal, and 
the standard-deviation scores for height of chil-
dren with LEPR mutations (Table 2) were similar 
to those of equally obese children without LEPR 
mutations.8 Serum levels of IGF-1 were appropriate 
for the age of the children (Table 2), and growth 
hormone was secreted in a pulsatile fashion (data 
not shown). However, final height was reduced in 
adults with LEPR mutations, owing to the lack of 
a pubertal growth spurt. This is reflected in the 
short statures of the 15-year-old male subject with 
a standard-deviation score for height of −1.7 and 
the four female subjects with a score of −2.0 
(Table 2).
All four adults (all of whom were female) had 
clinical evidence of hypogonadism, with lack of a 
pubertal growth spurt and reduced expression of 
secondary sexual characteristics; three had no 
menses until after 20 years of age. The 18-year-old 
female (Subject 1 in Family 2) and the 15-year-old 
male (Subject 2 in Family 2), both of whom were 
clinically prepubertal, had low sex-steroid levels 
and low follicle-stimulating hormone and lutein-
izing hormone levels, indicative of hypogonad-
otropic hypogonadism. In addition, Subject 2 in 
Family 1 had a complete loss of luteinizing hor-
mone pulsatility (see Fig. 1C in the Supplementary 
Appendix). Notably, the females who were 31, 41, 
and 55 years of age had irregular menses after the 
age of 20 years and had estradiol, luteinizing hor-
mone, and follicle-stimulating hormone levels that 
were consistent with their age. Free thyroxine and 
thyrotropin levels were within the normal range 
in all subjects (Table 2).
Serum leptin levels in subjects with LEPR mu-
tations (Table 2) were similar to those in equally 
obese subjects with a normal leptin-receptor gene 
sequence (Fig. 3D). Serum leptin levels correlat-
ed with the fat mass in subjects with LEPR muta-
tions and in age- and BMI-matched subjects (see 
Fig. 1D in the Supplementary Appendix).
Immune Function
All the children with LEPR mutations had more fre-
quent childhood infections (predominantly of the 
upper respiratory tract) than did their siblings with 
wild-type LEPR. The premature deaths of two obese 
children in these families were associated with 
acute respiratory tract infections. Since our group 
previously found that leptin-deficient subjects have 
a marked reduction in the CD4+ T-cell count and 
reduced T-cell proliferation,9 we analyzed the im-
munophenotype and T-cell responses in subjects 
with LEPR mutations and compared these data with 
those of age-matched control subjects. We observed 
a modest reduction in the absolute CD4+ T-cell 
counts in the leptin-receptor–deficient subjects 
(mean, 988±186 cells per cubic millimeter; 42± 
13%), as compared with those in control subjects 
(mean, 1100±892 cells per cubic millimeter; 44± 
7%), although the CD4+:CD8+ ratios were simi-
lar (2±2 and 2±1). However, leptin-receptor–defi-
cient subjects had a significant compensatory in-
crease in the CD19+ cell (B-cell) count (mean, 460± 
238 cells per cubic millimeter; 18±6%) as compared 
with control subjects (mean, 280±328 cells per cu-
bic millimeter; 11±3%) (P = 0.006). T cells from 
subjects with LEPR mutations showed reduced pro-
Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UC SHARED JOURNAL COLLECTION on October 29, 2007 . 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 356;3 www.nejm.org january 18, 2007242
liferative responses to a variety of polyclonal stim-
uli specific to T cells, such as muromonab-CD3 
(OKT3), phytohemagglutinin, phorbol myristate 
acetate (PMA) or ionomycin (Iono), and the recall 
antigen purified protein derivative (PPD) (see Fig. 
1E in the Supplementary Appendix). The cytokine 
pattern of the subjects with leptin-receptor defi-
ciency was less impaired than that of the leptin-
deficient subjects, with only a modest reduction 
in secretion of the proinflammatory cytokine in-
terferon-γ as compared with age-matched con-
trols — especially during OKT3 and PMA/Iono 
stimulation — and increased secretion of the in-
hibitory cytokine interleukin-10 during stimula-
tion with purified protein derivative (see Fig. 1F 
and 1G in the Supplementary Appendix), but no 
significant change in interleukin-4 secretion (see 
Fig. 1H in the Supplementary Appendix).
Heterozygote Phenotype
We assessed the level of obesity in the 22 family 
members who were heterozygous and the 6 who 
were homozygous for wild-type LEPR. Heterozy-
gous subjects were not severely obese, and their 
mean BMI standard-deviation score (0.6±0.8) was 
similar to that of their relatives who were homo-
zygous for wild-type LEPR (0.6±1.0). We compared 
the measured percentage of body fat and that pre-
dicted according to height and weight; the abso-
lute difference was significantly greater in the 14 
of the 22 heterozygotes for whom fat-mass data 
were available than in their relatives with wild-
type LEPR6 (mean, 8.2% vs. 2.1%; P = 0.009).
Discussion
The prevalence of pathogenic LEPR mutations in 
our subjects with hyperphagia and severe early-
onset obesity was 3%. The prevalence of LEPR mu-
tations in this highly selected cohort is unlikely to 
reflect that in unrelated populations of obese sub-
jects or in populations in which the age at the onset 
of obesity is more heterogeneous.24,25 Six of the 
probands were from consanguineous families, but 
two probands (including the compound heterozy-
gote) were whites in the United Kingdom whose 
parents were not known to be related. Although the 
prevalence of LEPR mutations is likely to be high-
er in ethnic groups in which consanguinity is com-
mon, LEPR deficiency should be considered in all 
patients with hyperphagic obesity of early onset.
None of the subjects with LEPR mutations char-
acterized in this study, including those with non-
sense mutations that were predicted to result in 
the loss of all isoforms, had disproportionately 
elevated serum leptin levels. Thus, serum leptin 
levels are not a generally useful marker of leptin-
receptor deficiency — contrary to a previous sug-
gestion.13
Congenital leptin-receptor deficiency is charac-
terized by severe, early-onset obesity associated 
with selective deposition of fat mass, as seen in 
subjects with leptin deficiency.9 All of our subjects 
had hyperphagia from an early age, and we dem-
onstrated that the ad libitum energy intake was 
greatly increased in children with leptin-receptor 
deficiency, with no evidence of a major deficit in 
basal energy expenditure.
Children with leptin-receptor deficiency had 
normal linear growth during childhood and had 
normal IGF-1 levels. However, because of the lack 
of a pubertal growth spurt, the final height of 
adult subjects was reduced. In the one previously 
described family, short stature and abnormal se-
rum growth hormone levels and IGF-binding pro-
tein 3 levels were noted in childhood.5 However, 
assessment of the growth hormone–IGF axis is 
difficult in obese children and adults, since obe-
sity is itself associated with abnormal results of 
basal and of dynamic tests of this axis.26,27 We 
conclude that impaired linear growth does not 
appear to be a common characteristic of patients 
with this disease.
Figure 2 (facing page). Pedigrees of Consanguineous 
Families and Nonconsanguineous Families with Muta-
tions in the Leptin-Receptor Gene That Segregate  
with Severe Obesity.
The squares represent male family members, and the 
circles female family members; open symbols repre-
sent unaffected family members, and solid symbols 
family members with obesity (in adults, defined as a 
BMI [the weight in kilograms divided by the square of 
the height in meters] of 30 or more; in children, de-
fined as a BMI above the 99th age-adjusted percentile). 
A slash through the symbol denotes a subject who has 
died. Below each symbol, age is given, followed by the 
BMI value, the BMI standard-deviation score, and the 
genotype, with N denoting the normal (wild-type) allele 
and M the mutant allele. In Family 8, MF denotes the 
frame-shift mutation, and MM the missense mutation. 
For subjects in whom it was available, the percentage 
of body fat, measured by dual-energy x-ray absorptiom-
etry, is listed below the genotype.
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Adults with leptin-receptor deficiency have hy-
pogonadotropic hypogonadism and do not under-
go puberty. Irregular menses developed in the 
third and fourth decades in the three oldest wom-
en in our study, as reported previously for one 
woman with leptin deficiency.28 It is plausible that 
the excess mass of adipose tissue leads to the pro-
duction of sufficient estrogen (owing to the action 
of aromatase) to result in uterine development and 
irregular menses in the absence of fully developed 
secondary sexual characteristics. However, this 
may not be the only explanation, since luteinizing 
hormone and follicle-stimulating hormone levels 
in these three subjects were within the normal 
range for the follicular phase of the menstrual cy-
cle, suggesting that even in the absence of leptin 
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Figure 3. Body-Mass Index (BMI) (Panel A), Percentage of Body Fat (Panel B), Ad Libitum Energy Intake (Panel C), 
and Serum Leptin Levels (Panel D) in Leptin-Receptor Deficiency.
Panel A shows the BMI standard-deviation score.14 Panel B shows the percentage of body fat as measured by dual-
energy x-ray absorptiometry. Panel C shows the ad libitum energy intake at a test meal (adjusted for kilograms of 
lean mass).8 In Panel D, the horizontal line indicates the geometric mean. The data in Panels A, B, and C are means 
±SD. Subjects 1, 2, and 3 in Family 4 were not able to travel to the United Kingdom, so data for 7 (rather than 10) 
subjects who were homozygous for LEPR mutations are presented in Panels B and C. The BMI is calculated as the 
weight in kilograms divided by the square of the height in meters. MC4R denotes melanocortin 4 receptor.
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activity, some activation of the hypothalamic–pitu-
itary–gonadal axis is possible, albeit temporally 
delayed.
Subjects with LEPR mutations tended to have a 
lower CD4+ T-cell count and a significantly great-
er compensatory B-cell count than age-matched 
control subjects — findings that are consistent 
with the known effects of leptin on immune func-
tion.29 Lymphocytes in the affected subjects showed 
decreased proliferation and altered cytokine re-
lease in response to nonspecific and antigen-spe-
cific stimuli. In two families, very obese children 
died after an infection in the first decade of life. 
It is likely that this immune dysfunction, perhaps 
together with impaired respiratory reserve as a 
result of severe obesity, contributed to these early 
deaths.
Heterozygotes who were leptin-receptor–defi-
cient but not obese had an increased fat mass, a 
finding consistent with our observation that 
heterozygote carriers of a leptin mutation had 
23% more fat than was predicted with anthropo-
metric methods.17 These findings are consistent 
with those of Chung et al., who found an in-
crease in the fat mass of mice that were hetero-
zygous for deletion of leptin or of the leptin re-
ceptor (ob+/− or db+/−).30
Our data suggest that several phenotypic fea-
tures seen in subjects with leptin-receptor defi-
ciency are not as severe as those in subjects with 
leptin deficiency.9,11 This is surprising, given the 
fact that the LEPR protein product is the only 
known receptor for leptin and given the pheno-
typic similarity between mice lacking leptin (ob/ob) 
and mice lacking the leptin receptor (db/db) that 
share the same genetic background.31 The differ-
Table 2. Metabolic and Endocrine Features of Leptin-Receptor Deficiency in Subjects Homozygous for LEPR Mutations.*
Variable Subject Normal Range†
Family no. 5 6 7 1 1 2 2 4 4 4
Subject no. 1 1 1 3 2 2 1 3 2 1
Age (yr) 4 8 8 10 11 15 18 31 41 55
Sex M F M M M M F F F F
Glucose (mg/dl) 76 76 81 88 83 94 72 99 157 130 75–115
Insulin (μU/ml) 4 14 17 28 81 26 29 15 Diabetes mellitus
Diabetes 
mellitus 5–20
Standard-deviation score for 
height 1.8 4.2 2.1 1.3 1.8 −1.7 −2.0 −2.0 −2.0 —
IGF-1 (U/ml) 4 29.1 27.3 19.5 16.5 8.4 8.0 8.5 5.7 — Age-specific
FSH (IU/L) 0.3 0.3 0.2 0.2 1.3 3.7 1.8 4.2 7.7 13.7 Age-specific
Luteinizing hormone (IU/L) 0.1 0.1 0.2 0.2 0.2 1.8 0.9 4.8 6.8 7.6 Age-specific
Estradiol (pg/ml) — 18.3 — — — — 17.2 54.8 50.4 13.6 Age-specific
Testosterone (ng/ml) — 0.058 0.058 0.058 0.26 — — — — Age-specific
Thyrotropin (mU/L) 3.3 1.6 4.1 0.8 2.1 0.9 0.9 2.9 4.2 3.8 0.6–4.6
Free thyroxine (ng/dl) 1.1 1.0 0.9 1.1 1.1 1.1 1.1 0.9 1.2 1.0 0.7–1.7
Serum leptin (ng/ml) 36 194 14 97 110 178 365 180 133 90
* To convert values for glucose to millimoles per liter, multiply by 0.05551; to convert values for insulin to picomoles per liter, multiply by 
6.95; to convert values for estradiol to picomoles per liter, multiply by 3.671; to convert values for testosterone to nanomoles per liter, multi-
ply by 3.467; and to convert values for thyroxine to picomoles per liter, multiply by 12.87.
† The age-specific normal ranges for insulin-like growth factor 1 (IGF-1) are 2.5 to 20.0 U per liter for 0.0 to 6.9 years, 4.5 to 37.5 for 7.0 to 9.9 
years, 7.0 to 50.0 for 10.0 to 10.9 years, 8.5 to 60.0 for 11.0 to 11.9 years, 10.0 to 75.0 for 12.0 to 12.9 years, and 7.0 to 50.0 for 13.0 years or 
older; for follicle-stimulating hormone (FSH), less than 0.2 U per liter for clinically prepubertal subjects, 2.9 to 8.4 for women in the follicu-
lar phase of the menstrual cycle, 21.0 to 140.0 for postmenopausal women, and 1.0 to 10.0 for men; for luteinizing hormone (LH), less than 
0.2 U per liter for clinically prepubertal subjects, 1.3 to 8.4 for women in the follicular phase, 16.0 to 75.0 for postmenopausal women, and 
1.5 to 6.3 for men; for estradiol, less than 22 pg per milliliter for clinically prepubertal persons, 27 to 204 for women in the follicular phase, 
and less than 30 for postmenopausal women; and for testosterone, less than 14.3 ng per deciliter for clinically prepubertal persons and 
229.0 to 1086.0 for men.
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ences seen between the two groups of subjects 
may relate to the fact that our leptin-receptor–
deficient subjects were, on average, older than the 
leptin-deficient subjects we studied previously.9 
Also, the leptin-deficient subjects were of Paki-
stani origin, whereas the leptin-receptor–deficient 
subjects were from various ethnic groups. How-
ever, the differences between these two groups are 
striking in magnitude and consistency and raise 
the possibility that in humans, the canonical leptin 
receptor may not be the only receptor that me-
diates the actions of leptin, at least when serum 
leptin levels are high.
Congenital leptin-receptor deficiency cannot be 
ruled out by measuring serum leptin levels, and 
this diagnosis should be considered in all patients 
with severe obesity and hyperphagia in the ab-
sence of developmental delay and dysmorphic 
features. This diagnosis has implications for the 
care of these patients, both in terms of genetic 
counseling of the affected families and in terms 
of future prospects for treatment, since these pa-
tients would be predicted to have a favorable re-
sponse to drugs targeted at pathways downstream 
of the leptin receptor.
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We report here that leptin can act as a negative
signal for the proliferation of human naturally
occurring Foxp3+CD4+CD25+ regulatory T
(Treg) cells. Freshly isolated Treg cells produced
leptin and expressed high amounts of leptin re-
ceptor (ObR). In vitro neutralization with leptin
monoclonal antibody (mAb), during anti-CD3
and anti-CD28 stimulation, resulted in Treg cell
proliferation, which was interleukin-2 (IL-2) de-
pendent. Treg cells that proliferated in the pres-
ence of leptin mAb had increased expression
of Foxp3 and remained suppressive. The phe-
nomena appeared secondary to leptin signaling
via ObR and, importantly, leptin neutralization
reversed the anergic state of the Treg cells, as
indicated by downmodulation of the cyclin-
dependent kinase inhibitor p27 (p27kip1) and
the phosphorylation of the extracellular-related
kinases 1 (ERK1) and ERK2. Together with the
finding of enhanced proliferation of Treg cells
observed in leptin- and ObR-deficient mice,
these results suggest a potential for therapeutic
interventions in immune and autoimmune
diseases.
INTRODUCTION
Thymus-derived, naturally occurring, regulatory T (Treg)
cells are a subset of T lymphocytes that constitutes about
5%–10% of peripheral CD4+ T cells. Treg cells constitu-
tively express the high-affinity interleukin-2 (IL-2) receptor
a chain CD25 and can inhibit effector T cell responses
in vitro and in vivo (Shevach, 2002; Sakaguchi, 2004;
Suri-Payer et al., 1998; Thornton and Shevach, 1998; Ng
et al., 2001). Treg cells express the forkhead family tran-
scription factor Foxp3, a key control gene for their devel-
opment and function (Shevach, 2002; Sakaguchi, 2004).
Given the importance of Treg cells in the mechanisms of
immune regulation and their protective role in severalImautoimmune conditions, there has been wide interest in
finding strategies that expand Treg cell numbers in the pe-
riphery (Kretschmer et al., 2005; Tang et al., 2004; Jiang
et al., 2003). However, technical difficulties including
hyporesponsiveness of freshly isolated Treg cells to T cell
receptor (TCR) stimulation in culture has hampered this
process (Thornton and Shevach, 1998; La Cava et al.,
2004). Nonetheless, murine and human Treg cell numbers
have been expanded in vitro up to 200-fold in the pres-
ence of high doses of IL-2 (Tang et al., 2004; Jiang et al.,
2003). These proliferated Treg cells continue to express
cell-surface molecules and intracellular markers consis-
tent with a regulatory phenotype and effectively suppress
in vitro proliferative responses to either anti-CD3 or alloge-
neic stimuli, in a fashion similar to naturally occurring Treg
cells (Tang et al., 2004; Jiang et al., 2003).
Leptin is a cytokine-like hormone structurally similar to
IL-6 and is involved in the control of food intake, metabo-
lism, and T cell function (Friedman and Halaas, 1998; La
Cava and Matarese, 2004). We report here that freshly iso-
lated human Treg cells constitutively expressed high
amounts of both leptin and the leptin receptor (ObR) and
that the leptin pathway can act as a negative signal for
the proliferation of Treg cells. These findings may partly ex-
plain why chronic leptin- and leptin-receptor deficiency
associate with increased susceptibility to infection and re-
sistance to autoimmunity (La Cava and Matarese, 2004;
Ikejima et al., 2005; Farooqi et al., 2002; Matarese et al.,
2002) and the increased risk of infection and reduced inci-
dence of autoimmunity in individuals with low leptin
(Matarese et al., 2002). These results may also suggest
new possibilities for leptin-based manipulation of the
Treg cells.
RESULTS
Human Treg Cells Express Higher Amounts of ObR
than Do CD4+CD25 Effector T Cells
Previous studies have shown that leptin receptor (ObR) is
expressed on CD4+ T cells and that it is able to switch
immune responses toward a T helper 1 (Th1) phenotype
(La Cava and Matarese, 2004). We sought to analyze the
expression of ObR on Treg cells and to correlate itsmunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 241
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Treg Cell Proliferation Controlled by LeptinFigure 1. Human Treg Cells Express High ObR, and Leptin Neutralization Reverses Their Hyporesponsiveness
(A) Representative flow cytometry plot of human T cells stained for CD4, CD25, and Foxp3.
(B and C) Immunoblot analysis of sorted CD4+ T cells on the basis of their CD25 expression. Graphs show quantitation of Foxp3 and ObR with respect
to tubulin. One representative out of five independent experiments is shown.
(D) Proliferation of CD4+CD25+ Treg cells treated with recombinant human leptin (250 ng/ml) in the presence or absence of leptin mAb (10 mg/ml). The
data are shown as mean ± SD (n = 5, *p < 0.0001; **p < 0.01).
(E) Dose dependency of Treg cell proliferation induced by leptin mAb. Proliferation was measured after treatment with indicated doses of leptin mAb.
The data are shown as mean ± SD (n = 5).
(F) Proliferation of Treg cells induced by a fixed dose of leptin mAb in the presence of increasing concentration of recombinant leptin. The data are
shown as mean ± SD (n = 5).
(G) Proliferation of CD4+CD25 effector T cells treated with recombinant human leptin (250 ng/ml) in the presence or absence of leptin mAb (10 mg/ml).
The data are shown as mean ± SD (n = 5, *p < 0.01; **p < 0.01).
(H) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in the presence or absence of leptin mAb (10 mg/ml). The
data are shown as mean ± SD (n = 5, *p < 0.01; **p < 0.0001).expression with Foxp3. CD4+CD25+ Treg cells and
CD4+CD25 effector T cells purified from human healthy
donors (Figure 1A, left) were analyzed for Foxp3 expres-
sion by FACS analysis and immunoblot (Figure 1A, right,
and Figure 1B, respectively). As expected, Treg cells
showed high amounts of Foxp3 protein whereas
CD4+CD25 did not show detectable amount of the pro-
tein in cell extracts (Figures 1A and 1B). Instead, ObR
was expressed on both freshly isolated cellular subsets,
although at significantly higher amounts (p < 0.001) in
Treg cells as compared to the CD4
+CD25 T cell effectors
(Figure 1C).
Leptin Neutralization Results in the Proliferation
of Human Treg Cells Stimulated with Anti-CD3
and Anti-CD28
Human Treg cells were hyporesponsive to anti-CD3 and
anti-CD28 stimulation (Figure 1D), in agreement with pre-
vious findings (Ng et al., 2001). Addition of exogenous
recombinant leptin to the cultures did not alter Treg cells
hyporesponsiveness (Figure 1D). However, addition of
neutralizing leptin monoclonal antibody (mAb) reversed
the hyporesponsiveness and promoted Treg cell prolifera-
tion (Figure 1D) in a dose-dependent fashion (Figure 1E).
Analogous results were observed with different leptin or242 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.ObR-blocking antibodies (see Figure S1 in the Supple-
mental Data available online). Confirming specificity,
addition of exogenous recombinant leptin to anti-CD3-
and anti-CD28-stimulated Treg cells antagonized the
proliferation induced by leptin mAb (Figure 1D). More-
over, dose-dependent increase of the proliferation of
stimulated Treg cells in the presence of leptin mAb
(Figure 1E) was reversed by addition of increasing doses
of recombinant leptin (Figure 1F). Interestingly, leptin mAb
inhibited the proliferation of purified effector CD4+CD25
T cells, a phenomenon that was reversed by addition of
exogenous leptin (Figure 1G). Thus, neutralization of lep-
tin had opposite effects on effector CD4+CD25 T cells
and Treg cells—it inhibited proliferation on the former
lymphocyte subset (Figure 1G), whereas it promoted ex-
pansion of the latter subpopulation (Figure 1D). This ef-
fect was also evident morphologically, as formation of
cell clumps in the cultures of Treg cells stimulated with
anti-CD3 and anti-CD28 and leptin mAb, but not in the
cultures of Treg cells stimulated with anti-CD3 and anti-
CD28 in the absence of leptin mAb (data not shown).
Finally, in coculture experiments, Treg cells efficiently sup-
pressed the proliferation of CD4+CD25 T cells, and
leptin neutralization reversed the suppression by Treg
cells (Figure 1H).
Immunity
Treg Cell Proliferation Controlled by LeptinFigure 2. Human Treg Cells Exhibit Partial Suppressive Capacity upon Leptin-mAb-Induced Proliferation
(A) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture treated with recombinant human leptin (250 ng/ml) in the
presence or absence of leptin mAb (10 mg/ml). The data are shown as mean ± SD (n = 3, *p < 0.0001; **p < 0.01).
(B–I) Proliferative response (B–E) and CD25 expression analysis (F–I) of CFSE-labeled-CD4+CD25 effector T cells alone or in coculture with untreated
or leptin-mAb-treated unlabeled Treg cells. The thin line represents the isotype-matched negative control and the thick line represents the CD25 stain-
ing. One representative out of three independent experiments is shown (*p < 0.0001; **p < 0.01; ***p < 0.05, as compared with CD4+CD25CFSE+).Proliferated Treg Cells Have Partial Suppressive
Capacity that Attains Full Activity when They Enter
the Resting Phase
The suppressive capability of Treg cells in the presence of
leptin mAb was tested in coculture experiments of Treg
cells together with CD4+CD25 T cells. Addition of exog-
enous leptin did not affect suppression of Treg cells on
CD4+CD25 T cells (Figure 2A). In contrast, suppression
of proliferation was apparently abrogated in the presence
of leptin mAb (Figure 2A, gray columns). Concomitant ad-
dition of leptin together with the leptin mAb partly reduced
the anti-leptin-induced reversal of suppression, confirm-
ing specificity for leptin neutralization in the coculture
experiments (Figure 2A, gray columns).
To understand whether Treg cells during anti-leptin-in-
duced proliferation could exert suppressive capacity, we
performed coculture experiments with CFSE-labeled
CD4+CD25 T cells in the presence of unlabeled Treg cells
(Figures 2B–2E). As expected, Treg cells suppressed the
expansion of CD4+CD25 effectors (Figure 2D), and sup-
pression was partially maintained in the presence of leptin
mAb (Figure 2E)—albeit at a lower degree when compared
with untreated Treg cells (Figure 2D). This suggested that
Treg cells during anti-leptin-induced proliferation are par-
tially functional in terms of suppressive capability.
Moreover, the coculture experiments of Treg cells with
CD4+CD25 T cells, in the presence of leptin mAb, indi-
cated that the reversal of suppression (Figure 2A, gray col-
umns) was apparent only because CD4+CD25 effectors
were inhibited in part in their proliferation, as indicated
by the CFSE dilution (Figure 2E). Thus, the high amount
of [3H]thymidine incorporation in coculture of Treg cellsImwith CD4+CD25 T cells in the presence of leptin mAb
(Figures 1H and 2A) has to be ascribed to both Treg cell
proliferation and partly to CD4+CD25 T cells. These phe-
nomena were confirmed in terms of expression of the
activation marker CD25 on CFSE-labeled CD4+CD25
effector T cells. The anti-CD3 and anti-CD28 activation
induced a substantial upregulation of CD25 on the cell sur-
face (Figure 2F) and was significantly inhibited in the pres-
ence of Treg cells (Figure 2H). A significant reduction of
CD25 expression on effector T cells was observed in the
presence of anti-leptin-expanding Treg cells (even if at
lower extent when compared with untreated Treg cells)
(Figure 2I). In any case, the suppressive capacity of anti-
leptin-expanding Treg cells was diminished by about
40%, and a certain number of CD4+CD25 T cells was still
able to proliferate and divide (Figure 2E).
Next, we performed two-step experiments to address
whether anti-leptin-proliferated Treg cells in the resting
phase could retain their suppressive capacity over time.
8 days after the first expansion, stimulated Treg cells
were still suppressive for CD4+CD25 effector T cells in
in vitro coculture experiments (Figures S2A–S2C). Al-
though effector CD4+CD25 T cells cultured in the pres-
ence of leptin mAb proliferated upon restimulation and
did not suppress allogeneic CD4+CD25 T cells expan-
sion in coculture experiments (Figure S2B), the anti-
leptin-expanded Treg cells maintained their hyporespon-
siveness after restimulation and were capable of
suppressing proliferation of allogeneic CD4+CD25 effec-
tor T cells (Figure S2C). These data suggested that the
anti-leptin-proliferated Treg cells, once in the resting
phase, maintain their suppressive capacity over time.munity 26, 241–255, February 2007 ª2007 Elsevier Inc. 243
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Treg Cell Proliferation Controlled by LeptinFigure 3. Treg Cells Produce Leptin and Express High Amounts of ObR
(A) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in three different serum- and leptin-free media in the
presence or absence of leptin mAb. The data are shown as mean ± SD (n = 6, *p < 0.01; **p < 0.001).
(B) Flow cytometry plot of BrdU incorporation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in serum-free medium
(X-VIVO), in the presence or absence of leptin mAb during anti-CD3 and anti-CD28 stimulation. One representative out of three independent exper-
iments is shown (*p < 0.05; **p < 0.001).
(C) Confocal microscopy of freshly isolated and 1 hr-stimulated Treg cells and CD4
+CD25 effectors stained for leptin (in green) and leptin receptor
(ObR) (in red). One representative out of three independent experiments is shown.
(D) Immunoblot for leptin on cell lysates from Treg cells and CD4
+CD25 effectors. The graph shows quantitation of leptin with respect to total ERK1/2.
One representative out of three independent experiments is shown.Leptin Production from Human Treg Cells
Leptin is present in media supplemented with human se-
rum, such as the medium used in our experiments (see Ex-
perimental Procedures). To test whether human Treg cells244 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.could expand in the absence of leptin, we stimulated Treg
cells with anti-CD3 and anti-CD28 in three different types
of serum- and leptin-free media (Figure 3A). Under these
conditions, Treg cells maintained hyporesponsiveness
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Treg Cell Proliferation Controlled by Leptineven in the absence of exogenous leptin. Surprisingly,
addition of leptin mAb to the cultures resulted in Treg cell
proliferation (Figure 3A). This finding was also confirmed
by BrdU incorporation in serum-free medium cultures
(Figure 3B). This finding suggests the possibility that leptin
may be produced by Treg cells in a fashion similar to the
production of leptin by CD4+ T cells and monocytes in
multiple sclerosis (Sanna et al., 2003; Matarese et al.,
2005). To test this possibility, we examined leptin and
ObR expression on Treg cells and CD4
+CD25 T cells.
Both freshly isolated Treg cells and CD4
+CD25 T cells
stained positive for leptin and ObR, with different intensity
patterns (Figure 3C). Moreover, after 1 hr culture, Treg cells
showed higher leptin production than did CD4+CD25 T
cells, and this tendency was maintained during anti-CD3
and anti-CD28 stimulation, both in the presence and in
the absence of leptin mAb (Figure 3C). Parallel quantita-
tion by immunoblotting analysis for leptin on cell lysates
confirmed the difference (Figure 3D). Indeed, the presence
of a basal production of leptin increased significantly after
anti-CD3 and anti-CD28 stimulation (Figure 3D), and Treg
cells always produced more leptin than did CD4+CD25
T cells (Figure 3D). Interestingly, leptin neutralization in-
duced a compensatory leptin production and ObR upre-
gulation in both Treg cells and CD4
+CD25 T cells, and
again, to a higher amount in the Treg cells (Figures 3C
and 3D). These results were confirmed at 12 hr by confo-
cal microscopy and immunoblotting studies (data not
shown). Additionally, to address the capacity of Treg cells
and CD4+CD25 T cells to secrete leptin, we performed
a human leptin-specific ELISA (see Experimental Proce-
dures) and confocal microscope analysis at different
time points (12 hr and 36 hr) on culture supernatants
(Figure S3). At 12 hr, the secretion of leptin was similar in
both Treg cells and CD4
+CD25 T cells, whereas at 36 hr
the amount of leptin secreted was significantly higher
in the Treg cells, either unstimulated or treated with
anti-CD3 and anti-CD28 plus leptin mAb (Figure S3). The
finding was confirmed by the observation of a reduced
content of leptin in Treg cells at 36 hr (Figure S3) in confocal
microscopy and immunoblotting studies on cell lysates
(data not shown). Finally, these results on leptin secretion
were also confirmed by immunoblotting for leptin on cul-
ture supernatants (data not shown). Thus, these results
suggest the presence of an autocrine loop of leptin secre-
tion by Treg cells controlling their hyporesponsiveness.
Leptin-mAb-Induced Proliferation of Treg Cells Is IL-2
Dependent, and IL-2-Supported Expansion
of Treg Cells Is Not Affected by Leptin
To test whether the leptin-mAb-induced proliferation of
Treg cells was IL-2 dependent, we evaluated the effects
of IL-2 neutralization on the Treg cell proliferative re-
sponses and IL-2 production. Addition of human IL-2-neu-
tralizing mAb enhanced the inhibitory effects of leptin mAb
treatment on the CD4+CD25 T cell proliferation and IL-2
secretion (Figures 4A and 4B, white bars). IL-2 mAb re-
duced both Treg cell proliferation and IL-2 production in-
duced by the neutralization of leptin (Figures 4A and 4B,Imblack bars). Moreover, the apparent reversal of suppres-
sion in coculture experiments resulting from anti-leptin-in-
duced Treg cells proliferation was inhibited by anti-IL-2
(Figures 4A and 4B, gray bars). IL-2 secretion was evalu-
ated via CTLL-2 proliferation (Figure 4B). These results
were also confirmed by intracellular staining for IL-2 in
FACS analysis and ELISA (Figure S4).
Next we compared IL-2-induced proliferation versus
anti-leptin-induced proliferation on Treg cells. Addition of
exogenous IL-2 reversed Treg cells unresponsiveness
upon anti-CD3 and anti-CD28 stimulation (Figure 4C,
left), as expected. Of interest, IL-2-induced proliferation
was less than that observed upon leptin blockade
(Figure 4C, left). To also address whether anti-leptin treat-
ment affected the ability of Treg cells to proliferate in the
presence of IL-2 but in the absence of TCR stimulation,
we measured the proliferation of unstimulated Treg cells
cultured with leptin mAb or IL-2 and anti-leptin plus IL-2.
No proliferation was observed in the absence of TCR en-
gagement in all the above conditions (Figure 4C, left). Fi-
nally, we tested whether leptin could inhibit IL-2-induced
expansion of Treg cells. The anti-proliferative effect of in-
creasing doses of recombinant leptin on Treg cell prolifer-
ation induced by IL-2 was not significant (Figure 4C, right),
suggesting that IL-2 signaling may be independent and
dominant of the leptin-mediated inhibitory effects on the
cell proliferation.
Treg Cells Expandedwith LeptinmAbHave Increased
Expression of Foxp3
We next addressed whether leptin neutralization could af-
fect the amount of Foxp3 in Treg cells. Foxp3 expression
was evaluated after leptin neutralization at 1 hr and 12 hr
during anti-CD3 and anti-CD28 stimulation. As shown in
Figure 4D, Foxp3 expression was increased at early time
points after anti-CD3 and anti-CD28 stimulation, and lep-
tin mAb treatment did not alter Foxp3 protein amounts.
Conversely, at 12 hr, Treg cells that proliferated after leptin
mAb showed increased Foxp3 amounts when compared
to those activated with anti-CD3 and anti-CD28 alone
(Figure 4E). As expected, Foxp3 was undetectable in
CD4+CD25 T effectors after 1 hr of stimulation in all the
experimental conditions (Figure 4D), whereas at 12 hr,
there was a little expression of Foxp3 after anti-CD3 and
anti-CD28 stimulation either in the presence or in the ab-
sence of leptin mAb that did not reach statistical signifi-
cance (Figure 4E). All these data were confirmed by real-
time PCR (data not shown).
The Effect of Leptin Neutralization on ObR
and STAT3 Activation Pathway
The molecular effects of leptin mAb were studied at early
(1 hr) or late (12 hr) time points on highly purified human
Treg cells or effector CD4
+CD25 T cells, activated or not
with anti-CD3 anti-CD28.
We first analyzed the leptin-ObR-STAT3 biochemical
pathway: 1 hr and 12 hr cultures confirmed that in unsti-
mulated cells, the ObR was expressed at higher amounts
in Treg cells than in CD4
+CD25 T cells (Figures 3C, 5A,munity 26, 241–255, February 2007 ª2007 Elsevier Inc. 245
Immunity
Treg Cell Proliferation Controlled by LeptinFigure 4. Leptin-mAb-Induced Proliferation of Human Treg Cells Is IL-2 Dependent, and Foxp3 Expression Is Increased during
Proliferation
(A) Proliferation of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in the presence or absence of leptin mAb and IL-2-
neutralizing mAb. The data are shown as mean ± SD (n = 5, *p < 0.01, **p < 0.05, white bars; *p < 0.001, black bars; *p < 0.01, gray bars).
(B) IL-2 secretion of CD4+CD25 effector T cells, Treg cells, and of both cell types in coculture in the presence or absence of leptin mAb and IL-2-
neutralizing mAb. The data are shown as mean ± SD (n = 5, *p < 0.01 and **p < 0.05, white bars; *p < 0.001, black bars; *p < 0.01, gray columns).
(C) Proliferation of Treg cells in the presence of either leptin mAb or recombinant IL-2 (left), stimulated or not with anti-CD3 and anti-CD28. The data are
shown as mean ± SD (n = 5, *p < 0.0001; **p < 0.01; ***p < 0.05). Addition of scalar doses of recombinant leptin to proliferating Treg cells (right) stim-
ulated with anti-CD3 and anti-CD28 in the presence of recombinant IL-2. The data are shown as mean ± SD (n = 5, NS, not significant).
(D) Immunoblot analysis of CD4+CD25 effector T cells and Treg cells in the presence or absence of leptin mAb, at 1 hr stimulation with anti-CD3 and
anti-CD28. The graph shows quantitation of Foxp3 with respect to tubulin. One representative out of five independent experiments is shown.
(E) Immunoblot analysis and flow cytometry plot of CD4+CD25 effector T cells and Treg cells in the presence or absence of leptin mAb, at 12 hr stim-
ulation with anti-CD3 and anti-CD28. The graph shows quantitation of Foxp3 with respect to tubulin. One representative out of five independent ex-
periments is shown (*p < 0.01, as compared with anti-CD3 and anti-CD28).and 5B). In vitro stimulation with anti-CD3 and anti-CD28
induced an upregulation of the ObR expression on both
cell types and was more evident at 1 hr than at 12 hr (Fig-
ures 3C, 5A, and 5B). Leptin neutralization on both Treg
cells and CD4+CD25 T cells further upregulated the ex-
pression of ObR, particularly at 1 hr, suggesting that leptin
blockade might induce a compensatory upregulation of its
receptor.
As readout of ObR activity, we measured phospho-
STAT3 (P-STAT3) amounts, because STAT3 is known to
participate in the intracellular signaling pathways of ObR
(reviewed in La Cava and Matarese, 2004). Activation of
CD4+CD25 T cells induced strong STAT3 phosphoryla-
tion at 1 hr and 12 hr and anti-leptin treatment reduced
the P-STAT3 amounts, particularly at 1 hr (Figures 5A
and 5B). Conversely, stimulation of Treg cells was not as-
sociated with a marked increase of P-STAT3, whereas
anti-leptin induced amounts of P-STAT3 at 1 hr and246 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.12 hr comparable to those observed in proliferating
CD4+CD25 T cells (Figures 5A and 5B). Of note, at 1 hr,
CD4+CD25 T cells expressed both STAT3 spliced iso-
forms (Maritano et al., 2004)—STAT3a and STAT3b—
whereas Treg cells mainly expressed the STAT3a isoform.
This phenomenon was not as evident after 12 hr when the
two spliced isoforms were similar in both cell subsets,
suggesting that the tissue-culture conditions could induce
STAT3b in Treg cells, independently of the different type of
stimulation. Finally, in unstimulated or anti-CD3- and anti-
CD28-stimulated Treg cells, at both 1 hr and 12 hr, the
amounts of P-STAT3 were higher than those observed in
unstimulated CD4+CD25 cells, suggesting an increased
‘‘basal’’ leptin-mediated signaling in Treg cells. This result
could be secondary to higher basal expression of ObR
on Treg cells (Figures 1C, 3C, 5A, and 5B). No induction
of P-STAT3 was observed in Treg cells treated with leptin
mAb alone without TCR stimulation (Figure S5).
Immunity
Treg Cell Proliferation Controlled by LeptinFigure 5. Molecular Effects of Leptin Neutralization on Human Treg Cells
(A and B) Immunoblot for ObR, STAT3, and SOCS3 on CD4+CD25 T cells and Treg cells in the presence or absence of leptin mAb stimulated with anti-
CD3 and anti-CD28 at 1 hr and 12 hr, respectively. Graphs show quantitation of each specific protein. One representative out of five independent
experiments is shown.
(C and D) Immunoblot for ERK1/2, STAT1, and p27kip1. Graphs show quantitation of each specific protein. One representative out of five independent
experiments is shown.Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 247
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Treg Cell Proliferation Controlled by LeptinWe also investigated in our system the expression of
suppressor of cytokine signaling 3 (SOCS3), a key nega-
tive regulator of cytokine signaling, including leptin (Kinjyo
et al., 2006; La Cava and Matarese, 2004). SOCS3 in anti-
CD3- and anti-CD28-stimulated CD4+CD25 T cells in-
creased markedly and was further increased by leptin
neutralization at 1 hr (Figure 5A). This finding inversely cor-
related with the corresponding P-STAT3 expression. At
a later time point (12 hr), SOCS3 was undetectable and
could be found at low amounts upon leptin neutralization
(Figure 5B). At 1 hr, SOCS3 in Treg cells was markedly
higher than in CD4+CD25 cells in all the experimental
conditions. Specifically, SOCS3 expression was high in
unstimulated Treg cells and increased after anti-CD3 and
anti-CD28 stimulation despite little STAT3 activation.
Treatment with anti-leptin, which induced P-STAT3, did
not alter the SOCS3 amounts (Figure 5A). At 12 hr, basal
SOCS3 expression was higher in the Treg cells than in
CD4+CD25 cells and was markedly reduced after anti-
CD3 and anti-CD28 stimulation. In conclusion, leptin
mAb treatment—which associates with STAT3 activation
in Treg cells—also induced SOCS3 expression (Figure 5B).
The Effect of Leptin Neutralization on Biochemical
Pathways Involved in T Cell Activation and Anergy
To evaluate whether leptin neutralization could affect T
cell activation and anergy, we studied tyrosine-phosphor-
ylation of the extracellular signal-regulated kinases 1 and
ERK2 (ERK1/2). Leptin neutralization in the presence of
anti-CD3 and anti-CD28 in CD4+CD25 T cells increased
ERK1/2 phosphorylation as compared to anti-CD3 and
anti-CD28 stimulation alone, particularly at 12 hr (Figures
5C and 5D). Treatment of Treg cells with anti-CD3 and
anti-CD28 did not induce phospho-ERK1/2 (P-ERK1/2),
confirming their anergic state. However, leptin mAb in-
duced high amounts of ERK1/2 tyrosine-phosphorylation
at both 1 hr and 12 hr, concomitantly with the induction
of Treg cell proliferation and a reversal of their hyporespon-
siveness (Figures 5C and 5D).
Moreover, we investigated whether leptin neutralization
could alter STAT1, another transcription factor whose ac-
tivity is required for the development and function of Treg
cells (Nishibori et al., 2004). We found that leptin neutrali-
zation did not affect STAT1 phosphorylation (P-STAT1) in
CD4+CD25 effectors at both time points. In contrast, P-
STAT1 was markedly induced in the leptin-neutralized
Treg cells (Figures 5C and 5D).
Last, we studied the modulation of the cyclin-depen-
dent kinase inhibitor p27 (p27kip1), a molecule involved in
the control of cell cycle, T cell anergy and known to block
the cell-cycle progression in Treg cells (Li et al., 2005; Wells
et al., 2001). p27kip1 was downmodulated by anti-CD3 and
anti-CD28 stimulation in CD4+CD25 effectors whereas
anti-leptin did not downmodulate p27kip1 expression at 1
hr and markedly increased its expression at 12 hr (Figures
5C and 5D), explaining, at least in part, the inhibition of
CD4+CD25 T cells proliferation induced by leptin neutral-
ization. In contrast, Treg cells showed elevated amounts of
p27kip1 before and after anti-CD3 and anti-CD28 stimula-248 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.tion, confirming their anergic state associated with cell-
cycle arrest. Leptin mAb treatment induced degradation
of this molecule at both 1 hr and 12 hr, which could explain
reversal of their anergic state and subsequent proliferation
(Figures 5C and 5D).
Leptin Deficiency Promotes Proliferation
of Treg Cells in Mice
Treg cells, despite their in vitro hyporesponsiveness, can
expand in vivo in normal, nonlymphopenic hosts (Trenado
et al., 2003; Gavin et al., 2002). We used nonirradiated,
nonlymphopenic recipient mice to avoid a homeostatic ex-
pansion of the Treg cells that would occur in lymphopenic
hosts (Trenado et al., 2003; Gavin et al., 2002). The
in vivo proliferative capacity of Treg cells in anti-leptin-
treated wild-type (WT) mice versus control-Ig-treated
mice was tested with CFSE-labeled-CD4+ T cells from nor-
mal WT mice and by measuring the CFSE dilution in the
CD4+Foxp3+ cells (Figure 6A). Mouse Treg cells expanded
in vivo more robustly and earlier (day 4 and day 7 after
transfer) when adoptively transferred into leptin-neutral-
ized WT mice (Figure 6A). This result was confirmed by
adoptive transfer of CFSE-labeled-CD4+ T cells from nor-
mal WT mice into leptin-deficient ob/ob mice, in which the
Treg cells expanded more robustly and earlier (day 4 and
day 7 after transfer) when compared with cells transferred
into normal WT mice (Figure 6B). We also confirmed our
data in a transgenic antigen-specific system utilizing donor
mice carrying the (TcrAND)53Hed transgene (AND-TCR
Tg mice) expressing the clonotypic Va11.1/Vb3 TCR
chains, specific for the carboxy-terminal fragment of pi-
geon cytochrome c (PCC) (Kaye et al., 1989). Assessment
4 and 7 days after adoptive transfer revealed that trans-
ferred CFSE-labeled clonotypic AND-TCR Treg cells prolif-
erated more vigorously in ob/ob mice as compared with
normal WT controls (Figure 6C). This phenomenon was
reversed by recombinant leptin administration to leptin-
deficient ob/ob mice (Figure 6C). To avoid interference
of CD4+ T cell lymphopenia on the Treg cell expansion
in vivo, in the adoptive transfer experiments in ob/ob
mice, we utilized 6-week-old mice (in which the leptin de-
ficiency has not yet determined significant reduction of the
CD4+ T cell number). The in vivo results were also con-
firmed by CFSE dilution experiments gating on the
CD4+CD25+ Treg cells in both leptin-neutralized WT and
leptin-deficient ob/ob mice, respectively (Figures S6A
and S6C, respectively). Foxp3 expression was increased
in the Treg cells of the leptin-neutralized WT mice (Fig-
ure S6B). Finally, to confirm our data, we tested the ability
of Treg cells to expand in the presence of an anti-leptin re-
ceptor (anti-ObR)-blocking antibody. The data showed
a marked increase in the percentage of CD4+Foxp3+ Treg
cells in treated WT mice (data not shown).
Proliferative Potential and Functional Capacity of
Treg Cells from Leptin Receptor-Deficient Mice
We studied the in vitro proliferation and suppressive ca-
pacity of CD4+CD25 effectors and Treg cells from con-
genitally leptin-receptor-deficient db/db mice and normal
Immunity
Treg Cell Proliferation Controlled by LeptinFigure 6. In Vivo Leptin Neutralization or Congenital Leptin Deficiency Associate with Proliferation of Treg Cells
(A) Proliferation measured as CFSE dilution of CFSE-labeled Treg cells obtained from WT mice and transferred into control (CTR)-Ig or mouse leptin
neutralizing Ab-treated WT mice. The histogram shows the percent of CFSE+ Treg cells (gated on CD4
+Foxp3+ cells) that had divided 4 and 7 days
after transfer. One representative out of three independent experiments with 3 mice per group is shown (*p < 0.01; **p < 0.001).
(B) CFSE dilution profile of CFSE-labeled Treg cells (gated on CD4
+Foxp3+ cells) obtained from WT mice and transferred into WT or leptin-deficient ob/
ob mice, 4 and 7 days after transfer. One representative out of three independent experiments with 3 mice per group is shown (*p < 0.01; **p < 0.001).
(C) CFSE dilution profile of PCC-specific CFSE-labeled AND-TCR Treg cells (gated on Va11.1
+/Vb3+Foxp3+ cells) adoptively transferred into WT,
ob/ob, and ob/ob treated with recombinant leptin, 4 and 7 days after transfer. One representative out of two independent experiments with
4 mice per group is shown (**p < 0.001; *p < 0.01).db/+ heterozygous controls (Figures 7A–7C). Stimulation
with anti-CD3 and anti-CD28 of CD4+CD25 effector T
cells from db/db mice was less effective in inducing prolif-
eration than stimulation on CD4+CD25 from db/+ mice
(Figure 7A). Conversely, in vitro stimulation of Treg cells
from db/db mice induced significantly higher proliferation
than that of Treg cells from db/+ heterozygous controls
(Figure 7B). These data suggested that the absence of
the ObR impaired the expansion of CD4+CD25 effectors
and enhanced the proliferative potential of Treg cells. The
ObR deficiency seemed to affect the proliferative potential
of the Treg cells rather than their qualitative or functional
activity, because Treg cells from db/db mice suppressed
the proliferation of CD4+CD25 T cells in a fashion similar
to that of Treg cells from db/+ control mice (Figure 7C),Imconfirming the finding that addition of exogenous leptin
did not alter the suppressive capacity of Treg cells in vitro
(Figure 2A).
Subsequent studies were performed analyzing antigen-
specific responses in an autoimmune disease model: the
in vitro proliferative capacity of Treg cells against the pan-
creatic autoantigen glutamic acid decarboxylase (GAD)65
was evaluated in autoimmune diabetes nonobese diabetic
(NOD/LtJ) mice versus leptin-receptor mutant NOD-
Leprdb5J/LtJ mice (Figure 7D; Lee et al., 2005). These re-
cently isolated ObR mutant mice display obesity, hyper-
phagia, and resistance to the development of pancreatic
b-islets infiltration (Lee et al., 2005). We found that after
5 days of splenocyte cultures, Treg cells from NOD-
Leprdb5J/LtJ proliferated more robustly against mousemunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 249
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Treg Cell Proliferation Controlled by LeptinFigure 7. ObR Deficiency Increases Treg
Cells Proliferative Potential, Does Not Al-
ter Their Suppressive Capacity, and Im-
pairs CD4+CD25 Proliferation
(A) Proliferation of CD4+CD25 effector T cells
from db/+ and leptin receptor-deficient db/db
mice stimulated with anti-CD3 and anti-
CD28. The data are shown as mean ± SD
(n = 5, *p < 0.001).
(B) Proliferation of Treg cells from db/+ and
db/db mice stimulated with anti-CD3 and
anti-CD28. The data are shown as mean ±
SD (n= 5, **p < 0.01).
(C) Proliferation of CD4+CD25 effector T cells
from db/+ mice in the presence of increasing
number of either db/+ or db/db Treg cells, stim-
ulated with anti-CD3 and anti-CD28. The data
are shown as mean ± SD (n = 5).
(D) CFSE dilution of Treg cells (gated on
CD4+Foxp3+ cells) from leptin receptor mutant
NOD-Leprdb-5J/LtJ mice stimulated with
mouse recombinant GAD65, after 5 days cul-
ture. One representative out of five indepen-
dent experiments is shown (*p > 0.01).GAD65 than Treg cells from NOD/LtJ females, suggesting
an increased autoantigen-specific proliferative potential
of the Treg cells from mice with impaired ObR signaling
(Figure 7D). In contrast, Foxp3 T cells from NOD-
Leprdb5J/LtJ proliferated significantly less than that of
NOD/LtJ controls (data not shown), suggesting that an ab-
sence of ObR impaired the expansion of Foxp3 effectors
and enhanced the proliferative potential of Treg cells.
Leptin-Deficient Mice Have Increased Numbers
of Treg Cells that Can Be Reduced
by Administration of Leptin
Mice with genetic deficiency of leptin (ob/ob) or leptin-
receptor (db/db) have reduced susceptibility to autoim-
munity (Matarese et al., 2001; Sanna et al., 2003; Sieg-
mund et al., 2004; Faggioni et al., 2000; Lee et al., 2005).
Treg cells play a central role in regulating autoimmunity
(Shevach, 2002; Sakaguchi, 2005), so we tested whether
genetic deficiency of leptin associated with effects on
Treg cells. A significant increase of the percentage of pe-
ripheral Treg cells was observed in ob/ob as compared
to WT (Figures S7A and S7B, respectively). Administration
of leptin reduced the elevated number of Treg cells in the
ob/ob mice to a number comparable to that found in the
WT mice (Figures S7A and S7B).
DISCUSSION
In this study we establish a unique link between Treg cells
and leptin by showing that leptin can modulate the hypo-
responsiveness and proliferation of Treg cells both in vitro
and in vivo. Freshly isolated human Treg cells express high
amounts of ObR and produce substantial amounts of lep-
tin that are responsible for an autocrine inhibitory loop that
constrains the expansion of Treg cells. Although leptin neu-
tralization inhibits the proliferation of effector CD4+CD25
T cells, this condition leads to an expansion of the Treg250 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.cells, which maintain their suppressive phenotype in the
resting phase. The opposite effects of leptin blockade
on CD4+CD25 T cells and Treg cells associate with a dif-
ferential expression of intracellular leptin and cell-surface
ObR in the two cell subsets.
It must be noted that in our experimental system, the
culture media supplemented with human serum contained
low—albeit significant—concentrations of human leptin
(0.5–1 ng/ml in the 5% human serum [HS]/95% RPMI).
The contribution of HS-derived leptin versus Treg cell-de-
rived leptin was analyzed in cultures with three different
serum-free media—all tested for the absence of leptin.
The anti-leptin-induced expansion of the Treg cells in se-
rum-free conditions indicated that the Treg cell-derived
leptin was sufficient to act as negative signal for the ex-
pansion of the Treg cells. It is possible to speculate that
a leptin-mediated negative autocrine loop may operate
on Treg cells, because both freshly isolated and cultured
Treg cells stain positive for and secrete leptin. On the other
hand, the leptin present in the culture medium and se-
creted by the CD4+CD25 T cells could act as a positive
signal for T cell proliferation. These differential effects in-
duced by leptin could rely upon the different ObR levels
and leptin secretory capacity, which would ultimately af-
fect the intracellular signaling differentially.
Our Treg cells were cultured in medium supplemented
with 5% HS because fetal calf serum (FCS) is rich in bo-
vine leptin (10–20 ng/ml in RPMI 10% FCS) that is not neu-
tralized by human leptin mAb (data not shown). We also
found that 10% FCS abrogated the effects induced by hu-
man leptin mAb on human Treg cells (data not shown).
Therefore, it was crucial, for efficient leptin neutralization,
to avoid exposure to FCS for the ObR-expressing Treg
cells. The same issue has to be taken into account had
the Treg cells been isolated by positive selection and
thus undergone repeated steps of FCS exposure compro-
mising leptin neutralization. Moreover, we also noted that
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Treg Cell Proliferation Controlled by LeptinTreg cells isolated by positive selection with anti-CD25
mAb (either by FACS or magnetic bead cell sorting) had
a reduced capacity to proliferate in vitro after leptin neu-
tralization when the anti-CD25 mAb was not removed
from the cell surface after isolation. The reasons for an in-
terference of the anti-CD25 mAb with leptin neutralization
process and Treg cell expansion are currently being inves-
tigated and might include an interference with IL-2 signal-
ing, a functional inactivation of the Treg cells by the anti-
CD25 mAb recently demonstrated (Kohm et al., 2006),
and an influence on the kinetics and the degree of leptin
secretion by the Treg cells. In any case, detachment of
the anti-CD25 mAb after cell isolation completely elimi-
nates possible problems of proliferation for the anti-
leptin-treated stimulated Treg cells (see Experimental
Procedures for details).
Previous experimental evidence suggests that the
growth, homeostasis, and function of the Treg cells is de-
pendent on IL-2 in vitro and in vivo (Setoguchi et al.,
2005; Fontenot et al., 2005). Our data also indicated that
leptin neutralization could induce IL-2 secretion by Treg
cells and that leptin mAb-induced-proliferation was IL-2
dependent. When comparing the efficiency of leptin
neutralization and IL-2 to expand Treg cells in vitro, we
observed that leptin mAb had a better efficiency than
recombinant IL-2 (as indicated by Treg cell proliferation
and number after 8 days culture). Conversely, addition of
increasing doses of recombinant leptin to the cell cultures
did not affect the IL-2-mediated proliferation of the Treg
cells, suggesting that the control of leptin on the expan-
sion of the Treg cells was independent and not overcome
by IL-2 signaling. McHugh et al. (2002) demonstrated
that cultures of Treg cells with neutralizing glucocorti-
coid-induced TNF receptor (GITR) mAb allowed the Treg
cells to respond to exogenous IL-2 in the absence of
TCR stimulation. We also tried to induce Treg cell prolifer-
ation in the absence of TCR stimulation by adding high
concentration of IL-2 and anti-leptin, but we found lack
of proliferation, indicating that anti-leptin-induced prolifer-
ation of the Treg cells needs concomitant TCR engage-
ment. This evidence was also confirmed at biochemical
level; anti-leptin alone in the absence of TCR stimulation
did not induce significant P-STAT3 levels in Treg cells.
Foxp3—the master gene for Treg cell development and
function (Sakaguchi, 2005)—was induced in leptin-neu-
tralized Treg cells at late time points (12 hr), supporting
the evidence that removal of leptin from culture medium
not only expanded the Treg cells but also allowed the main-
tenance of their phenotype. The phenomenon might pos-
sibly be ascribed to the increased IL-2 secretion induced
by leptin neutralization, because others have shown that
IL-2 is capable of upregulating Foxp3 expression in hu-
man Treg cells (Zorn et al., 2006).
At the molecular level, Treg cells expressed high levels of
ObR and of p27kip1 but no phosphorylation of ERK1/2 or
STAT1 and little phosphorylation of STAT3. In contrast,
leptin neutralization upon anti-CD3 and anti-CD28 stimu-
lation and Treg cell expansion was associated with a rapid
degradation of p27kip1 as well as a marked phosphoryla-tion of ERK1/2, STAT1, and STAT3 (phosphorylation of
STAT3 in Treg cells could be partly explained by both the
induction of the ERK1/2, which is known to phosphorylate
STAT3 independently of ObR [Quadros et al., 2004; Bar-
boza et al., 2004], as well as by the secretion of STAT3-ac-
tivating cytokines, i.e., IL-2 and IL-6 [Doganci et al., 2005]).
Recently, Zorn and collegues (Zorn et al., 2006) showed
that IL-2 upregulates Foxp3 expression in human Treg cells
through a STAT3-dependent mechanism, confirming that
induction of Foxp3 (in our case, during leptin neutraliza-
tion) may occur via a STAT3-dependent mechanism. In-
triguingly, CD4+CD25 T cells, after leptin neutralization,
showed an increase of p27kip1 associated with sustained
ERK1/2 phosphorilation—a phenotype often observed in
anergic T cells (Wells et al., 2001; Chen et al., 1999; Waic-
zies et al., 2005) and in effector T cells from mice treated
with anti-leptin antibodies during autoimmune encephalo-
myelitis (De Rosa et al., 2006). The fact that leptin neutral-
ization reduced the levels of STAT3 phosphorylation and
had little effect on STAT1 needs an explanation. This par-
tial effect on the ObR-STAT3-mediated signaling could be
ascribed to the fact that also other cytokines activate
STAT3 (Doganci et al., 2005). As such, removal of leptin
could only inhibit in part STAT3 phosphorylation. In this
context, it is interesting to note that SOCS3, a key nega-
tive regulator of STAT3-activating cytokines (Kinjyo
et al., 2006), also was differentially expressed in the Treg
cells and in the CD4+CD25 T cells. The regulation of
STAT3 signaling by SOCS3 in CD4+CD25 effectors was
biphasic, with a first peak at 1 hr and a rapid degradation
at 12 hr, as previously described (Wormald et al., 2006).
Leptin neutralization increased SOCS3 amounts concom-
itantly with a reduced phosphorylation of STAT3. This is
also consistent with the SOCS3 inhibition of IL-2 produc-
tion and T cell proliferation that we observed in our work
(Matsumoto et al., 2003). In Treg cells, SOCS3 was highly
expressed in basal conditions and markedly induced dur-
ing acute stimulation, in agreement with the anergic state
of the Treg cells and their reduced IL-2 secretion.
Our results indicate that leptin neutralization can ‘‘un-
lock’’ the hyporesponsiveness of Tregs via a rapid degra-
dation of the cell-cycle inhibitor p27kip1, associated with
the phosphorylation of ERK1/2. These biochemical events
would allow the Treg cells to enter the G1/S phase of the
cell cycle, induce IL-2 gene transcription, and, conse-
quently, reverse their anergic state (Li et al., 2005). Our
data also indicate that these changes associate with the
activation of STAT1 and STAT3, two transcription factors
related with cytokine signaling and proliferation of the Treg
cells (Doganci et al., 2005; Nishibori et al., 2004).
Incidentally, this study also describes a novel strategy
to expand human peripheral Treg cells, via leptin neutrali-
zation, although this approach needs to be further investi-
gated. Current strategies to expand Treg cells employ ex
vivo addition of cytokines to cultured cells during TCR
stimulation (Tang et al., 2004; Jiang et al., 2003). Because
neutralization of the leptin present in human serum of tis-
sue cultures and of leptin produced by Treg cells may be
sufficient to determine an expansion of the Treg cells, itImmunity 26, 241–255, February 2007 ª2007 Elsevier Inc. 251
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with exogenous IL-2, may improve the protocols of expan-
sion for Treg cells. We are currently investigating this pos-
sibility.
In vivo studies in leptin-deficient ob/ob mice show
higher percentage and absolute number of circulating
Treg cells. They can expand up to 90% in vivo in normal
nonlymphopenic hosts by day 28 after transfer (Trenado
et al., 2003). Adoptive transfer experiments of CFSE-la-
beled Treg cells from WT mice into leptin-deficient ob/ob
mice showed a significant in vivo expansion of Treg cells.
It is also noteworthy that chronic leptin deficiency allows
higher expansion of Treg cells when compared with acute
leptin neutralization induced by leptin Ab (the percentage
of proliferating Treg cells in ob/ob mice was always higher
than that observed in leptin-neutralized WT mice). Impor-
tantly, in vivo leptin neutralization also determined an
increased Foxp3 expression in the Treg cells, suggesting
maintenance of their suppressive phenotype after expan-
sion in vivo. Taken together, our data suggest that the
presence of ObR may be crucial in the control of the ex-
pansion of Treg cells because stimulated Treg cells from
db/dbmice proliferated better than Treg cells from controls
in vitro, whereas the suppressive capability of Treg cells
from db/db mice was similar to that of control mice.
Confirmation of the crucial function of ObR came in an
antigen-specific system of autoimmune diabetes in the
NOD/LtJ mouse with the finding of increased anti-
GAD65 proliferative response of Treg cells from ObR mu-
tants NOD-Leprdb5J/LtJ mice.
The fact that leptin can act as a negative signal for the
proliferation of Treg cells envisions new possibilities of
anti-leptin-based approaches for the immunotherapy of
conditions characterized by low numbers of Treg cells.
Leptin might act as an endogenous ‘‘sensing’’ factor link-
ing the environment (availability of nutrients) to circulating
Treg cell number. Because nutritional deprivation in-
creases susceptibility to infection and associates with
amelioration of clinical manifestations of autoimmunity
(Kuchroo and Nicholson, 2003; Payne, 2001), it will be im-
portant to address how this relates to the influence of lep-
tin on Treg cells and whether anti-leptin-based intervention
can be applied to tune cognate T cell responses in im-
mune regulation.
EXPERIMENTAL PROCEDURES
Purification, Cultures, and Assays with T Cells
Human CD4+CD25+ and CD4+CD25 T cells were purified from human
healthy donors PBL either by magnetic cell separation with the Dynal
CD4+CD25+ Treg Kit (Dynal-Biotech, Oslo, Norway) or by flow cytome-
try cell sorting (MoFlo high-performance cell sorter, Dako, Glostrup,
Denmark) and were rapidly cleaned with the Detach reagent (Dynal-
Biotech) from surface-bound CD25 mAb. Both magnetic beads-based
and flow cytometry-based purification techniques yielded a highly ex-
pressing CD25+ population (95%–98% pure by FACS analysis), 90%
of which expressed Foxp3. The Treg cells:effector ratio in the suppres-
sion experiments was 1:1. Cells were cultured (5 3 104 cells/well) in
round-bottom 96-well plates (Becton-Dikinson Falcon, Franklin Lakes,
NJ) with RPMI medium supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (all from Life Technologies252 Immunity 26, 241–255, February 2007 ª2007 Elsevier Inc.Inc., Gaithersburg, MD) and 5% AB human serum (Sigma-Aldrich, St.
Louis, MO). Cells were stimulated for 3 days in the presence of anti-
CD3/CD28 Dynabeads (0.1 bead/cell) (Dynal-Biotech). On the last
day, [3H]thymidine (0.5 mCi/well) (Amersham-Pharmacia Biotech, Co-
logno Monzese, Italy) was added to the cultures and cells harvested
after 12 hr. Radioactivity was measured with a b-cell-plate scintillation
counter (Wallac, Gaithersburg, MD).
For suppression experiments in the mouse, Treg cells were isolated
with the Regulatory T Cell Isolation Kit (Miltenyi Biotec, Gladbach, Ger-
many) and stimulated with Dynabeads mouse anti-CD3/CD28 (0.5
bead/cell; 5 3 104 cells/well). The Treg cells:effector ratio in the sup-
pression experiments was 1:2. Purified cells (98% pure by FACS anal-
ysis) were cultured in round-bottom 96-well plates (Becton-Dikinson
Falcon) with RPMI medium supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin (Life Technologies) and
5% FCS or 5% mouse serum (Hyclone-Pierce, Rockford, IL). Cells
were stimulated for 3 days, labeled with [3H]thymidine (0.5 mCi/well)
for the last 16 hr of culture, and harvested similarly to what done for hu-
man T cell cultures.
Incorporation of Bromodeoxyuridine (BrdU) and FACS analysis were
performed in T cell cultures in serum-free medium (X-VIVO) with the
BrdU Flow Kit from BD-Pharmingen in accordance to the manufac-
turer’s instructions.
IL-2 Measurement
IL-2 measurement was done with the CTLL-2 cell line (kindly provided
by N. Davey, Imperial College London, UK) according to a previously
described method (Ng et al., 2001). Cells were maintained in culture
in supplemented RPMI medium with 10% FCS (Hyclone-Pierce) and
human recombinant (rh)-IL-2 (10 U/ml, Boehringer Mannheim, Man-
nheim, Germany). They were subcultured every 2 to 3 days. Cells
were rested in medium without IL-2 overnight prior to use in the assays.
Reagents, Leptin-Neutralizing Antibodies,
and Leptin Measurement
For in vitro blocking experiments, human leptin-neutralizing mAb (R&D
Systems, Minneapolis, MN) was used at a final concentration of 0.25 to
25 mg/ml; controls were irrelevant isotype-matched antibodies (Bio-
vendor Laboratory Medicine Inc., Brno, Czech Republic). Human re-
combinant leptin was purchased from R&D Systems. Human IL-2-neu-
tralizing mAb (MQ1-17H12) was from BD Pharmingen and was utilized
at final concentration of 5–10 mg/ml. FITC-anti-human-CD4 and PE-
anti-human-CD25 were from BD Pharmingen; the anti-human Foxp3
staining set was from eBiosciences (San Diego, CA). Recombinant
mouse GAD65 was purified from GAD65-producing cells that were
kindly provided by R. Tisch (University of North Carolina, Chapel Hill,
NC); recombinant GAD65 was tested for purity by SDS-PAGE and sil-
ver staining before the experimental use. The endotoxin content in the
preparations was below the detection limit (about 10 pg of endotoxin/
mg of protein) of the Limulus amebocyte lysate (LAL) method. Human
leptin-specific ELISA was purchased from R&D Systems and mea-
surements were performed according to the manufacturer’s instruc-
tions (Matarese et al., 2005). Serum-free media were RPMI (Life Tech-
nologies), HyQ-ADCF (Animal Derived Component Free, from
Hyclone-Pierce), and X-VIVO (BioWittaker).
Mice and In Vivo Experiments
6-week-old female leptin-deficient C57BL6/J-ob/ob (ob/ob),
C57BL6/J, leptin-receptor deficient C57BL/Ks-db/db (db/db), and
C57BL/Ks-db/+ lean controls (db/+) mice were purchased from Harlan
Italy s.r.l. (Corezzana, Italy); B10.Cg.Tg(TcrAND)53Hed/J (AND-TCR
Tg) PCC-specific transgenic mice were purchased from The Jackson
Laboratory (Bar Harbor, ME); NOD/LtJ and NOD-Leprdb5J/LtJ mutants
were kindly provided by E. Leiter from The Jackson Laboratory. Exper-
iments were conducted in accordance with the animal welfare guide-
lines under an approved protocol of the Istituto Superiore di Sanita`,
Roma, Italy. Mice were age-matched for individual experiments and
housed with a 12 hr light/dark cycle in the animal facility at the
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toneally twice daily for 10 days with mouse recombinant leptin (R&D
Systems) dissolved in 200 ml of PBS at a dose of 1 mg/g of body weight.
The mouse leptin-blocking antibody was produced in our laboratory
after immunization of C57BL/6J mice with mouse recombinant leptin
(R&D Systems) emulsified in complete Freund’s adjuvant (CFA) CFA
(Difco Laboratories, Detroit, MI); mouse leptin-specific antibodies (of
the IgM class) were affinity purified with recombinant mouse leptin
(R&D Systems) bound to AminoLink Plus Immobilization Gel (Amino-
Link Plus Immobilization Kit from Pierce, Rockford, IL) from serum
and ascites of immunized mice. Affinity-purified IgM were used as con-
trol (BD Pharmingen). WT mice were treated for 3 days either with
100 mg of control mouse IgM or with mouse leptin Abs intraperitoneally
in a total volume of 100 ml of PBS.
Adoptive transfer experiments were performed by labeling highly
purified (98% pure by FACS analysis) CD4+ T cells obtained from
C57BL6/J WT mice (cells were purified with the mouse CD4+ negative
isolation kit from Dynal) with the fluorescent dye CFSE (5-, 6-carboxy-
fluorescein diacetate succinimidyl ester) from Molecular Probes (Eu-
gene, OR) used at 1 mg/ml. In brief, 107 CFSE-labeled CD4+ T cells
were adoptively transferred into mice intravenously. 4 and 7 days later,
spleen cells were harvested from mice and stained with PE-anti-Foxp3
(eBioscience) and Cy-anti-CD4 (BD PharMingen). In experiments of
adoptive transfer performed with CFSE-labeled AND-TCR Tg CD4+ T
cells (98% pure), after 4 and 7 days, spleen cells were harvested
from recipient mice and stained with anti-clonotypic PE-anti-Va11.1
(RR8.1), biotynilated-anti-Vb3 (KJ25) (both from BD PharMingen),
and APC-anti-Foxp3 (eBioscience). Flow cytometric analysis of
CFSE dilution was performed by gating on CFSE+CD4+Foxp3+ cells
(in non-Tg mice) (Figures 6A and 6B) and on CFSE+Va11.1+/
Vb3+Foxp3+ cells (in AND-TCR Tg mice) (Figure 6C) with a FACScalibur
(Becton-Dickinson, San Diego, CA) and analyzed by Cell Quest soft-
ware (Becton-Dickinson).
Western Blots, Biochemical Analyses,
and Confocal Microscopy
Total cell lysates were obtained in 50 mM HEPES (pH 7.5), 250 mM
NaCl, 1 mM EDTA, 1.0% Triton X-100, 10 mM sodium fluoride,
1 mM sodium orthovanadate, and 2 mg/ml aprotinin, 2 mg/ml leupeptin,
and 2 mg/ml pepstatin. 50 mg of total proteins were subjected to SDS-
PAGE under reducing conditions. After electrophoresis, proteins were
transferred onto a nitrocellulose filter membrane (Protan, Schleicher &
Schuell) with a Trans-Blot Cell (Bio-Rad) and transfer buffer containing
25 mM Tris, 192 mM glycine, 20% methanol. Membranes were placed
in 5% nonfat milk in phosphate-buffered saline, 0.5% Tween 20 (PBST)
at 4C for 2 hr to block the nonspecific binding sites. Filters were incu-
bated with specific antibodies before being washed three times in
PBST and then incubated with a peroxidase-conjugated secondary
antibody (Amersham Biosciences). After washing with PBST, peroxi-
dase activity was detected with the ECL system (Amersham Biosci-
ences) or Femto (Pierce). The antibodies used were the following:
anti-p27Kip-1, anti-STAT3 and anti-phospho-STAT3 (Y705), anti-
STAT1 and anti-phospho-STAT1 (Y701) (Cell Signaling Technology,
Beverly, MA); anti-leptin, anti-ObR, anti-ERK 1/2, and anti-phospho-
ERK 1/2 (all from Santa Cruz Biotechnology Inc., Santa Cruz, CA);
anti-Foxp3 (eBioscience); anti-SOCS3 (Serotec Ltd, Kidlington, UK).
The filters were also probed with a tubulin antibody (Sigma) to normal-
ize the amount of loaded protein. Only for the human leptin western
blots, performed on a 15% SDS-PAGE gel to better visualize 16 kDa
leptin, normalization was performed against total ERK1/2. All filters
were quantified by densitometric analysis of the bands utilizing the
program ScionImage 1.63 for Mac (Scion Corporation, Frederick, MD).
Confocal microscopy was performed in parallel with proliferation
and biochemistry at 1 hr and 36 hr on 98% pure Treg cells and
CD4+CD25 cells. Cells were washed in PBS and 104 cells were
seeded on multitest slide (ICN Biomedicals Inc., Aurora, OH), air-dried
and fixed for 1 min in methanol, washed in PBS, permealized in PBS
containing 0.2% Triton X-100 for 3 min, and incubated in blocking so-Imlution (PBS 1% BSA) for 1 hr. Cells were then washed three times in
PBS and incubated overnight at 4C with primary antibodies (rabbit
polyclonal anti-leptin and mouse anti-ObR mAb, both from Santa
Cruz Biotechnology Inc.) diluted 1:100 in blocking solution, washed
in PBS, and incubated with the secondary antibody (goat anti-rabbit
488 and goat anti-mouse 543, both from Molecular Probes Inc.) for
1 hr at room temperature diluted 1:100 in blocking solution, washed
in PBS, and finally mounted in PBS/Glycerol 1:1. Immunofluorescence
analysis was performed with a confocal laser scanner microscope
Zeiss LSM 510. The wavelength of the Argon ion laser was set at
488 nm; that of the HeNe laser was set at 543 nm. Fluorescence emis-
sion was revealed by BP 505–530 band pass filter for Alexa Fluor 488
and by BP 560-615 band pass filter for Alexa Fluor 543. Double-stain-
ing immunofluorescence images were acquired simultaneously in the
green and red channels at a resolution of 1024 3 1024 pixels.
Statistical Analysis
Analyses were performed with the Mann-Whitney U-test for unrelated
two-group analyses and the Kruskal-Wallis ANOVA test for three or
more group analyses with the StatView software (Abacus Concepts
Inc., Cary, NC). Results are expressed as mean ± SD. p values <
0.05 were considered statistically significant.
Supplemental Data
Seven Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/26/2/241/DC1/.
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Recent	evidence	has	indicated	that	leptin,	an	adipocyte-secreted	hormone	belonging	to	the	helical	cytokine	
family,	significantly	influences	immune	and	autoimmune	responses.	We	investigate	here	the	mechanisms	by	
which	in	vivo	abrogation	of	leptin	effects	protects	SJL/J	mice	from	proteolipid	protein	peptide	PLP139–151-
induced	EAE,	an	animal	model	of	MS.	Blockade	of	leptin	with	anti-leptin	Abs	or	with	a	soluble	mouse	leptin	
receptor	chimera	(ObR:Fc),	either	before	or	after	onset	of	EAE,	improved	clinical	score,	slowed	disease	pro-
gression,	reduced	disease	relapses,	inhibited	PLP139–151-specific	T	cell	proliferation,	and	switched	cytokine	
secretion	toward	a	Th2/regulatory	profile.	This	was	also	confirmed	by	induction	of	forkhead	box	p3	(Foxp3)	
expression	in	CD4+	T	cells	in	leptin-neutralized	mice.	Importantly,	anti-leptin	treatment	induced	a	failure	to	
downmodulate	the	cyclin-dependent	kinase	inhibitor	p27	(p27Kip-1)	in	autoreactive	CD4+	T	cells.	These	effects	
were	associated	with	increased	tyrosine	phosphorylation	of	both	ERK1/2	and	STAT6.	Taken	together,	our	data	
provide	what	we	believe	is	a	new	molecular	basis	for	leptin	antagonism	in	EAE	and	envision	novel	strategies	
of	leptin-based	molecular	targeting	in	the	disease.
Introduction
Leptin is a cytokine-like hormone that links nutritional status with 
the immune system (1, 2). It is mainly produced by adipose tissue 
in proportion to body mass index and at lower levels by organs 
such as the stomach and placenta (1, 2). Leptin regulates body 
weight through inhibition of food intake and stimulation of ener-
gy expenditure. Moreover, leptin affects both innate and adaptive 
immunity (2, 3). On innate immunity, leptin modulates the activ-
ity of neutrophils, increases the phagocytosis of monocytes/mac-
rophages, and enhances the secretion of inflammatory mediators 
of the acute phase response (2, 3). On adaptive immunity, leptin 
promotes proliferation and IL-2 secretion by naive T cells, whereas 
on memory T cells it promotes the switch toward Th1 immune 
response by increasing IFN-γ and TNF-α secretion (2, 3). Another 
important role of leptin in adaptive immunity is highlighted by 
the observation that leptin-deficient ob/ob mice are resistant to 
induction of EAE, an animal model of MS (2, 4).
EAE can be induced in susceptible strains of mice by immuniza-
tion with self antigens derived from myelin. The disease is charac-
terized by chronic or relapsing/remitting paralysis due to autore-
active Th1 CD4+ cells that infiltrate the brain and spinal cord and 
damage the self antigen myelin (5, 6). A direct role of CD4+ T cells 
in the pathogenesis of EAE has been demonstrated in adoptive 
transfer studies, where myelin-reactive Th1 CD4+ T cells induced 
the disease after transfer (5, 6).
We have recently reported that leptin administration to sus-
ceptible mice worsens EAE by increasing secretion of proinflam-
matory cytokines (4). In a similar fashion, leptin replacement in 
leptin-deficient ob/ob mice restores susceptibility to both active 
and passive EAE (4). Since we and others have also described that 
leptin is expressed in active inflammatory lesions of the CNS dur-
ing acute EAE and MS (7–9), we investigated the molecular effects 
of leptin neutralization either with anti-mouse leptin Abs or with 
soluble mouse leptin receptor chimera-Fc (ObR:Fc), on induction 
and progression of EAE.
Results
Leptin blockade improves clinical score and delays disease progression in 
actively induced EAE. We evaluated the ability of either anti-leptin 
neutralizing Abs or ObR:Fc to affect induction and progression 
of EAE after  immunization with proteolipid protein 139–151 
(PLP139–151) myelin peptide. Treatment with anti-leptin Abs or 
ObR:Fc was initiated prior to immunization (from day –1 to day 1 
relative to immunization) or during the acute phase of the disease 
(days 8–11), for 3 and 4 consecutive days, respectively (Figure 1, 
A and B, and Table 1; see Methods for details). In both cases, leptin 
neutralization led to a statistically significant reduction in EAE 
clinical score and percentage of initial body weight loss as well as 
a reduced number of inflammatory infiltrates (Figure 1, A and B, 
and Table 1). These effects led to significant clinical improvement 
and delayed disease progression during the following 40 days of 
observation (Figure 1, A and B, and Table 1), indicating that leptin 
blockade inhibited both development and progression of EAE. 
Moreover, observation of animals over a longer period of time 
(90–120 days) revealed a significant reduction in relapse rate (Table 1), 
suggesting that this protection was long lasting.
Nonstandard	abbreviations	used: DTH, delayed-type hypersensitivity; Foxp3, fork-
head box p3; ObR:Fc, leptin receptor chimera-Fc; PLP, proteolipid protein; p27Kip-1, 
cyclin-dependent kinase inhibitor p27; VLA-4, very late antigen-4.
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Leptin blockade improves clinical score and delays disease progression in 
passively induced EAE. We next tested the ability of either anti-leptin 
Abs or ObR:Fc to modify the onset and progression of adoptively 
transferred EAE (Figure 2, A and B, and Table 1). Treatment with 
Abs was repeated for 3–4 consecutive days, before (from day –1 to 
day 1) or after (days 8–11) the adoptive transfer of 2 × 107 puri-
fied PLP139–151-specific CD4+ T cells (see Methods). Mice treated 
with control Igs all developed severe 
EAE (Figure 2A and Table 1). In con-
trast, mice treated with anti-leptin Abs 
from day –1 to day 1 displayed a milder 
disease (Figure 2A and Table 1), while 
those treated on days 8–11 were fully 
protected  (Figure  2A  and  Table  1). 
Treatment with ObR:Fc from day –1 
to day 1 also led to a reduction of EAE 
clinical signs and delayed progression 
of the disease with significantly more 
efficiency than did anti-leptin Ab treat-
ment from day –1 to day 1 (Figure 2, 
A and B, and Table 1). A  significant 
reduction in the relapse rate was also 
found in animals observed for 90–120 
days (Table 1).
Leptin blockade is accompanied by inhi-
bition of delayed-type hypersensitivity and 
reduces autoreactive T cell proliferation to 
PLP139–151 peptide during EAE. To deter-
mine the nature of the in vivo T cell 
response against PLP139–151 peptide in 
leptin-neutralized mice, delayed-type 
hypersensitivity (DTH) reactions were 
performed in all groups of mice. On day 35 of observation, mice 
were challenged with 25 µg PLP139–151 peptide injected intra-
dermally in the footpad. The degree of local footpad swelling 
was measured as readout for the DTH reaction (see Methods). 
Typical DTH kinetics were observed with  footpad  swelling 
peaking between 24–48 hours and subsiding after 72–96 hours. 
DTH responses to the PLP139–151 peptide priming epitope were 
Figure 
Leptin blockade during actively induced EAE with either anti-leptin Abs or ObR:Fc reduces the clini-
cal severity of EAE. (A) Mean clinical score of SJL/J female mice treated with anti-mouse leptin Abs 
injected either from day –1 to day 1 or on days 8–11 (100 µg/d i.p.). Leptin blockade significantly 
delayed disease onset and reduced clinical score and body weight loss (see Table 1). Data are from 
1 representative experiment of 3. (B) Mean clinical score of SJL/J female mice treated with mouse 
ObR:Fc chimera injected either from day –1 to day 1 or on days 8–11 (100 µg/d i.p.). Data are from 1 
representative experiment of 3. §P = 0.01, day –1 to day 1, #P = 0.02, day –1 to day 1, and †P = 0.04, 
days 8–11, versus PBS or control Ig.
Table 
Effect of treatment with either anti-leptin Abs or ObR:Fc chimera on neurological impairment during active and passive EAE in SJL/J 
female mice
Group	 Incidence,	 Day	of	onset	 Peak	clinical	 Average	 Body	wt	at	disease	 No.	inflammatory	 Relapse	rate	
	 no./total	(%)	 (range)	 score	 CDIA	 peak	(%	of	original)	 foci	 after	treatmentB
PBS (active EAE) 18/18 (100.0) 9.0 ± 0.5 (8–9) 3.6 ± 0.9 70.9 ± 13.0 71.5 ± 0.8 45.5 ± 10.0 2.00
Control IgM 18/18 (100.0) 8.1 ± 0.5 (8–9) 3.5 ± 1.0 70.3 ± 8.5 74.7 ± 0.5 40.1 ± 5.0 1.94
Anti-leptin (–1 to 1) 18/18 (100.0) 11.8 ± 1.0 (10–13) 2.0 ± 0.5C 30.7 ± 6.0C 83.8 ± 0.6C 15.5 ± 10.0C 0.55
Anti-leptin (8–11) 18/18 (100.0) 12. 1 ± 3.0 (8–16) 1.6 ± 0.8D 20.1 ± 10.7D 95.1 ± 0.6D 9.0 ± 4.0D 0.33
PBS (active EAE) 18/18 (100.0) 8.0 ± 0.5 (8–9) 2.7 ± 0.8 51.7 ± 8.0 77.0 ± 0.5 31.0 ± 10.0 1.55
Control IgG1 18/18 (100.0) 8.1 ± 0.4 (8–9) 2.6 ± 0.5 49.5 ± 7.0 77.5 ± 0.5 31.9 ± 12.0 1.66
ObR:Fc (–1 to 1) 18/18 (100.0) 9.4 ± 1.0 (8–12) 1.2 ± 0.4C 28.5 ± 10.0C 87.5 ± 0.4C 15.0 ± 7.0C 0.55
ObR:Fc (8–11) 17/18 (94.4) 9.0 ± 0.5 (8–10) 0.9 ± 0.5D 22.1 ± 12.0D 101.4 ± 0.1D 11.0 ± 5.0D 0.55
PBS (passive EAE) 18/18 (100.0) 7.1 ± 1.0 (6–8) 2.8 ± 1.0 39.0 ± 5.0 75.1 ± 1.0 27.0 ± 5.0 1.38
Control IgM 18/18 (100.0) 7.0 ± 0.7 (6–8) 2.6 ± 0.8 36.6 ± 3.0 79.0 ± 0.8 27.5 ± 6.0 1.44
Anti-leptin (–1 to 1) 18/18 (100.0) 8.8 ± 2.0 (6–11) 1.6 ± 0.8C 25.9 ± 6.0C 81.5 ± 1.2C 10.5 ± 9.0C 0.61
Anti-leptin (8–11) 14/18 (77.7) 17.8 ± 1.1 (17–20) 0.3 ± 0.4D 6.6 ± 2.0D 106.0 ± 2.0D 0.2 ± 0.5D 0.05
PBS (passive EAE) 18/18 (100.0) 7.2 ± 1.2 (7–8) 3.1 ± 1.0 44.5 ± 3.0 78.0 ± 1.0 35.5 ± 6.0 1.27
Control IgG1 18/18 (100.0) 7.5 ± 0.7 (7–8) 3.0 ± 0.9 41.5 ± 2.5 78.0 ± 2.0 34.3 ± 10.5 1.33
ObR:Fc (–1 to 1) 14/18 (77.7) 9.5 ± 0.7 (8–10) 0.5 ± 0.0D 8.6 ± 1.0D 101.4 ± 1.2D 0.5 ± 0.1D 0.00
ObR:Fc (8–11) 13/18 (72.2) 10.0 ± 0.7 (8–10) 0.5 ± 0.0D 10.5 ± 1.0D 102.9 ± 2.0D 0.5 ± 0.4D 0.00
Data were cumulated and averaged from 3 independent experiments, each performed with 6 mice per group, and are presented as mean ± SD. See Meth-
ods for details of isotype controls utilized. CDI, cumulative disease index. AThe sum of daily scores was determined for each mouse of the indicated group 
and averaged. BCalculated as total number of relapses per group divided by the total number of mice in that group (mice were observed up to 90–120 days 
after disease induction to asses the relapse rate). CP = 0.001 and DP = 0.0001 versus respective PBS and control Ig groups.
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significantly reduced in mice treated with anti-leptin Abs and 
ObR:Fc, whereas the controls exhibited a marked DTH reaction 
(Figure 3A and Figure 4A).
We also examined whether leptin blockade could affect pro-
liferation of PLP139–151-specific T cells in vitro. T cell response to 
PLP139–151 peptide was tested on draining lymph nodes taken from 
all groups of treated mice 15 days after immunization and cul-
tured in the presence of increasing concentrations of PLP139–151. T 
cells derived from either anti-leptin Abs– or ObR:Fc-treated mice 
showed a significant reduction in proliferation (Figure 3B and Fig-
ure 4B, respectively), whereas no difference was observed when T 
cells were stimulated in parallel with a polyclonal stimulator such 
as the anti-CD3ε mAb (2C11 hybridoma, Figure 3C and Figure 4C, 
respectively; see Methods). Of note, inhibi-
tion of in vitro anti-PLP139–151 proliferation 
was more efficient in mice treated with the 
ObR:Fc chimera (Figure 3B and Figure 4B).
Leptin blockade in EAE is associated with a 
switch of the cytokine profile toward a Th2/regu-
latory phenotype and upregulation of forkhead 
box p3 expression. We next asked whether 
EAE  protection was  associated with  an 
immune  response characterized by con-
siderable cytokine switching. The produc-
tion of  IFN-γ was  significantly  reduced 
by both leptin-neutralizing treatments in 
the presence of increasing concentrations 
of PLP139–151 as well as during polyclonal 
anti-CD3ε stimulation (Figure 5, A and B, 
and Figure 6, A and B). In addition, a sig-
nificant  increase  in  the Th2/regulatory-
type cytokines such as  IL-4  (Figure 5, C 
and D, and Figure 6, C and D) and IL-10 
(Figure, 5, E and F, and Figure 6, E and F) 
was observed during both anti-PLP139–151–
specific proliferation and polyclonal stimu-
lation with anti-CD3ε. In addition, to determine whether treatment 
with ObR:Fc induced forkhead box p3 (Foxp3) expression in CD4+ 
T cells, we isolated these cells from mice with EAE and measured 
Foxp3 expression by Western blot. Leptin neutralization induced 
significant increase of Foxp3 levels (Figure 7, A and B), suggesting 
induction of regulatory T cell markers in leptin-neutralized mice.
Leptin neutralization reduces the expression of ICAM-1 and OX-40 
and upregulates very late antigen-4 on CD4+ T cells during EAE. We 
then investigated in more detail the cellular events leading to 
an improvement of clinical symptoms and progression of EAE. 
Cytofluorimetric analysis of CD4+ T cells from mice treated with 
anti-leptin Abs or ObR:Fc obtained on day 15 after immunization 
with PLP139–151 revealed a significant reduction of ICAM-1 and 
Figure 
Leptin blockade during adoptively transferred EAE with either anti-leptin Abs or ObR:Fc chi-
mera reduces the clinical severity of EAE. (A) Mean clinical score of SJL/J female mice treated 
with anti-mouse leptin Abs injected either from day –1 to day 1 or on days 8–11 (100 µg/d i.p.). 
Leptin blockade significantly reduced clinical score and body weight loss (see Table 1). Data are 
from 1 representative experiment of 3. #P = 0.02, day –1 to day 1, and **P = 0.001, days 8–11, 
versus PBS or control Ig; ‡P = 0.02, day –1 to day 1 versus days 8–11. (B) Mean clinical score 
of SJL/J female mice treated with mouse ObR:Fc chimera injected either from day –1 to day 1 
or on days 8–11 (100 µg/d i.p.). Data are from 1 representative experiment of 3. **P = 0.001, 
day –1 to day 1 and days 8–11 versus control Ig.
Figure 
In vivo leptin neutralization with anti-mouse leptin Abs in SJL/J mice inhibits DTH response and induces T cell hyporesponsiveness to PLP139–151 
myelin peptide. (A) DTH reaction in leptin-neutralized and control Ig–treated mice measured as footpad swelling. Data are from 1 representative 
experiment of 2. (B) Proliferative response of lymph node–derived T cells against PLP139–151 was impaired after treatment with anti-mouse leptin-
neutralizing Abs compared with the control Ig–treated group. Data are from 1 representative experiment of 3. (C) Anti-mouse leptin treatment did 
not affect polyclonal T cell proliferation induced with anti-CD3ε stimulation. #P = 0.02, day –1 to day 1 and days 8–11 versus control Ig.
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OX-40 (Figure 8, A and B, respectively), both classically involved 
in the pathogenesis of EAE (10–12). Conversely, the overall expres-
sion of the α4β1 integrin, very late antigen-4 (VLA-4) (13), was 
increased, with particular upregulation of the population at high 
fluorescence intensity (Figure 8C). The effects of leptin blockade 
on lymphocytes could not be ascribed to intrinsic toxicity of the 
molecule, as the circulating number and apoptosis (measured by 
annexin V staining) of CD4+, CD8+, B, γδ, NK, and monocytes in 
the spleen and lymph nodes of treated mice were not different 
from controls (data not shown).
Ex vivo CD4+ T cells from leptin-neutralized mice fail to downregulate the 
anergy factor cyclin-dependent kinase inhibitor p27 and induce the ERK1/2 
and STAT6 pathways. To evaluate whether leptin neutralization 
affects the molecular machinery of autoreactive CD4+ T cells, we 
analyzed a series of biochemical markers specific to T cell activa-
tion, anergy, and Th2/regulatory-type cytokine secretion (14–18). 
More specifically, we studied ex vivo purified CD4+ autoreactive 
T cells from spleens and lymph nodes of ObR:Fc-treated mice on 
day 15 of disease, previously immunized with PLP139–151 peptide 
(see Methods). In CD4+ T cells ObR:Fc treatment led to a failure to 
downmodulate the cyclin-dependent kinase inhibitor p27 (p27Kip-1; 
Figure 9A) associated with increased tyrosine phosphorylation of 
ERK1/2 (Figure 9B). Moreover, we observed an upregulation of 
STAT6 tyrosine phosphorylation levels (Y641, known to be associ-
ated with Th2/regulatory-type cytokine secretion; ref. 18) in ObR:
Fc-treated mice compared with control mice (Figure 9C).
Discussion
Previous studies by our group and others have shown the relevance 
of leptin in the pathogenesis of EAE (4, 7–9). In particular, it was 
previously reported that ob/ob mice are resistant to induction of the 
disease (4), whereas in wild-type, EAE-susceptible controls, a surge 
of serum leptin precedes acute EAE (7). In this work, we show for 
the first time to our knowledge that in vivo neutralization of leptin 
is effective at blocking initiation, progression, and clinical relapses 
of EAE, an animal model of MS (Figures 1 and 2 and Table 1).
We and others have previously reported that in the CNS of 
EAE mice, both infiltrating T cells and neurons express leptin 
during the acute phase of the disease, and the degree of leptin 
expression within the lesions correlates with CNS inflammatory 
score and disease severity (7, 9). Because of the possibility of an 
autocrine loop sustaining autoreactive Th1 lymphocytes in EAE 
(7, 8), we investigated the DTH response as well as T cell prolif-
eration and cytokine secretion in response to PLP139–151 in treat-
ed mice versus controls. Anti-leptin–treated animals showed 
reduced DTH and T cell proliferative responses to PLP139–151 
peptide associated with a Th2/regulatory-type cytokine shift 
(Figures 3–6). This evidence was also supported by increased 
expression levels of the regulatory T cell master gene Foxp3 in 
CD4+ T cells from mice with EAE (Figure 7).
It is interesting to note that in vivo leptin neutralization differ-
entially affected proliferative responses and regulatory cytokine 
switch during polyclonal anti-CD3 stimulation (Figures 3–6). 
Indeed, while we observed a reduction of proliferation and a 
Th2/regulatory  cytokine  switch  toward PLP139–151,  anti-CD3 
polyclonal stimulation was only affected in terms of cytokine 
secretion and not of proliferative response at the relatively low 
doses of leptin blockers utilized in vivo. The evidence that leptin 
itself differentially  influences polyclonal versus antigen-spe-
cific proliferation and cytokine secretion may account for these 
apparently contrasting effects (19). On the other hand, it is also 
possible to speculate that leptin neutralization–induced pertur-
bations of the cytokine milieu during antigen-specific stimula-
tion may preferentially modulate cytokine profile rather than 
proliferative responses induced by anti-CD3.
Leptin blockade also affected expression of ICAM-1, OX-40, and 
VLA-4 on CD4+ T cells (Figure 8). In particular, reduced expression 
of ICAM-1 was consistent with our previous findings showing that 
leptin treatment increases surface expression of this adhesion mol-
ecule on T cells (20). This finding suggested the possibility that 
neutralization of leptin directly affects the cognate interaction 
leading to reactive and/or autoreactive T cell activation. More-
Figure 
In vivo leptin neutralization with mouse ObR:Fc chimera in SJL/J mice inhibits DTH response and induces T cell hyporesponsiveness to PLP139–151 
myelin peptide. (A) DTH reaction in ObR:Fc leptin-neutralized and control Ig–treated mice measured as footpad swelling. Data are from 1 rep-
resentative experiment of 2. #P = 0.02, day –1 to day 1 and days 8–11 versus control Ig. (B) Proliferative response of lymph node–derived T 
cells against PLP139–151 was impaired after treatment with mouse ObR:Fc chimera compared with the control Ig–treated group. Data are from 1 
representative experiment of 3. **P = 0.001, day –1 to day 1, and #P = 0.02, days 8–11, versus control Ig. (C) ObR:Fc treatment did not affect 
polyclonal T cell proliferation induced with anti-CD3ε stimulation.
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over, marked reduction of OX-40 was also observed after leptin 
blockade. Since OX-40 is an important costimulatory molecule 
with prosurvival activity for CD4+ T cells, and signaling through 
this molecule breaks peripheral T cell tolerance (11, 21), our data 
suggest that leptin may affect expression of key molecules on T 
lymphocytes involved in the mechanisms of immune tolerance. 
Surprisingly, we also observed that leptin neutralization induced 
increased expression of VLA-4, the α4β1 integrin shown to play an 
integral part in the homing and migration of cells that induce EAE 
(13). However, experimental evidence has shown that administra-
tion of anti–VLA-4 ameliorated EAE only if it was initiated before 
disease onset, whereas treatment during acute disease exacerbated 
EAE and enhanced the accumulation of T cells in the CNS (13). 
Therefore, we are tempted to hypothesize that the induction of 
VLA-4 on CD4+ T cells after leptin neutralization could be associ-
ated in part with an increased cell capability to migrate into the 
CNS and produce regulatory cytokines able to downmodulate 
EAE. Of note, these data are in agreement with other findings 
showing that adhesion molecules are increased on regulatory T 
cells in experiments of protection from EAE (22, 23).
To further address, at the biochemical level, whether in vivo 
leptin neutralization interferes with the signalling capacity of 
autoreactive T cells, we analyzed several molecular pathways asso-
ciated with T cell anergy/activation and cytokine switch (14–18). 
We found that CD4+ T cells from mice treated with leptin antago-
nists showed hyporesponsiveness to PLP139–151 peptide, which 
was indicated by accumulation of p27Kip-1. This negative cell cycle 
regulator plays a central role in blocking clonal expansion of 
T cells and is therefore critical for anergy induced by blockade 
of costimulatory pathways (14, 17, 24). We also found that the 
hyporesponsive state induced by leptin antagonism was associ-
ated with marked increase of ERK1/2 phosphorylation, confirm-
ing involvement of ERK1/2 in the improvement of EAE (25). It is 
interesting to observe that our findings with leptin antagonism 
seem to involve pathways affected by statins, cholesterol-lower-
ing drugs that have recently been shown to reduce production of 
leptin by adipocytes (26), promote Th2 responses, and improve 
EAE (27) by disabling downregulation of p27Kip-1 and upregulat-
ing phosphorylation of ERK1/2 (28). Finally, we also observed 
at the biochemical level the induction of phosphorylation of the 
Figure 
In vivo leptin neutralization with anti-mouse leptin Abs inhibits IFN-γ production and induces the secretion of IL-4 and IL-10 regulatory cytokines. 
(A and B) IFN-γ secretion of lymph node–derived T cells was inhibited by anti-leptin treatment when T cells were stimulated with the myelin anti-
gen PLP139–151 (A) and by anti-CD3ε (B). (C and D) IL-4 secretion of lymph node–derived T cells was enhanced by anti-leptin treatment when T 
cells were stimulated with the myelin antigen PLP139–151 (C) and by anti-CD3ε (D). (E and F) IL-10 secretion of lymph node–derived T cells was 
markedly increased by anti-leptin treatment when T cells were stimulated with the myelin antigen PLP139–151 (E) and by anti-CD3ε (F). (A, C, and 
E) #P = 0.02, day –1 to day 1 and days 8–11, and **P = 0.001, days 8–11, versus control Ig. Data are from 1 representative experiment of 3. (B, 
D, and F) #P = 0.02, **P = 0.001, *P = 0.002, †P = 0.04 versus control Ig.
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STAT6 transcription factor, well known to be able to induce the 
transcription of IL-4 and associated with a classical Th2/regula-
tory-type cytokine response during EAE (18).
In conclusion, we report that  leptin neutralization was able 
to improve clinical onset, progression, and clinical relapses of 
both actively induced and passively transferred EAE. This effect 
was associated with marked inhibition of DTH reaction against 
PLP139–151 peptide, CD4+ T cell hyporesponsiveness, and increased 
IL-4 and IL-10 production against myelin antigens. Foxp3 expres-
sion was also induced on CD4+ T cells in leptin-neutralized mice, 
suggesting the induction of a regulatory phenotype. At the bio-
chemical level, T cell hyporesponsiveness might be explained by 
the failure to downmodulate the anergy factor p27Kip-1 and by 
the increase in the tyrosine phosphorylation levels of ERK1/2 
and STAT6. Taken together, our results provide a framework for 
leptin-based intervention in EAE and identify molecules with pos-
sible therapeutic potential for the disease.
Methods
Mice. Female SJL/J mice (H-2s), 6–8 weeks old, were obtained from Harlan-
Italy. All animal experiments were approved by the Istituto Superiore di 
Sanità (Rome, Italy). All mice were age matched for individual experiments 
and were group housed (2–6 mice per standard cage according to the differ-
ent experimental protocol) with a 12-
hour light/dark cycle. Paralyzed mice 
were afforded easier access to food 
and water to prevent dehydration.
Reagents and Abs.  We  used  the 
immunodominant mouse PLP139–151 
peptide (HSLGKWLGHPDKF) in this 
study. It was synthesized by INBIOS 
s.r.l.; purity was assessed by HPLC 
(>97% pure), and amino acid compo-
sition was verified by mass spectrom-
etry. PLP139–151 peptide batches for in 
vivo and in vitro assays were all from 
1 preparation initially solubilized in 
LPS-free saline solution at 4 mg/ml 
concentration and stored at –80°C.
ObR:Fc was  from R&D Systems. 
It is constituted by the extracellular 
domain  of  mouse  leptin  receptor 
(ObR) fused to the Fc region of human 
IgG1. The endotoxin level for all exper-
imental Abs was ≤0.1 ng/µg protein. 
The mouse anti-leptin polyclonal Ab 
was produced in our laboratory after 
immunization of C57BL/6J mice with 
mouse recombinant leptin (R&D Sys-
tems) emulsified in CFA (Difco; BD 
Diagnostics — Diagnostic Systems); 
anti-mouse  leptin-specific  Abs  (of 
the IgM class) were affinity purified 
from serum and ascites of immunized 
mice, with recombinant mouse leptin 
bound to AminoLink Plus Immobili-
zation Gel (AminoLink Plus Immobi-
lization kit; Pierce Biotechnology Inc.). 
For treatment with anti-leptin Abs, 
affinity-purified IgM was used as a 
control (BD Biosciences — Pharmingen); for ObR:Fc fusion protein treatment, 
affinity-purified IgG1 was used as a control (BD Biosciences — Pharmingen).
EAE induction and clinical and histological assessment. For active induction of 
EAE, mice (n = 6 per group) were immunized s.c. in the flank with 100 µl 
CFA (Difco; BD Diagnostics — Diagnostic Systems) emulsified with 100 µg 
PLP139–151 peptide on day 0 and with 200 ng pertussis toxin (Sigma-Aldrich 
s.r.l.) i.p. on days 0 and 1. Control mice (n = 5 per group) were injected with 
CFA emulsified with PBS plus pertussis toxin according to the same sched-
ule (data not shown). For adoptively transferred EAE, 9–10 female donor 
SJL/J mice (6–8 weeks old) were primed s.c. with 200 µg PLP139–151 peptide 
in CFA distributed over 4 sites. After 9–10 days, draining lymph nodes (axil-
lary and inguinal) and spleens were harvested, homogenized into single-
cell suspension, and cultured separately in vitro in 24-well plates (8 × 106 
cells/well, Falcon; BD) in the presence of 25 µg/ml PLP139–151 peptide. After 
4 days in culture, nonadherent cells were harvested and centrifuged over 
Ficoll gradient (Pharmacia), and CD4+ T cells were purified by passing the 
cells over the CD4+ subset columns (R&D Systems). Recipient syngene-
ic naive female SJL/J mice received, in a 200-µl PBS i.v. injection, 2 × 107 
highly purified PLP139–151-specific CD4+ T cells. Mice also received 200 ng 
pertussis toxin immediately after cell transfer as well as 1 day later.
Individual mice were observed daily for clinical signs of disease for up to 40 
days after immunization and after adoptive transfer. Mice were weighed and 
scored daily in a blinded fashion according to clinical severity of symptoms 
Figure 
In vivo leptin neutralization with ObR:Fc inhibits IFN-γ production and induces the secretion of IL-4 and 
IL-10 regulatory cytokines. (A and B) IFN-γ secretion of lymph node–derived T cells was inhibited by ObR:
Fc treatment when T cells were stimulated with the myelin antigen PLP139–151 (A) and by anti-CD3ε (B). 
(C and D) IL-4 secretion of lymph node–derived T cells was enhanced by ObR:Fc treatment when T cells 
were stimulated with the myelin antigen PLP139–151 (C) and by anti-CD3ε (D). (E and F) IL-10 secretion of 
lymph node–derived T cells was markedly increased by ObR:Fc treatment when T cells were stimulated 
with the myelin antigen PLP139–151 (E) and by anti-CD3ε (F). Data are from 1 representative experiment of 3. 
(A) **P = 0.001, day –1 to day 1 and days 8–11 versus control Ig. (C) **P = 0.001, day –1 to day 1, and 
†P = 0.04, days 8–11, versus control Ig. (E) **P = 0.001, days 8–11, and #P = 0.02, day –1 to day 1, versus 
control Ig. (B, D, and F) #P = 0.02, *P = 0.002, †P = 0.04 versus control Ig.
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on a scale of 0 to 6, with 0.5 points for intermediate clinical findings: grade 
0, no abnormality; grade 0.5, partial loss of tail tonicity, assessed by inability 
to curl the distal end of the tail; grade 1, reduced tail tone or slightly clumsy 
gait; grade 2, tail atony, moderately clumsy gait, impaired righting ability, 
or any combination; grade 3, hind limb weakness or partial paralysis; grade 
4, complete hind limb paralysis or fore limb weakness; grade 5, tetraplegia 
or moribund state; grade 6, death. The data were plotted as daily 
mean clinical score for all animals in a particular treatment group. 
Scores of asymptomatic mice (i.e., scores of 0) were included in 
the calculation of the daily mean clinical score for each group. A 
relapse was defined as a sustained (more than 2 days) increase in 
clinical score by at least 1 full grade after the animal had improved 
previously by at least 1 full grade and stabilized for at least 2 days. 
The data are plotted as the relapse rate of all the animals of that 
group (total number of relapses per group divided by total number 
of mice in the group; see Table 1). The brains and spinal cords were 
dissected between 15 and 20 days after immunization, according 
to the clinical stage of disease, and fixed in 10% formalin. Paraffin-
embedded sections of 5 µm thickness were cut and stained with 
H&E (Sigma-Aldrich). Sections from 4–10 segments per mouse 
were examined blindly for the number of inflammatory foci by 
using a previously published scoring system (7, 8).
In vivo Ab treatment. Mice were treated 3 or 4 times with 100 µg 
control mouse IgM or control mouse IgG1 or with anti-mouse 
leptin-specific blockers (either anti-leptin Abs or ObR:Fc chimera, 
respectively) i.p. in a total volume of 100 µl of PBS. Treatment was 
initiated with PLP139–151 peptide or the adoptive transfer of patho-
genic T cells for 3 consecutive days (days –1, 0, and 1) or during the 
acute phase of the disease for 4 consecutive days (days 8–11).
Induction of DTH (footpad-swelling assay). DTH responses  to 
PLP139–151 peptide during induction of disease were also quan-
titated using a time-dependent (12–72 hours) footpad-swelling 
assay. Briefly, mice previously sensitized with PLP139–151 in CFA 
were challenged by s.c. injection of 25 µg PLP139–151 (in 50 µl PBS) into the 
right hind footpad. PBS alone was injected into the left footpad to serve 
as a control for measurements. As a negative control, we used mice sensi-
tized with CFA alone. Footpad thickness was measured 12, 24, 48, and 72 
hours after challenge by an experimenter blinded to sample identity using 
a caliper-type engineer’s micrometer. The footpad swelling response was 
calculated as the thickness of the right footpad (receiving antigen) minus 
the baseline thickness of the left footpad (receiving PBS).
Proliferation assays and cytokine analysis. Spleen and lymph node cells were 
obtained from mice 15 days after PLP139–151 sensitization, dissociated into 
single-cell suspension, and cultured	for proliferation assays in flat-bot-
tomed, 96-well microtiter plates (Falcon; BD) at a density of 5 × 105 viable 
cells per well in a total volume of 200 µl RPMI-1640 medium (Invitrogen 
Figure 
Increased expression of Foxp3 in CD4+ T cells induced by leptin 
neutralization in mice with EAE. (A) Western blot analysis for Foxp3 
on purified CD4+ T cells obtained from SJL/J mice immunized with 
PLP139–151 revealed significant increase of the expression of this mol-
ecule after leptin neutralization with ObR:Fc. (B) Results are presented 
as Foxp3 protein level normalized to tubulin expression. Data are from 
1 representative experiment of 3.
Figure 8
Leptin neutralization suppresses ICAM-1 and OX-40 expres-
sion on CD4+ cells but upregulates VLA-4 in mice with EAE. (A) 
Flow cytometric analysis of cell-surface ICAM-1 molecules on 
CD4+ T cells from ObR:Fc-treated mice and controls (left) and 
mean fluorescence intensity (MFI) from 3 independent experi-
ments (right). (B) OX-40 surface expression was also reduced 
by ObR:Fc treatment. (C) VLA-4 expression was enhanced by 
ObR:Fc treatment, particularly on CD4+ T cells at high inten-
sity. #P = 0.02, *P = 0.002, †P = 0.04 versus control Ig.
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Corp.) supplemented with 2% FCS (Invitrogen Corp.), 2 mM l-glutamine 
(Invitrogen Corp.), 0.1 mM nonessential amino acids (Invitrogen Corp.), 
1 mM sodium pyruvate (Invitrogen Corp.), 50 µM 2-mercaptoethanol 
(Sigma-Aldrich), and 100 U/ml penicillin and 100 µg/ml streptomycin 
(Invitrogen Corp.). Cells were cultured at 37°C in 100% humidity and 5% 
CO2 in the presence or absence of varying concentrations of PLP139–151 
peptide (0–50 µg/ml). As a control for proliferation, anti-CD3 Ab stimula-
tion (2C11, 0.5 µg/ml final concentration; BD Biosciences – Pharmingen) 
was also performed. After 48–60 hours’ culture, cell supernatants (100 µl) 
were removed from single wells and frozen at –80°C for cytokine assay. IFN-γ, 
IL-4, and IL-10 were measured by ELISA developed in our laboratory using 
cytokine-specific capture and detection Abs (Abs R4-6A2 and XMG1.2 for 
detection of IFN-γ; Abs BVD4-1D11 and BVD6-24G2 for the detection of 
IL-4; and Abs JES5-2A5 and SXC-1 for the detection of IL-10) according to 
the manufacturer’s instructions (BD Biosciences — Pharmingen). Standard 
curves for each assay were generated using recombinant mouse cytokines 
(IFN-γ, IL-4, and IL-10; BD Biosciences — Pharmingen), and the concentra-
tion of the cytokines in the cell supernatants was determined by extrapola-
tion from the appropriate standard curve. The lower limits of detection for 
each assay were 2 pg/ml for IFN-γ, 0.6 pg/ml for IL-4, and 3 pg/ml for IL-10. 
The remaining cells were incubated for an additional 16 hours, pulsed with 
0.5 µCi/well of [3H] thymidine (Amersham Pharmacia Biotech), harvested 
on glass-fiber filters using a Tomtec (Orange) 96-well cell harvester, and 
counted in a 1205 Betaplate liquid scintillation counter (Wallac). Results 
obtained from triplicate cultures are expressed as mean cpm ± SD.
Flow cytometry analysis. FITC-conjugated mAbs to CD11c, CD44, CD25, 
CD4, and Pan B (B220); PE-conjugated mAbs to CD14, CTLA-4 (CD152), 
CD40, VLA-4 (CD49d), ICAM-1 (CD54), OX-40, CD8, γδ, and NK; and allo-
phycocyanin-conjugated mAbs to CD45RB and CD4 were all purchased 
from BD Biosciences — Pharmingen. Isolated spleens and lymph nodes 
were prepared for flow cytometry by incubating cells with the appropriate 
Abs or control isotype–matched Abs followed by PBS washes. Data collec-
tion and analyses were performed on a FACScalibur flow cytometer (BD 
Biosciences — Immunocytometry Systems).
Western blot and biochemical analyses. Total cell lysates were obtained in 50 mM 
HEPES (pH 7.5), 250 mM NaCl, 1 mM EDTA, 1.0% Triton X-100, 10 mM 
sodium fluoride, 1 mM sodium orthovanadate, and 2 µg/ml each of apro-
tinin, leupeptin, and pepstatin. Total proteins (50 µg) from each lysate 
were subjected to SDS-PAGE under reducing conditions. After electro-
phoresis, proteins were transferred onto a nitrocellulose filter membrane 
(Protan; Schleicher & Schuell BioScience) using a Trans-Blot Cell (Bio-Rad 
Laboratories) and transfer buffer containing 25 mM Tris, 192 mM glycine, 
and 20% methanol. Membranes were placed in 5% nonfat milk in PBS plus 
0.5% Tween 20 (PBST) at 4°C for 2 hours to block the nonspecific bind-
Figure 9
Leptin neutralization determines the failure to downmodulate the anergy factor p27Kip-1 and is associated with sustained phosphorylation of 
ERK1/2 and STAT6. (A and B) Western blot analysis for p27Kip-1 and tubulin on purified CD4+ T cells obtained from SJL/J mice immunized with 
PLP139–151. Ex vivo analysis revealed high levels of p27Kip-1 in resting CD4+ T cells from naive mice; this phenomenon was accompanied by a 
strong downmodulation of p27Kip-1 in control Ig mice that developed classical EAE. Conversely, ObR:Fc treatment either from day –1 to day 1 or 
on days 8–11 caused a failure to downmodulate p27Kip-1, resulting in massive p27Kip-1 accumulation. (C and D) Ex vivo analysis revealed very low 
levels of phosphorylation of ERK1/2 in resting CD4+ T cells from naive mice. Conversely, control Ig–treated mice with EAE showed an increase 
in ERK1/2 phosphorylation. Leptin neutralization either from day –1 to day 1 or on days 8–11 induced sustained phosphorylation of the ERK1/2 
molecule compared with control Ig–treated mice. (E and F) Ex vivo analysis revealed low levels of STAT6 phosphorylation in resting CD4+ T 
cells from naive mice; conversely, control Ig–treated mice with EAE showed a modest increase in STAT6 phosphorylation. Leptin neutralization 
also induced marked phosphorylation of STAT6. For each panel, 1 representative experiment of 5 is shown.
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ing sites. Filters were incubated with specific Abs before being washed 3 
times in PBST and then incubated with a peroxidase-conjugated secondary 
Ab (Amersham Biosciences). After further washing with PBST, peroxidase 
activity was detected by using the ECL system (Amersham Biosciences). 
The Abs used were the following: anti-p27Kip-1, anti–STAT6, and anti–
phosphorylated STAT6 (Y641; all from Cell Signaling Technology Inc.); 
anti-ERK1/2 and anti–phosphorylated ERK1/2 (Santa Cruz Biotechnol-
ogy Inc.); and anti-Foxp3 (eBioscience). The filters were also probed with 
an anti-tubulin Ab (Sigma-Aldrich) to normalize the amount of loaded 
protein. All filters were quantified by densitometric analysis of the bands 
utilizing the program ScionImage (version 1.63 for Mac; Scion Corp. Inc.)
Statistics. Analyses were performed using Mann-Whitney U  test  (for 
unpaired 2-group analysis) and Kruskal-Wallis ANOVA test (for analysis 
of 3 or more groups). Results are expressed as mean ± SD; P values less than 
0.05 were considered statistically significant.
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Abstract 17 
The immunosuppressive properties of naturally occurring regulatory T cells (Tregs) have 18 
classically been linked to an intrinsic state of hyporesponsiveness, yet paradoxically Tregs are 19 
phenotypically in an activated state and have intact proliferative capacity. In consideration of 20 
several recent biochemical reports on the intracellular signalling pathways operating in activated 21 
CD4+CD25+ Tregs, we argue that the responsiveness of Tregs depends highly on the local 22 
microenvironment. In particular, what influences Tregs to remain anergic or to proliferate arises 23 
from their ability to probe the extracellular milieu to respond to external stimuli for the modulation 24 
of intracellular signalling events leading to very different quantitative and qualitative functional 25 
outcomes. 26 
 27 
 28 
 3
Regulatory T cells: history of a renaissance  29 
A central problem in immunology has been to detail how peripheral tolerance is maintained. The 30 
phenomenon of T cell-mediated suppression of autoimmunity was initially described in the late 1960s 31 
(though it was not appreciated as such  at the time) (1), and the concept expanded further in the 1970s (2, 32 
3) before a demise of this field of investigation. New impetus came in the mid-1990s after to the description 33 
of Sakaguchi and colleagues of the surface expression of CD25 (the IL-2 receptor α chain) as a marker for 34 
the identification of a subset of suppressor T cells, the CD4+CD25+ regulatory T cells (Tregs) (4). Depletion 35 
of the CD25+ cells from splenocytes and transfer of the resulting CD25- T cells to immunocompromised 36 
hosts induced autoimmunity, whereas co-transfer of CD4+CD25+ cells inhibited the induction of 37 
autoimmunity (4, 5).  38 
 39 
Although several additional immune cell subsets with suppressive capacity have been identified so far, the 40 
CD4+CD25+ Tregs that suppress proliferation and release of pro-inflammatory cytokines from effector cells 41 
(6, 7) and/or directly inhibit antigen presenting cells (8, 9) represent by far the most studied 42 
immunoregulatory cell type.  43 
 44 
In mice kept under specific pathogen free laboratory conditions, the CD4+ T cells that co-express CD25 45 
represent a rather homogeneous immune regulatory cell population, while in humans there is a 46 
considerable number of activated, non-regulatory CD4+ T cells that express CD25 (10, 11). Typically, Tregs 47 
are more abundant in mice (3 to 10%, depending on the strain) than in humans, in which they only 48 
constitute about 1-2% of the CD4+ T cells with highest surface expression of CD25 (12). More recently, they 49 
have been also further characterized and identified by their nuclear expression of the forkhead winged-helix 50 
transcription factor, Foxp3 (forkhead box p3), whose expression has been proposed to be the crucial factor 51 
in the induction of the Tregs population (13). Tregs are classically hyporesponsive to antigenic stimulation 52 
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in vitro, a condition reversible upon exposure to interleukin (IL)-2 or strong costimulation (14-18). Because 53 
of this property, IL-2 has been used to expand Tregs for adoptive immune therapy and the suppression of 54 
autoimmune responses (19, 20). In that regard, it must be noted that significant heterogeneity exists among 55 
the Tregs. In addition to the naturally occurring, thymus-derived Foxp3+ Tregs which have a contact-56 
dependent, cytokine-independent mechanism of action, other subsets of CD4+ regulatory T cells with a very 57 
similar phenotype and mechanism of action are generated in the periphery (21). Of the peripheral 58 
(adaptive) Tregs, two subsets have cytokine-dependent mechanisms of action. One, called Tr1 cells, 59 
produce predominantly IL-10 (22), and another, called Th3 cells, produce predominantly TGF-β (23). Each 60 
of these Tregs subsets can also express CD25, at least transiently. Horwitz et al. have proposed a useful 61 
nomenclature in which the natural Tregs would be called “Trn” cells, to differentiate them from the Tregs 62 
cells induced in the periphery, and the Th3 cells would be renamed “Tr2” cells (24). Notably, Trn Tregs can 63 
induce conventional CD4+ cells to become suppressor cells through a phenomenon called “infectious 64 
tolerance” (25), and that Trn-like Tregs generated ex vivo can educate CD4+CD25− cells to become 65 
suppressors (26).  66 
Another way to discriminate between CD25+ Tregs with immunosuppressive properties and recently 67 
activated CD25+ T cells relates to a downregulated phenotypic expression of the IL-7 receptor (CD127) (27, 68 
28).  69 
Given all these premises, the best marker for their suppressive capacity remains the expression of the 70 
nuclear transcription factor Foxp3 (13), both in mice and in humans (29).  71 
 72 
Anergy of regulatory T cells: is it the whole story? 73 
As mentioned above, one central aspect of the biology of essentially all Tregs is their anergic state in vitro. 74 
Tregs and effector T cells respond differently to TCR stimulation: the former without proliferation or cytokine 75 
production; the latter activating specific intracellular pathways that result in the induction of effector 76 
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functions including the production of IL-2. These events can be linked in part to a difference in the 77 
biochemistry of the two cell types, i.e. Tregs have defects in calcium mobilization as compared to effector T 78 
cells (30), and a reduced CD3ζ phosphorylation and ZAP70 recruitment following TCR engagement (31). 79 
On the other hand, Tregs can proliferate in vitro in response to T cell receptor (TCR) ligation after addition 80 
of exogenous IL-2, and the reduced TCR-activated signalling pathways in these cells can be overcome by 81 
providing a second messenger such as diacylglycerol, or bypassing the TCR by using phorbol myristate 82 
acetate (PMA) and ionomycin (32). These data indicate that Tregs are not unable to signal, but rather have 83 
altered signalling which makes them respond to stimuli differently than activated effector T cells. From a 84 
biochemical viewpoint, we could consider this aspect of Tregs cell biology similar to that of anergic T cells 85 
that have an abortive activation of the ras pathway, of the mitogen-activated protein kinase 1 and 2 86 
(MAPK1 and 2), and of the extracellular signal-regulated kinase 1 and 2 (ERK1/2), with concomitant 87 
blockade of cell-cycle progression secondary to decreased cyclin E and cyclin A and increased cyclin-88 
dependent kinase inhibitor of the cell-cycle p27kip1 (33).  89 
Regarding the presentation of antigen to Tregs, it appears that dendritic cells can have multiple effects 90 
(likely related to stage of maturation, subset of cells, or local microenvironment) on these cells. Dendritic 91 
cells can play a critical role in the induction and maintenance of immune tolerance via controlling the 92 
differentiation, expansion, and/or immunosuppressive ability of Tregs (34-36), and they could form with the 93 
Tregs a regulatory loop in the periphery in which tolerogenic dendritic cells would induce the generation of 94 
Tregs and, in turn, Tregs would program the generation of tolerogenic dendritic cells (37). At the same time, 95 
dendritic cells could also in some cases block the immunosuppressive capacity of the Tregs (38). In 96 
particular, Tregs could modulate phenotype and downregulate the function of dendritic cells (8), as 97 
indicated by the finding that Tregs can inhibit development of colitis dependent on accumulation of 98 
activated CD134L+ dendritic cells in mesenteric lymph nodes (9). One mechanism possibly involved in this 99 
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could be CTLA-4 expressed on the Tregs, which upregulates indoleamine 2,3-dioxygenase (IDO) 100 
expression initiating tryptophan catabolism in the dendritic cells (39). 101 
 102 
Anergy and proliferation of Tregs 103 
Despite the hyporesponsiveness to antigenic stimulation in vitro, Tregs have an intact proliferative potential 104 
(30). For example, Tregs unable to flux Ca++ after TCR engagement in vitro proliferate in response to 105 
lymphopenia, and such homeostatic proliferation does not abolish their anergic state but associates with 106 
augmented suppressive function (30). Studies of adoptive transfer of Tregs labelled with the fluorescent 107 
dye 5, 6-carboxy fluorescein succinimidyl ester (CFSE) have confirmed that Tregs can expand in vivo, in 108 
both lymphopenic and non-lymphopenic hosts (40, 41). Recently, using the deuterium labelling technique 109 
for cell cycling in vivo, it was shown that human CD4+CD25+Foxp3+CD45RO+ Tregs proliferate in vivo with 110 
a doubling time of 8 days, a time considerably shorter than the 24 days of the memory CD4+CD25-Foxp3-111 
CD45RO+ cells or the 199 days of naïve CD4+CD25-Foxp3-CD45RA+ T cells (40). Importantly, proliferating 112 
CD4+CD25+Foxp3+CD45RO+ Tregs were found to be highly susceptible to apoptosis, suggesting that 113 
ongoing homeostasis helps to control the rapid expansion and/or turnover of these cells in vivo (40). Thus, 114 
Tregs have the dichotomous capacity to both be anergic in vitro and to proliferate in vivo, but does this 115 
relate to their function? 116 
 117 
Anergy and suppression of Tregs 118 
Anergy and suppression of Tregs appear intimately linked, as Tregs operate in vitro as hyporesponsive 119 
cells capable of actively suppressing the proliferation and release of proinflammatory cytokines from target 120 
cells (32, 42). While acknowledging the possibility of resistance of effector immune cells to Tregs-mediated 121 
suppression, we will only consider here that in the Tregs the two phenomena of anergy and suppression 122 
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can be uncoupled, and high doses of anti-CD28 or exogenous IL-2 can abrogate suppression in co-cultures 123 
(43).  124 
Since Tregs have the capacity to proliferate, one can wonder how the proliferative state of the Tregs can 125 
affect their suppressive capacity. Several studies have indicated that in vitro expanded adaptive Tregs 126 
maintain or even increase their suppressive capacity on target cells (21, 43, 44). Considering that Tregs 127 
have a phenotypic profile of highly active cells –– and are in a very active metabolic state at the intracellular 128 
level – it is likely that they respond promptly to suitable signals coming from the environment to suppress 129 
depending on the environmental conditions. These signals would influence a numeric expansion of 130 
functional suppressor cells, an acquisition of a suppressive phenotype and/or an upregulated intracellular 131 
expression of Foxp3 in individual cells. To better clarify this point it has to be considered that while anergic 132 
T cells have suppressive activity in vitro (e.g. the so-called ‘Civil Service Model’ of Waldmann and 133 
colleagues) (45), adoptive transfer of anergic cells into animals is not necessarily linked to suppression - 134 
unless the anergic state associates with a Tregs cell phenotype. Also, freshly isolated natural Tregs are in 135 
an activated state but have relatively modest suppressive capacity as compared to adaptive Tregs that 136 
have received additional activation. These differences in the suppressive capabilities of the Tregs may 137 
depend, at least in part, on the expression of Foxp3, which promotes the suppression of the Tregs and 138 
stabilizes to a large extent anergy and dependence on IL-2, concomitantly repressing the intracellular 139 
expression of the cyclic nucleotide phosphodiesterase 3B (Pde3b), which is important in permitting 140 
homoeostasis and gene expression in the Tregs (46).  141 
 142 
Tregs, metabolism, and the environment  143 
The identification of the intracellular pathways that can modulate the suppressor program in the Tregs has 144 
raised great interest. Antigen stimulation of immune cells activates the transcription factor NFAT, which 145 
regulates the state of activation and anergy of T cells. NFAT can promote immune regulation in the Tregs 146 
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by switching transcriptional partners (47). This aspect is important in that it indicates that Tregs have the 147 
capability to “sense” specific signals and subsequently respond to them (Table 1 and Figure 1). A notable 148 
example in this regard comes from the work on murine CD4+CD25+CD127low suppressive Tregs, in which 149 
stimulation of the TCR upregulates the expression of CD44 (48). CD44 is a cell surface molecule that binds 150 
hyaluronan (HA), an extracellular matrix component. High molecular weight (HMW) HA has anti-151 
inflammatory properties (49). However, the activity of hyaluronidases - triggered e.g. by infection or injury - 152 
generates low molecular weight (LMW) HA that promotes inflammatory responses (50, 51). Recent work 153 
has shown that the state of HA in the extracellular matrix can significantly impact the function of the Tregs. 154 
In particular, both HMW and LMW HA bind to Tregs, but the size of HA differentially impacts the functional 155 
activity of these cells, and HMW-HA enhances the suppressive capacity of activated Tregs - causing an 156 
upregulation of their intracellular Foxp3 expression (52). These findings suggest that the state of HA in the 157 
local environment is one mechanism by which Tregs can receive cues about an inflammatory milieu (52) 158 
and respond accordingly. In this context, it could be suggested that although no specific homing receptor 159 
has been identified as specific for Tregs, the integrin αEβ7 (CD103) and the chemokine receptor CCR6 – 160 
which are selectively expressed by these cells at high levels - might help the direction and retention of 161 
Tregs in inflamed sites to locally balance the activity of effector T cells (53).  162 
Additional work pointing at the ability of Tregs to respond to the local environment comes from recent 163 
findings indicating that Tregs in mice can depend on folic acid for their maintenance in the periphery, and 164 
expression of a subtype of the receptor for folic acid, the folate receptor 4 (FR4), may enable them to bind 165 
and incorporate folic acid efficiently (Table 1 and Figure 1). Folic acid is a vitamin that downmodulates 166 
plasma homocysteine levels - which are frequently elevated in patients with autoimmune disease such as 167 
lupus and rheumatoid arthritis (54). The high constitutive surface expression on Tregs of FR4 – which is 168 
controlled by Foxp3 - makes the administration of FR4 monoclonal antibody responsible for a reduction of 169 
the number of Tregs and subsequent autoimmune disease in normal mice (55). 170 
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Another example is the expression on Tregs of membrane-bound CD39 and CD73, which are 171 
ectonucleotidases involved in catabolism that causes the generation of extracellular adenosine from 172 
extracellular nucleotides such as ATP and UTP (56, 57). For the immune system, extracellular ATP 173 
represents an indicator of tissue damage. Adenosine has important suppressive functions on activated T 174 
cells through the activation of adenosine receptors that lead to increased intracellular levels of cyclic 175 
adenosine monophosphate (cAMP), a second messenger present in cells with a high metabolic rate and 176 
well known for its ability to inhibit T cell proliferation (58). Tregs have a high intracellular content of cAMP 177 
(59). Of note, CD39 is expressed by Tregs, where it can convert extracellular ATP into the catabolite 178 
exerting suppressive properties on T cell proliferation and IL-2 secretion (56, 57). In normal conditions, after 179 
T cell activation through the TCR-MHC-CD28 complex, a peak of intracellular concentration of cAMP is 180 
detected rapidly, and is followed by rapid degradation by cAMP-phosphodiesterases (PDE) recruited into 181 
the cell membrane lipid rafts (58). Tregs could rapidly generate and directly provide cAMP to effector T 182 
cells in a cell contact-dependent fashion, through the formation of gap-junctions (59).  183 
Also considering that the local environment reflects the metabolic state of the host, Tregs may need to be 184 
able to rapidly adjust their activity depending on what would be most expedient for the overall economy of 185 
the host. The presence of the proinflammatory cytokine-like hormone leptin in the milieu – which reflects 186 
the caloric balance of the host - can provide an excellent example of how the presence of a molecule 187 
reflecting metabolic excess can promote negative signalling for the proliferation of Tregs through inhibitory 188 
signalling (via the leptin receptor - which is highly expressed on the cell surface of Tregs (60) (Figure 1). 189 
When Tregs are stimulated in vitro with anti-CD3 and CD28 and leptin is blocked with anti-leptin 190 
neutralizing antibodies, hyporesponsiveness of these cells is abrogated, and Tregs can proliferate 191 
vigorously, maintaining their suppressive capacity (60). 192 
 193 
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Another aspect worth consideration is how intracellular metabolism can affect the suppressive capacity and 194 
ability of Tregs to expand in vitro. A possible answer to this question may come from the analysis of Tregs 195 
responses to rapamycin, an immunomodulator that can both inhibit the proliferation of effector T cells and 196 
facilitate the expansion of natural Tregs in vitro expansion (61, 62). Rapamycin is an inhibitor of the 197 
nutrient-sensitive kinase mammalian target of rapamycin (mTOR) (63), a macromolecular protein complex 198 
with serine-threonine kinase activity that regulates cell-cycle progression and growth by sensing changes in 199 
the energy status of the extracellular milieu (Figure 1). mTOR represents a cellular “fuel sensor” activated 200 
by amino acids, glucose availability, growth factors, and certain hormones (64). The fact that rapamycin 201 
exerts opposite effects on Tregs and effector T cells (65) reiterates the concept that in basal conditions the 202 
two cell types may be under different metabolic conditions. Effector T cells may have mTOR inactive, and 203 
the inhibition would prevent cell growth and expansion. Conversely, Tregs may have mTOR active, and can 204 
thus proliferate in vivo. The fact that inhibition of mTOR with rapamycin results in the capacity of Tregs to 205 
grow and expand in vitro (61, 66) is in line with the observation that Tregs produce high levels of cAMP - 206 
which can activate mTOR (67) - suggesting an involvement of the intracellular metabolism of Tregs in the 207 
mechanisms of proliferation of these cells following influences by the local environment. 208 
 209 
The “on/off hypothesis” 210 
In view of the above considerations, we propose the “on/off hypothesis” to explain why Tregs, which have a 211 
very high metabolic rate, can be influenced in their activity and/or proliferative potential by the local 212 
environment more significantly than effector T cells (Table 1 and Figure 1). Tregs and effector T cells both 213 
appear somehow as lymphocytes in a resting phase, yet they differ significantly for their metabolic activity - 214 
high for the Tregs, slow for the T cell effectors. This condition could be compared to two cars that are 215 
aligned at a specific position and that are not moving. Looking at the two cars, an external observer would 216 
not know whether the engine of each car is “on” (high metabolic rate) or “off” (low metabolic rate). The car 217 
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consuming fuel and energy with the engine on would be the Tregs, the car not consuming fuel and energy, 218 
with the engine off, would be the T effector. Despite that the status of the two cars would not be readily 219 
apparent from afar, visibly different outcomes would appear when depressing the accelerator pedal in the 220 
two cars: Tregs would rapidly go, T effector would stay still unless “pre-activation” (ignition) had been 221 
provided. Ultimately, the environment (ignition) would maximally affect the subsequent ability to operate in 222 
the two conditions - the high metabolic rate making the Tregs more sensitive to immediate stimulation and 223 
response. While this would contrast with the T effectors, the latter cells would have more energy available 224 
for longer lasting responses (because they did not consume much energy). In general, this phenomenon 225 
would contribute to a capacity of Tregs to operate quickly and in accordance with environmental signals 226 
(i.e. catabolizing extracellular ATP and amino acids and/or using cAMP to inhibit effector T cell 227 
proliferation), yet this activity might be confined in time because of the elevated metabolic rate of these 228 
cells (Table 1 and Figure 1).  229 
 230 
Concluding remarks 231 
It has been suggested that tissues can send signals that initiate immunity and guide the type of effector 232 
responses (46). Since the delicate function of peripheral immune tolerance can be easily compromised by 233 
powerful, disruptive effector mechanisms, immune regulation needs to be preserved in the face of opposing 234 
immune effector mechanisms. We think that one such mechanism could be the ability of Tregs to probe the 235 
environment for rapid adjustment. As immune cells, Tregs are in constant communication with their 236 
environment through soluble mediators or via cell contact, to respond to cues that can positively or 237 
negatively tune their function. The recent discovery of biochemical events linked to the responsiveness of 238 
Tregs to environmental influences could be possibly exploited to harness the beneficial potential of these 239 
cells in the control of autoimmune responses.  240 
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Table I. Schematic aspects of the “on/off hypothesis”   384 
 Treg Teff References 
Metabolic rate ++ - 55-67 
Sensitivity to environmental stimuli +++ + 39, 55-60 
Rapidity of response +++ + 20, 40, 41, 44,  
Length of response + +++ 30-32 
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